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Abstract 
Hypersensitivity to the chicken egg is a widespread disorder mainly affecting 0.5 – 
2.5% of children worldwide. It is the second most common food allergy in children, 
next to cow’s milk allergy. Egg allergy is mainly caused by hypersensitivity to four 
allergens found in the egg white; ovomucoid, ovalbumin, ovotransferrin and 
lysozyme. In egg allergic individuals, these allergens cause conditions such as itching, 
atopic dermatitis, bronchial asthma, vomiting, rhinitis, conjunctivitis, laryngeal 
oedema and chronic urticaria, and anaphylaxis. Currently, there is no permanent cure 
for egg allergy. Upon positive diagnosis for egg allergy, strict dietary avoidance of 
eggs, and products containing traces of eggs, is the most effective way of avoiding 
future hypersensitivity reactions. However, it is difficult to fully avoid eggs since they 
are found in an extensive range of processed food products. Strict avoidance also 
poses nutritional disadvantages due to high nutritional value of eggs. In addition, 
allergen specific immunotherapy (SIT) is being pursued as a curative treatment, in 
which an allergic individual is gradually exposed to the allergen to induce tolerance. 
However, immunotherapy may cause unwanted immune reactions in individuals 
highly sensitive to eggs.  
 
Use of recombinant proteins for immunotherapy has been beneficial due to the 
purity of the recombinant proteins compared to natural proteins. In Chapter 2 and 
Chapter 3 of this thesis, IgE reactive recombinant egg white proteins, which may be 
used as novel reagents for future immunotherapy, were produced. Escherichia coli 
was used as an expression system to produce these recombinant versions of 
ovomucoid, ovalbumin and ovotransferrin that showed IgE reactivity when tested 
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against a pool of egg allergic patients’ sera. The IgE reactivity indicates that these 
recombinant proteins are capable of eliciting an immune response, thus being 
potential candidates for immunotherapy. The recombinant version of lysozyme did 
not show IgE reactivity for unknown reasons, which may be useful as a hypoallergen 
as is. The results also suggests that egg allergy in Australian populations may mainly 
be due to IgE reactivity to ovotransferrin and lysozyme, while ovomucoid showed 
higher IgE reactivity. The significance of this study is the potential use of the IgE 
reactive recombinant egg white proteins in immunotherapy to treat egg allergic 
patients.    
 
Chapter 4 of this thesis aimed at producing a hypoallergenic variant of a major egg 
white allergen. Ovomucoid is the dominant allergenic protein in chicken egg white. 
Hypoallergenic variants of this allergen may be used in immunotherapy as an egg 
allergy treatment approach with reduced adverse effects. Two cysteine residues at 
C192 and C210 in domain III of the protein were mutated to alanine using site-
directed mutagenesis, to disrupt two separate cysteine-cysteine bridges. Both 
mutated and non-mutated proteins were expressed in E. coli, which was confirmed 
by SDS-PAGE and immunoblotting. Immunoglobulin E (IgE) reactivity of the two 
proteins was analysed, by immunoblotting, with a pool of egg allergic patients’ sera. 
A pool of non-allergic patients’ sera was also used in a separate blot as a negative 
control. Mutant ovomucoid had significantly diminished IgE reactivity in the 
immunoblot, as demonstrated by lighter bands when compared to the non-mutated 
version, although there was more of the mutant protein immobilized on the 
membrane when compared to the wild-type protein. The non-allergic negative 
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control showed no bands indicating an absence of non-specific binding of secondary 
antibody. In conclusion, disruption of two cysteine bridges in domain III of ovomucoid 
reduces IgE reactivity. Following downstream laboratory and clinical testing, this 
mutant protein may be used in immunotherapy as an alternative to its natural 
counterpart to induce tolerance to ovomucoid with reduced adverse effects in egg 
allergy.  
 
Potential use of genetic engineering to produce hypoallergenic chicken eggs was 
scrutinized in Chapter 5 of this thesis. A CRISPR-Cas9 driven knockout of ovomucoid 
in chicken fibroblast cells was attempted first, however successful results were not 
obtained. Possible ways of improving this approach is discussed in this chapter. 
Secondly, a RNAi driven knockdown of ovomucoid in chicken was conducted. Initial 
cell based assays confirmed the efficacy of the RNAi targets and mechanism. Gonad 
assays following micro-injection into chicken embryos further confirmed that the 
RNAi mechanism may be active in the transfected cells of the embryos. qPCR 
conducted using sperm of an adult rooster from the G0 generation predicted ~1.5% 
transgenesis in the G1 generation. As a future direction from this study, the eggs of 
the G1 generation can be tested for IgE reactivity. If the G1 generation and their eggs 
seem healthy after reduced ovomucoid expression, a complete knockout of the gene 
may be feasible to produce a significantly hypoallergenic chicken egg.  
 
In conclusion, this PhD project aimed at developing recombinant allergenic and 
hypoallergenic variants of the egg white allergens that may be useful in treatment 
methods such as immunotherapy and diagnostic methods such skin prick tests. As a 
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novel approach for tackling egg allergy, genetic engineering tools were studied for 
their efficacy at producing hypoallergenic chicken eggs. The latter part of the project, 
although inconclusive, provided useful information for future research using genetic 
engineering in egg allergy. All approaches scrutinized in this project may, in the 
future, significantly improve egg allergy diagnosis, treatment and management.     
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CHAPTER 1 
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Cracking the egg: an insight into egg 
hypersensitivity 
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Chapter 1 
1.1 Allergy 
Allergy is a symptomatic and an abnormal overreaction by the immune system to 
innocuous environmental substances, such as grass pollen and eggs, known as 
allergens. Allergens are a type of antigen, which trigger a complex immune response 
upon contact with the immune system. Allergy is classified as a type 1 hypersensitivity 
reaction because of the immediate and inflammatory immune response that is 
characterized by the excessive production of the antibody IgE. An allergic response 
involves two reaction phases based on the contact of the allergen with the immune 
system; primary and secondary response. The primary response (upon initial contact 
with an allergen), stimulates the generation of IgE by B-lymphocytes. The secondary 
response (upon secondary contact with the same allergen) results in the 
degranulation of mast cells (mastocytes) and basophils (basophil granulocytes). The 
mediators (e.g. histamine) released by the degranulation process elicit clinical allergic 
symptoms such as bronchoconstriction, sneezing, rashes, itching or life threatening 
conditions such as anaphylaxis, just to name a few 1,2.  
 
Allergens, being proteins or chemical substances, originate from a variety of animals 
and plants and exist abundantly in the environment. In indoor environments, some 
of the most common allergens are dust mites, pet fur and dander, cockroach calyx, 
mould and wool. Outdoor allergens include, but not limited to, insect stings such as 
bees and wasps, grass pollen, weeds such as ragweed, and tree products such as birch 
sap and pollen 3. In addition to the above-mentioned sources, allergens can be found 
in many of the foods that humans consume including eggs, milk, legumes (e.g. 
peanuts), seafood, soy, tree nuts, and wheat (gluten). Many individuals are also 
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known to be allergic to artificial substances such as perfumes, latex and medications 
including penicillin and anaesthetics 3. 
 
The most common allergic diseases include allergic rhinitis, asthma, hay fever, atopic 
eczema, atopic dermatitis and celiac disease 2. The term ‘atopy’ is often used to 
describe a number of allergic diseases. Atopy refers to the strong hereditary 
predisposition to produce increased amounts of IgE in response to common 
environmental allergens. Individuals with atopy have a tendency to possess one or 
more allergies 2. The combination of atopy and allergens may sometimes lead to 
severe hypersensitivity conditions such as anaphylaxis, in which allergen-induced 
release of mediators from mast cells and basophils results in a systematic and 
catastrophic physiological reaction that has the potential to prove fatal 4. Allergies 
that arise independent of IgE, such as contact dermatitis and hypersensitivity 
pneumonitis are classified as non-atopic conditions 2.  
 
A marked increase in allergic diseases has been demonstrated in major industrialized 
countries such as Australia, United States and Europe over the last decade. In 2006, 
50% of the population of the US has been identified as allergic 5. In Australia, 1 in 5 
or 4.1 million people are affected by allergies, conferring a financial burden of over 
$7.8 billion per annum on the government. Prevalence of allergy in Australia is 
expected to rise by 70% (i.e. 7.7 million people) by 2050, provided that the current 
trend continues 6. The World Allergy Organisation has reported that 20-30% of the 
world population has been affected by allergy of some type in 2008 7.  
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1.2 Diagnosis of allergy 
Scientific advances in delineation of antigen presentation and molecular signalling 
have provided insights in to the underlying principles of the immune response to 
allergens and the subsequent synthesis of IgE, which leads to the clinical symptoms 
of allergy. This framework has assisted in developing the two widely used diagnostic 
approaches of allergy; skin tests and blood tests. A skin test involves the introduction 
of a small amount of a known concentrated allergen into the epidermis. If the 
individual is allergic to the introduced substance, a blister or a wheal (redness) takes 
place. The severity of the reaction is determined by measuring the diameter of the 
affected area 2. A blood test involves quantification of IgE both as total 
immunoglobulin concentration and as allergy-specific antibody concentration in the 
patient’s serum. The IgE levels are quantified mainly by using radioallergosorbent 
tests (RAST) in which radioisotope-labelled IgE binding antibodies are used to 
measure serum IgE levels 2. At present a similar, and commercial, method known as 
ImmunoCAP testing is used more frequently which is enzyme based rather than 
radioisotope based 8. 
 
 
1.3 Treatment 
The most common approach of allergy treatment focuses on allergen avoidance and 
pharmacotherapy to neutralize allergic symptoms. Pharmacotherapy exploits 
antagonistic drugs such as antihistamines, antileukotreines, corticosteroids, 
ĐƌŽŵŽůǇŶ͕ ŵĞƚŚǇůǆĂŶƚŚŝŶĞƐ͕ ɴ-antogonists, muscarinic antagonists and mast cell 
stabilisers to block allergic mediators or to alleviate the degranulation process 9,10. 
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However, such therapeutics do not yield curative results due to their inability to 
inhibit IgE production. Furthermore, antagonistic drugs are capable of promoting 
immunosuppression or non-immunological effects 11. 
 
Allergic desensitization through administration of appropriate concentrations of 
allergens has been conventionally used to improve immunological tolerance in 
allergic individuals. Allergen SIT is a desensitizing therapy that has been used 
practically for a century and represents the only remedial and allergen-specific 
treatment method 12. Allergen-SIT essentially involves weekly vaccination 
(subcutaneous) of increased doses of specific allergens into the patient with the aim 
of modifying Th2 lymphocytes into Th1 lymphocytes and therefore induce 
Immunoglobulin G (IgG) production instead of IgE 11. This method has been 
recognized as an effective treatment for rhinitis and asthma 13. Sublingual 
immunotherapy (SLIT) is another form of SIT, which involves administration of 
allergen doses via the sublingual mucosa. An analysis of multiple SLIT studies has 
confirmed the efficacy of SLIT on reducing rhinitis symptoms and the necessity of 
other medications 14. However, administration of increased amounts of allergens 
may cause excessive production of IgE and lead to therapy-induced anaphylaxis 15.       
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1.4 Allergic reaction  
1.4.1 Cells involved in allergic reactions 
Antigen presenting cells (APCs), also known as accessory cells, process and present 
foreign antigens to the class II major histocompatibility complex (MHC class II) and 
provide co-stimulatory signals necessary for T-cell activation (Figure 1.1) 16-18. T-cells 
are a type of lymphocytes that are activated by APC signalling. T-helper cells (Th or 
CD4+T), a sub-type of T-cells, possess the T-cell receptor which specifically recognizes 
antigens bound to MHC class II complex, and express the CD4 surface protein 19. 
When antigen-bound MHC class II complex interacts with naïve T-helper cells (Th0), 
they differentiate into Th1, Th2 or Th17 cells, secreting different types of cytokines, 
and prime as antigen specific memory T-cells capable of combating or reacting to 
future immune encounters. B-cells are another type of lymphocytes that exist as 
inactive non-dividing cells before the onset of an immune response. Cytokines 
released by T-cells induce B-cells to proliferate and differentiate into plasma cells 
secreting allergen specific antibodies 20-23.  
 
Mast cells and basophils perform a crucial role in allergy as effector cells. Derived 
from bone marrow, both types of cells possess cytoplasmic granules containing 
chemical mediators including histamine 24. These cells constitutively express the high 
ĂĨĨŝŶŝƚǇƌĞĐĞƉƚŽƌ&ĐɸZ/͕ǁŚŝĐŚďŝŶĚƐƚŽƚŚĞ&ĐƉŽƌƚŝŽŶŽĨ/Ő25. Cross-ůŝŶŬŝŶŐŽĨ&ĐɸZ/
by immune complexes stimulate imperative host defence mechanisms including cell 
cytotoxicity, phagocytosis and regulation of immune response, and the release of 
inflammatory mediators which is the hallmark of allergic response 25. 
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1.4.2 Non-allergic response  
In non-allergic individuals, when the immune system encounters an allergen, the 
allergen is engulfed by APCs which migrate to peripheral lymphoid tissues, including 
lymph nodes. Here, the allergen is processed and presented to the MHC class II 
complex (Figure 1.1). Allergen bound MHC class II complex binds to the T-cell 
receptor of Th0 cells, stimulating Th0 differentiation into Th1 in the presence of 
cytokines Interleukin 12 (IL-12) and Interferon-ɶ;/&E-ɶͿ;&ŝŐƵƌĞϭ͘ϮͿ26,27. Pro-allergic 
IL-12 is produced by peripheral blood mononuclear cells and APCs, which in turn 
induce the production of IFN-ɶ ďǇ ŶĂƚƵƌĂů ŬŝůůĞƌ cells 28-32. Th1 lymphocytes then 
further secrete IFN-ɶ͕ǁŚŝĐŚ ƐƚŝŵƵůates B-cells to proliferate and differentiate into 
plasma cells secreting the antibody IgG (Figure 1.2), a feature of non-allergic response 
33. Such IgG antibodies, which bind to the allergens, are known as blocking antibodies. 
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Figure 1.1: The presentation process of an allergen by an antigen presenting cell. 
The allergen is engulfed by the cell and transported via an endocytic vesicle, in which 
the allergen is processed to produce peptides. The peptides then interact with and 
bind to MHC class II molecules released by the Golgi apparatus. Subsequently, the 
complex of MHC class II and allergen is transported by vesicles and displayed on the 
cell surface, ready to interact with a T-cell receptor.        
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Figure 1.2: Illustration of the non-allergic reaction. In the non-allergic reaction, once 
the encountered allergen is processed and presented by APCs to the Th0 cells, the Th0 
cells differentiate into Th1 cells. IFN-ɶĐǇƚŽŬŝŶĞƌĞůĞĂƐĞĚďǇƚŚĞdŚϭĐĞůůƐŝŶĚƵĐĞ-cell 
differentiation into IgG producing plasma cells. The plasma cells then proliferate and 
produce large amounts of IgG, a characteristic of the non-allergic reaction.    
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1.4.3 Allergic response  
The allergic reaction can be divided into two phases; the humoral (primary) response 
and the cell-mediated (secondary) response. The former refers to the initial 
encounter of the immune system with an allergen that triggers the production of IgE, 
and the latter refers to the secondary encounter of the immune system with the same 
(unprocessed) allergen, which triggers the release of chemical mediators responsible 
for clinical manifestation of allergy. 
 
 
1.4.3.1 Allergic sensitization  
Upon contact with the immune system, an allergen is engulfed and processed by 
antigen presenting cells (APCs) (Figure 1.1) and presented to naïve T-helper cells 
(Th0). This causes Th0 cells to differentiate into T-helper type 2 (Th2) cells in the 
presence of cytokines including Interleukin-4 (IL-4). The source of pro-allergic IL-4 is 
thought to be mast cells and basophils 34-36. Th2 cells then further secrete IL-4, IL-5 
and IL-13, which induce B-cell differentiation into plasma cells secreting IgE. The IgE 
ĂŶƚŝďŽĚŝĞƐƐƵďƐĞƋƵĞŶƚůǇďŝŶĚƚŽƚŚĞŚŝŐŚĂĨĨŝŶŝƚǇ&ĐɸZ/ƌĞĐĞƉƚŽƌƐŽŶŵĂƐƚĐĞůůƐĂŶĚ
basophils, thus sensitizing the immune system to the allergen (Figure 1.3) 2,20,37.  
 
 
1.4.3.2 Allergic reaction  
Upon secondary exposure to the same allergen, the allergen binds to the membrane 
bound IgE molecules on mast cells and basophils. Cross-ůŝŶŬŝŶŐŽĨ&ĐɸZ/ŽĐĐƵƌƐǁŚĞŶ
multiple IgE molecules interact with the same intact allergen, triggering 
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degranulation of mast cells and basophils, consequently releasing granule-derived 
vasoactive chemicals such as histamine, serine protease tryptase, lipid mediators 
such as leukotrienes, prostaglandins and platelet activating factor, chemokines and 
cytokines IL-4, IL-5 and IL-13 (Figure 1.3). These mediators cause allergic symptoms 
such as airway smooth muscle constriction (bronchoconstriction), mucus 
hypersecretion, mucus cell metaplasia, redness, rashes, sneezing and anaphylaxis 2,38-
42 . 
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Figure 1.3: Illustration of the allergic reaction. This figure outlines the steps of an 
allergic reaction. Once the initially encountered allergen is processed and presented 
by APCs to the Th0 cells, the Th0 cells differentiate into Th2 cells in allergic individuals. 
These Th2 cells then further secrete IL-4, IL-5 and IL-13, triggering B-cell 
differentiation into plasma cells. Subsequently, these plasma cells proliferate and 
ƉƌŽĚƵĐĞĞǆĐĞƐƐŝǀĞĂŵŽƵŶƚƐŽĨĂůůĞƌŐĞŶƐƉĞĐŝĨŝĐ/Ő͕ǁŚŝĐŚďŝŶĚƚŽƚŚĞ&ĐɸZ/ƌĞĐĞƉƚŽƌƐ
on mast cells and basophils, thus sensitizing the immune system to the allergen. Upon 
secondary encounter of the immune system with the same allergen, the allergen binds 
ƚŽŵƵůƚŝƉůĞ/ŐŚĞůĚŽŶŵĂƐƚĐĞůůƐĂŶĚďĂƐŽƉŚŝůƐ͘ƌŽƐƐůŝŶŬŝŶŐŽĨƚŚĞ&ĐɸZ/ƌĞĐĞƉƚŽƌƐ͕
as a result of interaction between a single allergen and multiple IgE molecules, 
triggers the release of mediators including histamine, causing an allergic 
inflammation.   
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1.5 Food allergy 
1.5.1 Food allergy overview 
Food allergy is one of the major allergies in today’s society. In a double-blind placebo 
controlled food challenge study conducted by Bock et al 43, 80% of the subject 
children were found to develop hypersensitivity symptoms to food allergens. In the 
developed world, 10% of children are affected by food allergies, while emerging or 
developing nations has a prevalence of 7% 44.  Occurrence of food allergy, like other 
atopic diseases, is rising and remains a problem throughout the world. It is a major cause 
of anaphylaxis and treated worldwide in emergency departments and hospitals, 
incurring a massive financial burden on the governments and the public 45. Food 
hypersensitivities include abnormal overreactions caused by intolerance to food 
(non-allergic) and allergic responses caused by an antigen in the food. Intolerance to 
food is due to some physiological abnormality, such as the lack of lactase which 
causes intolerance to lactose, whereas the allergic food reactions are mediated by 
IgE or non-IgE immune responses 45. Food allergies arise through the interaction 
between the intestinal immune system and food allergens present in the food that 
we consume on a daily basis. Allergenic foods include, but not limited to, eggs, 
peanuts, fish and milk. Antigens (allergens) present in these foods are responsible for 
IgE-mediated hypersensitivity reactions. For example, people allergic to milk react to 
ƚŚĞŵŝůŬǁŚĞǇƉƌŽƚĞŝŶĂůůĞƌŐĞŶɴ-lactoglobulin 46 and patients allergic to egg may be 
due to the egg white protein ovomucoid 47. Most of these allergens are glycoproteins 
that can withstand heat, acids and proteases 45, which explains why most allergenic 
foods remain allergenic even after cooking or processing.   
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1.5.2 Intestinal immune system 
Food allergies arise through the involvement of the intestinal immune system, which 
is the largest, most complex and one of the most important parts of the immune 
system. The intestine plays a major role by distinguishing between harmless antigens 
and harmful antigens, pathogens and microorganisms. The intestine is exposed to 
different types of antigens and microorganisms than any other body part and this 
highlights the importance of having a powerful immune system to protect this tissue 
and the rest of the body. Non-allergic individuals demonstrate induction of intestinal 
local and systemic immunological tolerance to non-pathogenic antigens, a 
phenomenon known as oral tolerance. Antigens entering the intestine initially 
encounter microfold cells (M-cells) prior to being presented to APCs for processing. 
M-cells are a type of enterocytes found on the epithelium and they lack the mucus 
layer. APCs then present the antigen to Th0 cells. In areas such as the lamina propia 
of the intestine, MHC class II enterocytes act as APCs and present the antigens to Th0 
cells. In both cases, the Th0 cells prime as intolerant cells, which causes B-cells to 
differentiate into IgA secreting plasma cells 48. A strong physical barrier, presence of 
antigen altering luminal enzymes, presence of specific regulatory T-cells in the 
lymphoid tissue of the gut, and the production and secretion of IgA capable of 
functioning in the hostile gut environment ensures immunosuppression of the 
intestinal immune system upon contact with an antigen and therefore causing 
antigen tolerance 49,50. Antigen tolerance is essential because eliciting an active 
immune response to harmless food antigens can be wasteful. Food intolerance or 
food allergy arises due to defects in one or more of the components responsible for 
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tolerance. As in many other allergies, genetic predisposition to produce IgE causes 
oral tolerance to fail or break down 51.  
 
 
1.5.3 Mucosal barrier of the intestinal immune system 
Intestinal immune system functions mainly on suppressing immunity rather than 
promoting it, as a measure of protecting the host from unnecessary damage 49. The 
mucosal barrier plays a major role in this immunosuppression. An understanding of 
the mucosal barrier is important for understanding the early phase of food allergy. 
The mucosal barrier comprises cellular and non-cellular components 52,53. Enzymes 
and proteases present in the mouth and the intestine, combined with bile salts, 
lipases and carbohydrate breakdown enzymes facilitate digestion of food, and, at the 
same time make it almost impossible for an immune response to occur. However, 
many food antigens survive these harsh conditions and, as a defence mechanism, the 
intestinal immune system recognises potentially harmful antigens and elicits either a 
suppressive or an aggressive immune response, depending on the 
invasiveness/capabilities of the antigen. The goblet cells of the glandular epithelium 
secrete a range of mucin glycoproteins that line the outer epithelium of the entire 
digestive tract 54. These mucin glycoproteins collectively form mucus, which traps 
antigens and stops them from gaining access to the underlying epithelium, a process 
known as non-immune exclusion. The mucus layer also harbours secretory IgA which 
prevents viral and bacterial binding to the epithelium. The maintenance and potential 
repairs of the epithelium are carried out by an association of secretory proteins 
known as trefoil factors 55,56. Neonatal studies using rat and mouse have shown that 
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there is an increased permeability of the intestine in the neonate, allowing antigens 
to pass in to the lamina propria of the gastro intestinal tract 57-60. The lamina propria 
harbours lymphocytes and therefore an antigen entering this layer can cause an 
active immune response. If a food antigen enters lamina propria, APCs may present 
the antigen to T-cells, causing antigen specific priming of B-cells. In such situations, 
intestinal immune system of an individual genetically predisposed to allergy produces 
antigen specific IgE. This highlights the importance of the mucus barrier in the 
developed gut at suppressing an immune response to antigens. 
 
The epithelium is the other barrier that prevents an antigen from reaching the lamina 
propria to cause an immune response. Epithelial cell membranes are impermeable to 
macromolecules and each cell is joined to another by tight junctions, allowing only 
ions to pass through via ion channels 61. An abnormality in tight junctions can allow 
passage of antigens in to the lamina propia and this permeability may be present in 
allergic patients 62,63. Furthermore, epithelial cells themselves can act as APCs, which 
present the antigens to T-cells in lamina propria 64-66. In a non-allergic individual, this 
antigen presentation activates regulatory T-cells, such as Th3, which secretes 
cytokines capable of suppressing an immune response 67-73. In an allergic individual, 
activation of immunosuppressing T-cells is defective and antigen presentation may 
activate Th2 cells involved in the production of cytokines involved in allergic reactions 
74-76. In addition, trans-epithelial antigen transport has been shown to be carried out 
by cytokines such as IL-4 75,76, suggesting possible allergic reactions in sensitized 
individuals. This information highlights the importance of immunosuppressive 
activity of mucosal barrier in the intestinal immune system. 
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1.5.4 The role of IgA in the intestinal immunosuppression 
Immunoglobulin A is an antibody that inhibits bacterial and viral attachment to the 
intestinal epithelium. IgA is the most abundant antibody in the body, however, unlike 
other antibodies, it does not involve itself in the complement system, which causes 
inflammation. IgA assists in trapping antigens in the mucus layer and it also facilitates 
expulsion of antigens from the body 77-79. A glycoprotein known as the secretory 
component (SC) envelops the fragment crystallisable (Fc) region of IgA and covers the 
proteolytic cleavage sites, thus protecting IgA from proteases and other enzymes 
present in the intestine. It is reported that IgA deficiency cause high levels of food-
antigen-specific antibodies in serum 79. This further indicates the ability of IgA to 
suppress immune responses. The IgA system does not fully develop until the age of 
4, therefore it can be suggested that, when coupled with defects in the mucosal 
barrier during development, priming of T-cells and B-cells to food allergens/antigens 
occur. This explains why food allergy is common among children than in adults. 
 
 
1.5.5 Food allergens and types of food allergies 
Food allergies arise through the interaction between the intestinal immune system 
and food allergens present in the food that we consume on a daily basis. Allergenic 
foods include, but not limited to, eggs, peanuts, fish and milk. Table 1.1 highlights the 
prevalence of different food allergies in the United States. Food allergies also seem 
to be the major cause for conditions such as asthma, eczema and respiratory allergies 
in children when compared to non-food allergies 80.  Antigens (allergens) present in 
these foods are responsible for IgE-mediated hypersensitivity reactions. For example, 
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people allergic to peanuts react to the peanut seed storage protein Ara h 1. These 
allergens are glycoproteins that can withstand heat, acids and proteases 51, which 
explains why most allergenic foods remain allergenic even after cooking or 
processing.  A large number of plant and animal proteins responsible for food allergy 
have been identified and characterized. Majority of the plant food allergens belong 
to the cupin and prolamin superfamilies, profilin and plant defense proteins. Profilin 
allergens shows high cross-reactivity to pollen and other food allergens 51. When 
compared to plant allergens, animal food allergens are less diverse and have less 
cross-reactivity with other allergens. A few allergens include parvalbumin in fish, 
ovomucoid in eggs and alpha S1-casein in milk. A common component present in two 
or more allergens may cause cross-reactivity between the allergens. For example, 
serum albumin may sensitize an individual to both cow’s milk and beef, and 
potentially to other related meat products 81. An understanding of the structure and 
function of allergens themselves is important in many frontiers of allergy research. 
Allergens of interest for this project are reviewed and outlined further in this Chapter.    
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Table 1.1: Prevalence of food allergies in the United States (Table adapted from: 
Sampson 2004 51). 
Food Young Children (%) Adults (%) 
Milk 2.5 0.3 
Egg 1.3 0.2 
Peanut 0.8 0.6 
Tree Nuts 0.2 0.5 
Fish 0.1 0.4 
Shellfish 0.1 2 
Overall 6 3.7 
 
 
 
 
 
Figure 1.4: Percentage of children in the United States affected by asthma, eczema 
and respiratory allergy caused by food and non-food allergy. (Figure adapted from: 
Branum and Lukacs 2008 80). 
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1.6. Egg allergy 
1.6.1 Egg allergy overview 
Hypersensitivity to the chicken (Gallus gallus) egg is a widespread disorder mainly 
affecting children, with a recent meta-analysis suggesting a prevalence of 0.5-2.5% of 
children 82. It is the second most common food allergy next to cow’s milk allergy and 
it is the most common allergy among children with atopic dermatitis 83-85. According 
to an Australian study conducted by the Murdoch Children’s Research Institute 
(MCRI), 8.9% of infants are allergic to eggs 86. However, egg allergy is not limited to 
children, with cases that have been reported of adult onsets 87. Children allergic to 
egg generally grow out of the condition by school age 88,89.   Hypersensitivity to 
allergens present in the eggs causes conditions such as itching, atopic dermatitis, 
bronchial asthma, vomiting, angio-oedema, rhinitis, conjunctivitis, laryngeal oedema, 
chronic urticaria and allergic eosinophilic gastroenteritis 90-93. Egg allergic patients 
produce IgE specific to sequential (linear) and conformational epitopes of egg 
allergens. However, some sequential epitopes recognized by persistent egg allergic 
patients are not recognized by patients with transient egg allergy 94. This suggests a 
difference in severity of allergic reaction between persistent and transient egg 
allergic patients. Anaphylaxis can also occur in some individuals, however this 
depends on the processing of the egg. This may be due the reduction in IgE reactivity 
in heated egg, possibly due to the disruption of conformational IgE binding epitopes 
in the egg allergens. It has also been found that eggs heated on its own are more IgE 
reactive when compared to eggs heated in the presence of another substance such 
as wheat 95,96. This suggests that an egg allergic patient may show less reactivity to 
food items such as cakes or muffins than to fried or baked egg. 
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The prevalence of egg allergy and the aforementioned conditions highlight the 
importance of egg allergy research. An understanding of the different egg allergens, 
egg allergy diagnosis methods and treatment methods are imperative for future 
research.  
 
 
1.6.2 Allergy to egg white 
Egg allergy is mainly caused by 4 of the many different proteins that make up the egg 
white 97,98. However, these may not be the only allergenic egg white proteins, 
particularly in the wake of new discovery of a large number of minor proteins in the 
egg white 99. These allergens are namely ovomucoid, ovalbumin, ovotransferrin and 
lysozyme, with ovomucoid being the most allergenic of the four and ovalbumin being 
the most abundant (Table 1.2). A few studies have identified egg yolk allergens, such 
ĂƐɲ-livetin and YGB42, however these were not a focus of this project. The four 
aforementioned egg white allergens are produced by tubular gland cells, which 
comprise the majority of the magnum portion of the chicken oviduct 100,101. Induction 
of expression of these allergens are highly dependent on estrogens and this has been 
demonstrated in studies involving chicks, in which upon administration of estrogens 
the tubular gland cells started producing the allergenic proteins 102-104. Egg allergy can 
be caused by consumption of raw or cooked eggs, however a study conducted by 
Lemon-mule et al 105 indicates that majority of the egg allergy patients are tolerant 
to heated eggs, although the allergenicity of proteins are not exclusively dependent 
on their resistance to heat and enzymes 106. The same study shows that continued 
exposure to the heated egg is associated with immunological changes similar to the 
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changes observed in developing tolerance to raw eggs. These immunological changes 
include increasing IgG4 levels and a reduction in wheal sizes in egg white specific skin 
prick testing (SPT). IgA and IgA2 may also be of importance in developing tolerance to 
egg white 107. However, more studies involving a larger number of subject individuals 
are necessary to confirm the effects of heating on egg white allergens and the 
resulting IgE reactivity in patients.  Given that the structure of the proteins may play 
a crucial role in IgE binding and eliciting an allergic response 108, an understanding of 
the structure and function of each of the four allergens is essential for egg allergy 
research.  
 
 
Table 1.2: The four main egg white allergens and their properties (Table adapted 
from: Caubet and Wang 201183). 
Allergen Egg 
white 
(%) 
Molecular 
weight 
(kDa) 
Carbohydrate 
(%) 
IgE binding activity 
(Digestive) 
Allergenic 
activity 
Heat 
Treated 
Enzyme 
Treated 
 
Ovomucoid 11 28 25 Stable Stable +++ 
Ovalbumin 54 45 3 Unstable Unstable ++ 
Ovotransferrin 12 76.6 2.6 Unstable Unstable + 
Lysozyme 3.4 14.3 0 Unstable Unstable ++ 
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1.6.3 Allergens in the egg white 
1.6.3.1 Ovomucoid (Gal d 1 or OVM) 
Ovomucoid is the most allergenic and the dominant allergen found in the chicken egg 
white. Constituting 11% of the total egg white, ovomucoid is a trypsin inhibitory 
glycoprotein with a molecular weight of 28 kDa 109,110. It is comprised of 186 amino 
acids arranged in three tandem domains, each approximately 60 amino acids in 
length, containing nine intra-domain disulfide bonds and five carbohydrate side 
chains. The trypsin inhibitory activity is limited to the second domain, in which a 
putative reactive site is present for trypsin inhibition 109,111. The arrangement of the 
three domains is also similar to the pancreatic trypsin inhibitor. Previous studies have 
indicated that allergenicity or IgE binding capacity of ovomucoid is not affected 
considerably by heat and proteinase activity 94,112. This suggests that the structure of 
the IgE binding epitopes of ovomucoid is mainly linear, however there are some 
conformational epitopes present in all domains 110. This suggests that cooking of eggs 
may have little or no effect on the allergenicity of ovomucoid. In addition, the third 
domain of ovomucoid shows more IgE binding activity when compared to the other 
two domains 113. It can be suggested that the third domain would be an ideal target 
for studies focusing on the production of hypoallergenic variants of ovomucoid that 
may be used for treatment strategies such as immunotherapy, which forms the 
overall aim of Chapter 4 of this thesis.    
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1.6.3.2 Ovalbumin (Gal d 2 or OVAL) 
Ovalbumin is the most abundant (58%) protein in the egg white and it is considered 
to be the second most important allergen in egg hypersensitivity. Ovalbumin is a 
water soluble glycoprotein made up of 385 amino acids and has a molecular weight 
of 45 kDa 114. Mine and Zhang 115 reported that carboxymethylation, urea treatment 
or heat denaturing at 95°C of ovalbumin does not significantly affect its IgE binding 
capacity. This suggests that anti-ovalbumin IgE primarily recognizes linear epitopes 
than conformational epitopes. Similar to ovomucoid, this indicates that cooking may 
not significantly affect the allergenicity of ovalbumin, however digestive enzymes 
may affect the allergenecity. The major function of ovalbumin in the chicken egg is 
currently unknown, however it is a member of the serpin family of proteins, although 
it is incapable of inhibiting protease activity. This lack of protein inhibitory activity is 
explained by the absence of an important serpin conformational change in the 
reactive centre loop of ovalbumin 116. Ovalbumin is also known to exhibit biological 
functions including antibacterial and immunomodulating activities 117. The 
antibacterial properties are however not exerted by intact ovalbumin, instead, 
proteolytic digestion of the protein has shown to produce peptide fragments capable 
of acting against organisms such as, but not limited to, Bacillus subtilis and Candida 
albicans 118. It is also believed that ovalbumin may act as a source of amino acids for 
embryonic development 111.  
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1.6.3.3 Ovotransferrin (Gal d 3 or OVT) 
Transferrins are a group of iron-binding proteins found in vertebrates that has 
structural and functional similarities among each member. The molecular mass of 
these monomeric glycoproteins is about 76.6 kDa, and a molecule of transferrin can 
bind to two Fe3+ with high affinity. Ovotransferrin is one of the members of 
transferrins expressed in the chicken oviduct. Expression of ovotransferrin in the 
oviduct is under steroid control and it differs from serum hen transferrin only by an 
attached carbohydrate 119,120. In vitro, ovotransferrin exhibits antimicrobial and 
immunomodulating activities 117. Ovotransferrin is capable of penetrating the outer 
membrane of Escherichia coli, allowing selective penetration of ions which causes 
decadence of electrical potential of the cell, which in turn halts the ability of the 
bacteria to reproduce (bacteriostatis) 121. Some research has been conducted to 
study the changes in allergenicity and conformational structure of ovotransferrin 
when heated. A study conducted by Tong et al 122 showed that the allergenicity of 
ovotransferrin correlated with the structural changes caused by heating. Unfolding 
of the structure caused an increase in allergenicity and cleavage and rearrangement 
of disulfide bonds lead to a decrease in allergenicity 122. This suggests that 
ovotransferrin is one of the allergens responsible for hypersensitivities caused by 
consumption of cooked eggs as well as raw eggs. Therefore, it is wise to suggest that 
research should be focused on ovotransferrin as much as on ovomucoid and 
ovalbumin.            
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1.6.3.4 Lysozyme (Gal d 4 or LYS)  
Lysozyme, 14.3 kDa in size, is an enzyme that exhibits anti-microbial activity in the 
chicken egg, thus providing protection from potential microbial hazards. It is known 
to exert lytic activity on cell walls of microbes, therefore it is widely used in 
pharmaceutical products 123. It is also used in various food products such as cheese 
90,124, which therefore poses a risk to egg allergic patients. Structurally, lysozyme 
contains conformational and sequential epitopes and it has in vitro biological 
functions such as antibacterial, antiviral, immunomodulating and antitumor activities 
117,124. Although lysozyme is less allergenic than ovomucoid and ovalbumin 83, the 
high occurrence in many food and pharmaceutical products makes it an important 
target in egg allergy research.         
 
 
1.6.4 Allergy to egg yolk 
As mentioned earlier, hypersensitivity to chicken’s egg is not only caused by the egg 
white. Chicken’s egg yolk is also responsible for causing IgE-mediated allergy, 
although with much lower prevalence than egg white hypersensitivity. Unlike allergy 
to egg white, which is commonly seen in young children with atopic dermatitis, 
allergy to egg yolk mostly affects during the adulthood. However, underlying 
immunological reactions to egg yolk allergens are mainly IgE-mediated, and usually 
produce symptoms such as urticaria, vomiting, abdominal pain and diarrhoea, as in 
allergy to egg white 125-127. Egg yolk allergens include chicken serum albumin (ɲ-livetin 
or Gal d 5), yolk glycoprotein 42 (YGP42 or Gal d 6) and potential allergens known as 
apovitellenin I, apovitellenin VI and phosvitin 92,128,129. 
26 | P a g e  
 
Chapter 1 
Egg yolk allergy is sometimes caused through an IgE-mediated hypersensitivity 
disorder known as the bird-egg syndrome, in which an individual is initially sensitized 
to inhalant avian antigens derived from sources such as bird’s blood serum, feathers, 
droppings and dander 126 (Figure 1.5). This is different to allergen cross reactivity in 
which a patient allergic to a certain allergen is reactive to homologous or non-
homologous allergens from the same or other species 130,131. Majority of patients with 
bird-egg syndrome claim to have regular exposure to pet birds or poultry where 
sensitization to airborne avian allergens take place, which then proceed to egg yolk 
allergy. Patients suffering from bird-egg syndrome suffer from both respiratory and 
gastrointestinal allergic symptoms such as asthma, rhinoconjunctivitis, edema, 
diarrhoea and vomiting. However, unlike allergy to egg white, which is predominantly 
seen in children with atopic dermatitis, bird-egg syndrome mainly affects adults with 
an obvious gender predisposition where majority of patients tend to be females 126. 
In addition, allergens produced by birds at workplace may also increase IgG levels in 
excess and can lead to allergic alveolitis. Currently, these IgG levels can be quantified 
and qualitatively evaluated using the UniCAP system, a type of ImmunoCAP 132.   
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Figure 1.5: An illustration of the Bird-Egg syndrome. An individual develops allergy 
to hen’s egg yolk following exposure to birds, where sensitization to inhalant avian 
allergens takes place resulting in respiratory allergy symptoms. The cross reacting 
allergen which is responsible for producing both respiratory and gastrointestinal 
allergy symptoms in bird-ĞŐŐ ƐǇŶĚƌŽŵĞ ŝƐ ŝĚĞŶƚŝĨŝĞĚ ĂƐ ɲ-livetin (chicken serum 
albumin), a type of serum albumin present in birds and in the egg yolk as well.  
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1.6.5 Diagnosis of egg allergy 
Different diagnostic techniques are used for successful diagnosis of egg allergy. 
Similar to other allergic conditions, the foremost step in egg allergy diagnosis is 
assessment of the medical history of the patient for potential evidence for clinical 
reactivity to eggs and physical examination. This helps to determine whether the 
patient has experienced adverse reactions to eggs and the potential involvement of 
the immune system 133,134. The medical history examination essentially takes into 
consideration the allergic conditions the patient has been previously exposed to and 
evaluates these information with the current symptoms, the type and the amount of 
food ingested and the timing of the reaction. The physical examination involves 
testing for gastrointestinal symptoms and detection of atopic features in the body. 
The next step involves the use of in vitro or in vivo tests such as skin prick tests (SPT) 
and RAST/ImmunoCAP tests 135,136. These tests assist in determining if the patient 
possesses egg-allergen-specific antibodies in their immune system. Although these 
tests provide an estimation of allergen specific IgE in the patient, which positively 
correlates to the clinical reaction (wheal formation), they fail to fully ascertain 
diagnosis of clinical symptoms of egg allergy. Increasing levels of IgE may predict the 
presence of an allergy, however, there is no universal agreed level of IgE to confirm 
the condition as the IgE levels can differ between different individuals. This may also 
be due to the discrepancies between the testing method, testing criteria and 
prevalence of the allergy between studies. However, a recent study conducted by 
Sicherer et al 137 has further confirmed the significant predictive capacity of IgE as a 
marker in egg allergy. They also report of a web-based calculator that uses an 
algorithm, which is based on novel findings of egg specific IgE, that may allow 
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clinicians to predict the likelihood of the resolution or persistence of the disease. 
Supplementary studies on IgE, as a reliable egg allergy marker, may provide useful 
information for the development of effective diagnostic approaches.          
 
In addition to SPTs and ImmunoCAP tests, elimination diets and oral food challenges 
can be used for the diagnosis of egg allergy. In an elimination diet diagnosis, once the 
patient is suspected of being allergic to eggs, a diet excluding eggs is followed to study 
the ability of the patient to maintain the diet without any hypersensitive reactions 
over a period of time 138. In an oral food challenge, the patient is asked to eat/ingest 
a small amount of egg to reproduce the hypersensitivity symptoms. It is also done in 
a dose dependant manner where the egg ingestion is increased until the symptoms 
are observable. Oral food challenge can be done openly, single-blinded, double-
blinded and placebo controlled, with the latter being considered the gold standard in 
diagnosis of major food allergies because it provides information such as the amount 
of food needed to cause an allergic reaction and the extent of the patient’s reaction 
139. However, the safety of oral food challenge has not been well established or 
scrutinized and may not be ideal if the patient is known to be anaphylactic to eggs, 
therefore much care should be taken when implementing this method. Overall, 
medical history and physical examination, SPTs or ImmunoCAP tests and oral food 
challenge combined together provides successful diagnosis of egg allergy (Figure 1.6), 
which can lead to the implementation of treatment strategies for the condition. 
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Figure 1.6: A typical diagnosis procedure of egg allergy. Once a suspected reaction 
to egg is reported, a patient undergoes the appropriate steps shown in this figure. 
(Figure adapted and modified from Eggesbo et al 2001 140). 
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1.6.6 Treatment of egg allergy 
As for other food allergies, currently there is no temporary or permanent cure for egg 
allergy. Upon successful diagnosis for egg allergy, the most effective treatment is 
strict dietary avoidance of eggs and products containing traces of eggs. Eggs are an 
important source of nutrients and thus strict avoidance may cause malnutrition or 
eating disorders. The egg yolk is known to carry numerous health benefits, but since 
it is impossible to fully separate the egg yolk from the egg white without allergen 
contamination, complete avoidance of the egg is the only option, which results in 
reduced or no uptake of this important nutrient source 141,142. As a part of avoidance 
of eggs, it is important to educate patients how to identify potential egg allergens or 
traces of eggs in various food products such as cakes, biscuits, cereal and breads, as 
well as educate them about foods/supplements that can potentially replace eggs in 
their diet. This may include involvement of a dietician for patients with dietary 
limitations, such as vegetarians and multiple food allergic patients, to ensure proper 
intake of vital nutrients.  
 
In addition to dietary avoidance, egg allergic patients are required to avoid vaccines 
and medications derived from eggs. For example, influenza vaccine is developed in 
chicken extra embryonic fluid and used extensively worldwide every year 83. Although 
the majority of egg allergic patients may not have adverse effects upon 
administration of influenza vaccine 143, it is important to take caution to avoid severe 
or anaphylactic reactions in the individuals that may well react to the egg allergens 
144. These patients should receive the vaccine via a desensitization protocol upon 
diagnosis with a positive skin test. Yellow fever vaccine is another vaccine derived 
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from chicken egg, with few reported cases of anaphylaxis upon administration 145. 
Moreover, there are reported cases of anaphylaxis due to the use of lipid emulsions 
and pharmaceutical products derived from eggs 146-148. Occurrence of egg allergens 
in our daily diet, vaccines and other pharmaceutical products complicates strict 
avoidance of eggs. Therefore, alternatives are required to treat patients in case of 
accidental exposure to the egg allergens.  
 
In allergic conditions such as asthma, SIT is used to induce tolerance to the allergens. 
This method essentially involves administration of small amounts of an allergen to 
the patient, with slight increments, to induce tolerance to that particular allergen. A 
study conducted by Buchanan et al 149 indicates that oral immunotherapy (OIT), a 
form of SIT, may provide a promising treatment strategy for patients without 
anaphylactic history to eggs. The authors suggest that OIT may even cause a shift in 
food allergy treatment paradigm from allergen avoidance to active immunotherapy. 
This is further supported by a recent study in which OIT showed successful 
desensitization to eggs, however tolerance was maintained only in 1/3 of the study 
population following discontinuation of the egg diet 150. However, extreme care 
should be taken during immunotherapy to avoid potential anaphylactic reactions. In 
case of an accidental exposure to egg allergens, and acute anaphylaxis, the most 
common treatment is administration of the hormone and neurotransmitter 
epinephrine 51,151,152. Upon administration of epinephrine at the right dosage and 
appropriate route, peripheral vasodilatory effects and bronchoconstriction caused by 
histamines and other chemical mediators released by allergic reactions are reversed, 
conditions such as urticaria, erythema and angioedema are reduced and further 
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release of chemical mediators are suppressed. Currently, epinephrine is available for 
self-administration by auto-injectors such as Epipen. In summary, allergen avoidance, 
SIT and administration of epinephrine provides temporary relief from egg allergic 
reactions. However, these methods can be costly and may have negative effects on 
the lifestyle of the patient. Therefore, it is imperative to investigate and research on 
permanent and affordable ways to treat egg allergy.    
 
 
1.7 Future directions of egg allergy - Cracking the egg 
1.7.1 Production of recombinant allergens and hypoallergens 
Various research teams around the world are involved in finding answers or cures for 
different types of allergies. Among these, egg allergy research is no exception. 
Development of hypoallergenic variants of the egg allergens is given utmost priority 
by many researchers, because hypoallergens may be used in immunotherapy to 
desensitize egg allergic patients. In fact, a group from University of Guelph in Canada 
has studied the efficacy of an engineered ovomuoid third domain at desensitizing a 
murine model 153. This hypoallergenic third domain has been produced by directly 
targeting the IgE biding sites of that domain. A similar approach has been tested in 
2004 by an Australian research team in which they successfully developed a T-cell 
reactive hypoallergenic variant of the latex allergen, Hev b 6.10, by targeting the 
disulphide bridges of that allergen 154, therefore it can be suggested that similar 
methods can be used for the development of hypoallergenic variants of egg allergens. 
A study conducted by Chen et al 155  confirmed the efficacy of two house dust mite 
hypoallergens for immunotherapy and recommended one hypoallergen for vaccine 
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production. Another study conducted on the fish allergen parvalbumin has 
demonstrated that a hypoallergenic variant of the allergen can increase the 
production of IgG antibodies in the fish allergy patients, which binds to parvalbumin 
from various fish types, thus reducing binding of the allergens to IgE antibodies, 
which in turn reduced allergic reactivity 156. In addition to the aforementioned 
methods, it has been recently reported that allergen conjugation with reducing 
sugars through the Maillard reaction may help attenuate allergic reactivity to 
allergens 157.  Production of IgE reactive recombinant variants of egg allergens is also 
important in diagnostic methods such as SPT and treatment methods such as SIT. A 
few hundred allergens have been expressed in recombinant systems, these include, 
but not limited to birch pollen, dust mites, peanuts and egg allergens 98,158-161. 
Recombinant proteins offer accurate characterisation of the immunological 
properties of allergens, eliminate the contamination issues present in naturally 
isolated allergens and paves the way for development of immunotherapy and 
diagnosis methods with high pharmaceutical quality. Although the current results 
seem promising, all of the research conducted on hypoallergen and IgE reactive 
recombinant allergen production requires clinical trials before administration to 
patients.  
 
 
1.7.2 Production of hypoallergenic chicken eggs 
The focus of egg allergy research should not be limited to the aforementioned 
strategies and invention of drugs/vaccines. The advanced molecular and genetic 
techniques used in other medical research and life sciences can be utilised for tackling 
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egg allergy from the root of the cause. Genetic manipulation and protein engineering 
have become the most successful tools in producing disease free crops and animal 
products. A team in New Zealand has developed a transgenic calf lacking the milk 
allergen ɴ-lactoglobulin using RNAi technology 46. dŚĞƉƌŽƚĞŝŶɴ-lactoglobulin causes 
mild to severe allergic reactions in individuals, especially children, sensitised to this 
protein. Using RNAi technology, the research team developed a transgenic calf that 
ůĂĐŬĞĚƚŚĞɴ-lactoglobulin protein in milk that it produced after hormonal induction. 
The lack of a highly effective treatment method for chicken egg allergy highlights the 
importance of utilisation of similar techniques to produce eggs that lack the allergic 
components. As in cow’s milk allergy project mentioned above, it is possible to simply 
knockdown the expression of the allergens in the chicken eggs using RNAi technology, 
however knockdown of the four allergens may have negative effects as these 
proteins comprise the majority of the egg white proteins and may reduce the 
nutritional value of the eggs. Knockdown of the allergen genes and introduction of 
hypoallergenic variants to replace the depleted natural allergens appear to be more 
realistic and a feasible approach to produce hypoallergenic eggs.  
 
Production of hypoallergenic variants of proteins involves introduction of mutations 
to the IgE binding epitopes of the allergen and these mutations may alter the function 
of the protein. This is not an issue for hypoallergen production for SIT and SPT, 
however for the purpose of introducing hyapollergens into the genome of a chicken 
requires functional hypoallergens that can replace the normal allergens to produce 
functional eggs that can develop into hypoallergenic chicken. A study conducted by 
Resnik and Inga 162 has demonstrated that mutagenesis on the transcription factor 
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p53 has produced variants with different functions, however a large number of 
mutants retained their function. This is a concept known as conservative evolution in 
which protein function is retained with no detrimental effects on the organism after 
a mutation that changes an amino acid 163. This suggests that it is possible to alter the 
IgE binding epitopes of the egg white allergens and yet retain the overall protein 
function. A hypoallergenic variant of an egg white allergen can then be used to 
produce transgenic chicken. Production of transgenic chickens has been successfully 
done by some research groups. The methods used to produce transgenic chicken 
include gene gun technology, micro-injection, gene delivery to germ line and embryo 
and the use of nano-particles as gene carriers 164. Chicken primordial germ cells 
(PGCs), the precursors for sperm and eggs, are useful for introduction of exogenous 
genes into chickens and this technique is well established 165,166. It can be suggested 
that a germ line of PGCs carrying the hypoallergen may be introduced to a developing 
embryo to establish a transgenic model, and at the same time utilize RNAi to disrupt 
natural allergen expression.  
 
RNAi is not the only option for the development of hypoallergenic chicken eggs. The 
advancement of techniques such as CRISPR/Cas9 (clustered regularly interspaced 
short palindromic repeats/Cas 9) 167 based genome editing may also allow precision 
engineering of the chicken genome to edit/change the IgE binding epitopes to 
produce transgenic hens capable of producing hypoallergenic eggs. Establishment of 
a hypoallergenic lineage of chickens that can lay hypoallergenic eggs promises a 
solution for egg allergy patients struggling to completely avoid eggs and/or undergo 
immunotherapy.  If any of the current research on egg allergy proves successful in 
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the future, a large number of families will benefit by being less apprehensive about 
eggs or egg contaminated products.   
 
 
1.8 Synopsis and hypotheses  
In summary, the prevalence of egg allergy and the lack of highly effective treatment 
and management methods demand more research being conducted to develop 
effective solutions for this condition. Such therapeutics or novel management 
strategies will significantly improve the quality of life of egg allergic patients while 
reducing the burden on the governments and societies. This formed the overall 
hypotheses and aims of subsequent chapters of this thesis, as outlined below.  
 
Firstly, it was hypothesized that cloning and expression of cDNA of four major egg 
white allergens in Escherichia coli (E.coli) will allow production of IgE reactive 
recombinant versions that may be used in future diagnosis and treatment of egg 
allergy. Chapter 2 of this thesis aimed at cloning and expression of all four egg white 
allergens in E.coli to produce recombinant variants of the allergens and Chapter 3 
was aimed at confirming the IgE reactivity of the recombinant allergens produced in 
Chapter 2 using egg allergic patients’ sera.   
 
Secondly, it was hypothesized that disruption of cysteine-cysteine disulphide bridges 
using site-directed mutagenesis will allow production of a recombinant 
hypoallergenic variant of the major egg white allergen ovomucoid (Gal d 1) that may 
be used in immunotherapy for highly sensitive egg allergic patients. Chapter 4 of this 
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thesis aimed at disrupting cysteine-cysteine disulphide bridges in the third domain of 
ovomucoid to produce a hypoallergenic variant and elucidate its IgE reactivity using 
egg allergic patients’ sera.  
 
Thirdly, it was hypothesized that genetic engineering and manipulation using CRISPR-
Cas9 and RNAi will allow knockout/knockdown of ovomucoid in chicken as a 
hypoallergenic egg production strategy. The first aim of Chapter 5 of this thesis was 
to knockout ovomucoid from the genome of a chicken fibroblast cell line. The second 
aim of Chapter 5 was to knockdown ovomucoid in chicken embryos to develop 
chickens with reduced ovomucoid expression to scrutinize the feasibility of a 
complete knockout of the gene in chickens.       
 
Chapter 6 of this thesis broadly discusses the importance of the findings presented in 
Chapters 2-5 in relation to current understanding and position of egg allergy. This 
chapter also provides future directions of the current project and implications for 
future egg allergy research, followed by concluding remarks.      
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CHAPTER 2 
 Cloning and expression of major 
egg white allergens – from oviduct 
to recombinant protein 
 
Publication: 
Dhanapala P, Doran T, Tang M, Suphioglu C (2015): Production and 
immunological analysis of IgE reactive recombinant egg white allergens 
expressed in E. coli. Molecular Immunology: 65: 104-112.  
(This publication includes findings from Chapter 2 & 3 of this thesis) 
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2.1 Introduction 
Allergy to chicken (Gallus gallus) egg is a widespread condition affecting 0.5-2.5% of 
children worldwide 82. It is known to be the predominant food allergy among children 
with atopic dermatitis and, among all children, it is the second most common food 
allergy 83-85. A study conducted by the Murdoch Children’s Research Institute (MCRI) 
in Australia revealed that 8.9% of infants are allergic to eggs 86. Symptoms and 
conditions caused by hypersensitivity to chicken egg include, but not limited to, 
atopic dermatitis, bronchial asthma, IgE-mediated egg allergy (with urticarial, 
angioedema, vomiting, diarrhoea and anaphylaxis), and allergic eosinophilic 
gastroenteritis (with pain, irritability, colic, and possibly oesophageal stricture and 
food impaction) 90-93.  
 
Egg allergy is mainly caused by 4 major proteins within the egg white 97, namely 
ovomucoid (Gal d 1  or OVM), ovalbumin (Gal d 2 or OVAL), ovotransferrin (Gal d 3 or 
OVT) and lysozyme (Gal d 4) or LYS), with ovomucoid being the most allergenic of the 
four and ovalbumin being the most abundant. These proteins are produced in the 
magnum portion of the chicken oviduct, specifically by tubular gland cells 100,101. 
Previous studies involving administration of oestrogen into chicks have shown that, 
post injection of oestrogen, the chicks produced the allergenic proteins, indicating 
that expression of the allergens present in the egg white are highly dependent on 
oestrogen 102-104. Consumption of raw or cooked egg may cause allergic reactions, 
although the majority of patients with egg allergy are tolerant to cooked egg 105.  
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Production of recombinant versions of natural allergenic proteins is an option for 
treating allergies since these recombinant proteins can be used in treatment 
methods such as allergen SIT and diagnostic methods such as skin prick tests (SPT). It 
is a way of producing allergens with high purity without contamination from other 
allergens since individual proteins are expressed separately in host systems. SIT 
essentially involves desensitization of an individual to an allergy by gradually 
administering the allergen to the patient. The first study of desensitization was 
reported in 1911 by Leonard Noon, in which grass pollen extract was used for 
desensitization of hay fever 168. This methods has since then been used in SIT for other 
types of allergies 169-172. However, the use of crude extracts of allergen sources has 
shortcomings which lead to further complications, sometimes fatal, in the patient 160. 
These shortcomings include, but not limited to, contamination from other allergens 
or proteins and other non-allergenic material, underrepresentation of the allergen in 
the extract, changes in allergenic activities of the allergen and batch to batch 
variations during and after preparations 160. Therefore, recombinant production of 
allergens is an excellent option for SIT and SPT.         
 
Production of recombinant proteins in host systems such as Escherichia coli (E. coli) 
has revolutionized biomedical science for many years. The need to utilize large 
amounts of animal or plant material to isolate small volumes of a single protein can 
be considered ancient, simply because of the myriad of advantages offered by 
recombinant protein expression. E. coli has been an excellent choice for this purpose 
because of a number of reasons. It has extremely fast growth kinetics which is 
incomparable to other organisms, allowing it to propagate at a steady yet very fast 
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rate provided necessary media and ideal growth temperatures are given. E. coli also 
allows production of high density cultures for isolation of larger quantities of 
recombinant proteins. Media required to grow E. coli is also easy to prepare using 
inexpensive constituents. Different strains of E. coli also allow easy and efficient 
transformation of exogenous DNA. All of these features and the vast knowledge 
about the physiology of E. coli make it an excellent workhorse for recombinant 
protein production 173,174.         
 
This chapter aimed at producing recombinant versions of the major egg white 
allergens OVM, OVAL, OVT and LYS using E. coli as a host system. For this purpose, it 
was necessary to isolate mRNA coding the allergens from a chicken oviduct and 
convert the mRNA into cDNA, which would be cloned into an expression vector. The 
allergen-vector constructs were transformed into E. coli for protein expression. The 
expressed proteins were then detected/identified using immunoassays.    
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2.2 Methods 
2.2.1 mRNA extraction from oviduct  
Animal experimentation/sampling was conducted under protocol AEC1496, approved 
ďǇƚŚĞƵƐƚƌĂůŝĂŶŶŝŵĂů,ĞĂůƚŚ>ĂďŽƌĂƚŽƌǇ;^/ZK-AAHL) Animal Ethics Committee 
and in accordance with the Australian code of practice for the care and use of animals 
for scientific purposes. 
 
A 6-month old egg laying hen was humanely euthanized by gassing with CO2 at the 
animal facility at CSIRO-AAHL. The oviduct was carefully dissected out from the hen 
(Figure 2.1). The magnum portion of the oviduct was incised and submerged in 
RNAlater and transported to the laboratory. Upon delivery, the magnum was snap 
frozen with liquid nitrogen and ground into a fine powder using a sterile, pre-chilled, 
mortar and pestle, making sure the powder does not thaw in due course. The powder 
was homogenised according the instructions on the Oligotex Direct mRNA kit 
(Qiagen, Cat No. 72202). Essentially, 700 mg of the powder was measured and mixed 
ǁŝƚŚϰŵ>ŽĨďƵĨĨĞƌK>ϭĐŽŶƚĂŝŶŝŶŐϯϬђ>ͬŵ>ɴ-mercaptoethanol. 700 μL of the mix 
was loaded onto a QIAshredder spin column placed in a 2 mL collection tube and 
homogenised by centrifuging for 2 minutes at 13,000 rpm in a bench top 
microcentrifuge. 1.2 mL of buffer ODB was added to the homogenised lysate and 
centrifuged for 3 minutes at 13,000 rpm. The supernatant was transferred to a new 
RNase-free 2 mL tube and 120 μL of Oligotex suspension (pre-heated at 37°C, 
vortexed and cooled to room temperature) was added. The mix was incubated at 
room temperature for 10 minutes and centrifuged for 5 minutes at 13,000 rpm, and 
the supernatant was discarded. The pellet was resuspended in 100 μL of buffer OL1 
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and 400 μL of buffer ODB was added and incubated at 70°C for 3 minutes and then 
placed at room temperature for 10 minutes. The Oligotex-mRNA complex was then 
pelleted by centrifuging at 13,000 rpm for 5 minutes and the supernatant was 
removed by pipetting. The pellet was resuspended in 350 μL of buffer OW1 by 
pipetting and the suspension was transferred into a small spin column and placed in 
a microcentrifuge tube. The tube was then centrifuged at 13, 000 rpm for 1 minute 
and the flow-through was discarded. The spin column was transferred to a new 
RNase-free 2 mL tube and 350 μL of buffer OW2 was added, and centrifuged at 
13,000 rpm for 1 minute and flow-through discarded. Residual buffer was removed 
by briefly re-centrifuging. The spin column was transferred into a fresh RNase-free 
tube and the resin was resuspended in 100 μL of hot (70°C) buffer OEB. The mRNA 
was eluted by centrifuging the microcentrifuge tube containing the column at 13, 000 
rpm for 1 minute. The mRNA concentration was measured on a Thermo Scientific 
Nano Drop 3300 spectrophotometer (hereafter referred to as Nano Drop). The mRNA 
was stored at -20°C.    
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Figure 2.1: The oviduct from an egg laying hen. The figure shows the different parts 
ŽĨĂĐŚŝĐŬĞŶŽǀŝĚƵĐƚ͘dŚĞŚŝŐŚůŝŐŚƚĞĚŵĂŐŶƵŵƉŽƌƚŝŽŶǁĂƐƵƐĞĚƚŽŝƐŽůĂƚĞŵZEŽĨ
OVM, OVAL, OVT and LYS for this project.  
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2.2.2 Primer design and preparation 
The cDNA sequences of OVM, OVAL, OVT and LYS were obtained from the original 
published sequences to design the primers required to amplify the allergens 175-178. 
The primers were designed using the Sigma Aldrich DNA calculator. The primer 
sequences were designed to amplify the target sequence exactly from the start 
(forward primer or F) and the end (reverse primer or R) of the sequence coding for 
each allergen (Table 2.1). To make a working stock of 100 μM, the content in each 
primer tube was reconstituted in (number of nmol x 10) μL of nuclease free water.   
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Table 2.1: PCR primers for OVM, OVAL, OVT and LYS. 
Primer Restriction 
enzyme 
site 
Sequence: 5’-3’ 
(Restriction enzyme site bolded) 
 TM* °C Supplied 
nmol per 
tube 
OVM F XhoI CGCCTCGAGATGGCCATGGCAGGC 66 50.8 
OVM R HindIII CGCAAGCTTTCAGCATTTTCCAAA 57 47.6 
OVAL F BamHI CGCGGATCCATGGGCTCCATCGGTGCA 69 32.4 
OVAL R ĐŽZ/ CGCGAATTCTTAAGGGGAAACACATCT 58 66.6 
OVT F XhoI CGCCTCGAGATGAAGCTCATCCTCTGC 64 45.1 
OVT R HindIII CGCAAGCTTTTACTTGCCCTCAAGGAA 60 40.6 
LYS F BamHI CGCGGATCCATGAGGTCTTTGCTAATC 61 39.1 
LYS R EcorI CGCGAATTCTCACAGCCGGCAGCCTCT 66 38.8 
*TM = Melting temperature  
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2.2.4 PCR of allergens 
2.2.4.1 One step RT-PCR 
To amplify the cDNA coding for the allergens, Qiagen OneStep RT-PCR (Qiagen, 
Cat.No. 210210) was used. Template RNA, primer solutions for OVM, OVAL and LYS, 
dNTP mix, 5x Qiagen OneStep RT-PCR buffer, RNase-free water were thawed, 
thoroughly mixed and placed on ice. The PCR master mix for each allergen was 
prepared on ice in a PCR tube according to the parameters in Table 2.2. Please note 
that template RNA was added after the PCR master mix was prepared and thoroughly 
mixed by pipetting. The PCR reaction was then carried out in a thermal cycler 
according to the parameters outlined in Table 2.3. 
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Table 2.2: Reaction composition for OneStep RT-PCR. 
Component Volume in reaction Final concentration 
RNase-free water Variable (to total 50 μL) - 
5x Qiagen OneStep RT-
PCR buffer 
10 μL 1 x 
dNTP mix (containing 10 
mM of each dNTP) 
2 μL 400 μM of each dNTP 
Forward primer Variable 0.6 μM 
Reverse primer Variable 0.6 μM 
Qiagen OneStep RT-PCR 
enzyme mix 
2 μL - 
RNase inhibitor  5-10 units/reaction 
Template RNA Variable 1 pg- 2 μg/reaction 
Total 50 μL - 
 
 
Table 2.3: PCR conditions for OneStep RT-PCR. 
Cycle step Time Temperature 
Reverse transcription 30 minutes 50°C 
Initial PCR activation 
step 
15 minutes 95°C 
Denaturation 1 minute 94°C 
Annealing 1 minute 50-68°C 
Extension 1 minute 72°C 
ZĞƉĞĂƚĞŶĂƚƵƌĂƚŝŽŶ-Annealing-Extension cycle for 35 times 
Final extension 10 minutes 72°C 
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2.2.4.2 Long Range PCR 
To amplify the cDNA coding for OVT, a Qiagen LongRange 2-step RT-PCR was used 
(Qiagen, Cat.No. 206401).  Initially, the mRNA was reverse transcribed; the template 
mRNA, oligo-dT, 5x LongRange RT buffer, dNTP mix and RNase-free water were 
thawed at room temperature, and stored on ice immediately after thawing. A master 
mix was prepared according to Table 2.4 in an Eppendorf tube. The tube was briefly 
spun to collect residual liquid from the tube walls. The tube was incubated at 42°C 
for 90 minutes. The reaction was then stopped by heating the tube at 85°C for 5 
minutes. The reaction mix was stored on ice until the following PCR.  
 
For the PCR, 10x LongRange PCR buffer, dNTP mix, primer solutions (OVT in Table 2.1) 
and RNase-free water were thawed and mixed thoroughly. A PCR master mix was 
prepared according to Table 2.5, along with cDNA prepared by reverse transcription. 
A second reaction was prepared with the PCR optimisation reagent Q-solution added. 
The PCR was carried out according to the parameters outlined in Table 2.6. The PCR 
products were then analysed by gel electrophoresis.  
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Table 2.4: Reverse transcription master mix.  
Component Volume Final concentration 
LongRange RT buffer 4 μL 1x 
dNTP mix (10 mM of each dNTP) 2 μL 1 mM of each dNTP 
Oligo-dT (20 μM) 1 μL 1 μM 
LongRange RNase inhibitor (4 U/μL) 0.2 μL 0.04 U/μL 
LongRange Reverse Transcriptase 1 μL 1x 
Template mRNA 11.8 875 ng  
Total 20 μL  
 
Table 2.5 LongRange PCR master mix.  
Component Volume in 
reaction 
Final concentration 
LongRange PCR buffer with Mg2+ 
10x 
5 μL 1x ; 2.5 mM Mg2+ 
dNTP mix (10mM each) 2.5 μL 500 μM of each dNTP 
OVT forward primer Variable 0.4 μM 
OVT reverse primer Variable 0.4 μM 
RNase-free water Variable  
LongRange PCR enzyme mix 0.4 μL 2 units per 50 μL 
reaction 
Template cDNA 6 μL 100 ng 
Total 50 μL  
   
Table 2.6 PCR conditions for LongRange PCR. 
Cycle step Time Temperature 
Initial activation step 3 minutes 93°C 
Denaturation 15 seconds 93°C 
Annealing 30 seconds 58°C 
Extension 3 minutes 68°C 
ZĞƉĞĂƚĞŶĂƚƵƌĂƚŝŽŶ-Annealing-Extension cycle for 35 times 
End of PCR 4°C Indefinite 
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2.2.5 Gel electrophoresis of PCR products 
1 g of agarose was combined with 100 mL of TAE buffer (Tris-Acetate-EDTA) in an 
Erlenmeyer flask and warmed up in a microwave to melt the agarose. 5 μL of GelRed™ 
nucleic acid gel stain (Biotium, Cat.No. 41003) was added to the molten gel mixed 
thoroughly by swirling. The mixture was then poured into a gel cassette containing a 
gel comb and set at room temperature. The comb was removed and the gel was 
placed in an electrophoresis chamber and filled with TAE buffer until the gel was 
covered. In to the first well of the gel, 20 μL of 1 kb+ DNA ladder was added. 20 μL of 
each PCR product was then combined with 2 μL of sample loading dye and pipetted 
in to the remaining wells of the gel. The gel was then run at 100 V for 45 minutes. 
Upon completion, a gel image was captured using a Chemidoc system.    
 
 
2.2.6 Gel purification 
The PCR products run on the gel (Section 2.2.5) were purified using a QIAquick Gel 
Extraction kit (Qiagen, Cat.No. 28704). The gel bands containing the PCR products 
were excised using a clean, sharp scalpel blade and the gel slices were weighed. Each 
slice (one for each allergen) was put in an Eppendorf tube and 300 μL of buffer QG 
was added to each tube (1 volume of gel: 3 volumes of buffer). The tubes were 
incubated at 50°C for 10 minutes, with vortexing every 2-3 minutes, to dissolve the 
gel slices. Once the gel slices are completely dissolved, 100 μL of isopropanol was 
added to each tube and mixed. The tubes were places in 2 mL collection tubes and 
centrifuged for 1 minute at maximum speed and the flow-through was discarded. The 
tubes were then washed with 500 μL of buffer QG by centrifugation and the flow-
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through was discarded. Then the tubes were washed with 750 μL of Buffer PE, let the 
columns stand for 5 minutes, centrifuged for 1 minute to remove flow-through and 
re-centrifuged to remove residual wash buffer. The columns were placed in clean 
microcentrifuge tubes and the DNA was eluted by adding 50 μL of buffer EB and 
centrifuging. After adding buffer EB, the columns were let stand for 4 minutes before 
centrifugation to increase yield. The DNA concentrations were then measured using 
a Nano Drop. 
 
 
2.2.7 Restriction enzyme digestion of PCR products 
The four gel-purified PCR products (1 μg of each) were digested with the appropriate 
restriction enzymes (purchased from New England Biolabs); OVM and OVT with XhoI 
and HindIII & OVAL and LYS with BamHI and EcoRI. Separately, two 1 μg batches of 
pTrcHisA vector (Invitrogen, Cat.No. V360-20) were digested with XhoI and HindIII & 
BamHI and EcoRI (Please note that the pTrcHis expression vector comes in 3 different 
frames (A, B and C). The sequence of version A is in frame with allergen sequences, 
therefore pTrcHisA was used in this study). The restriction enzyme reactions were set 
up in microcentrifuge tubes as shown in Table 2.7, mixed thoroughly by pipetting, the 
tubes were briefly spun and incubated for 1 hour at 37°C. The digests were then gel 
purified using E-Gel Clonewell 0.8% SYBR Safe agarose gels and concentrations were 
measured. 
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Table 2.7: Restriction enzyme digestion of the allergens and the expression vector. 
Ovomucoid Ovalbumin 
OVM PCR product    
HindIII      
XhoI    
NE Buffer 2     
BSA      
Nuclease free water  
Total                               
1 μg 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
OVAL PCR product     
EcoRI  
BamHI    
EcoRI Buffer (10x)     
BSA      
Nuclease free water  
Total                             
1 μg 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
Ovotransferrin Lysozyme 
OVT PCR product   
HindIII      
XhoI    
NE Buffer 2     
BSA      
Nuclease free water  
Total                               
1 μg 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
LYS PCR product   
EcoRI  
BamHI    
EcoRI Buffer (10x)     
BSA      
Nuclease free water  
Total                             
1 μg 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
pTrcHisA vector digest 1 pTrcHisA vector digest 2 
pTrcHis A    
HindIII      
XhoI    
NE Buffer 2     
BSA      
Nuclease free water  
Total                               
2 μL(1 μg) 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
pTrcHis A  
EcoRI  
BamHI    
EcoRI Buffer (10x)     
BSA      
Nuclease free water  
Total    
2 μL (1 μg) 
1 μL (10 units) 
1 μL (10 units) 
5 μL (1x) 
0.5 μL 
Add to 50 μL 
50 μL 
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2.2.8 Ligation of PCR products into pTrcHisA expression vector 
The four digested PCR fragments and the pTrcHisA vectors were then used in 
separate ligation reactions. The ligations were carried out with a vector:insert ratio 
of 1:1 (~20 ng of each) and T4 DNA ligase and ligase buffer with ATP (Promega, 
Cat.No.: 1801). Ligation reactions were incubated overnight at 4°C. All reactions (one 
for each allergen) were set up as follows: 
 20 ng of vector DNA (pTrcHisA) 
 20 ng of insert DNA (allergen) 
 1 μL of Ligase buffer 
 0.3 μL (0.9 Weiss units) of T4 DNA ligase 
 X μL amount dH20 to a total of 10 μL 
 
 
2.2.9 Chemical transformation into E. coli TOP10 strain 
The ligated constructs were then transformed into chemically competent E. coli 
TOP10 cells (Life Technologies, Cat.No. C4040-10). Essentially, 1 vial of frozen E. coli 
TOP 10 cells for each allergen construct was thawed on ice. 5 μL of ligation was added 
to each vial and mixed gently by tapping the tube 5-6 times. The vials were incubated 
on ice for 30 minutes. The cells were then heat-shocked on a heat-block for exactly 
30 seconds at 42°C without any shaking or missing. The vials were placed on ice for 2 
minutes. Then, 250 μL of pre-warmed LB media was added to each vial aseptically 
and the tightly capped vials were incubated at 37°C for 1 hour at 225 rpm. The cells 
from each vial was then plated on LB agar plates with 50 μg/mL ampicillin and 
incubated overnight at 37°C. Please note that content of each vial was plated on LB 
agar at different volumes to obtain well separated colonies; 20 μL, 50 μL and 100 μL.     
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2.2.10 Isolation of plasmid by mini-prep 
Five transformant colonies of each allergen were grown separately overnight in LB 
media with 50 μg/mL ampicillin at 37°C with shaking 225 rpm. The next day, 2 mL of 
each overnight culture was centrifuged at maximum speed for 5 minutes to pellet the 
cells. Allergen-pTrcHisA plasmids from these cells were then isolated using a QIAprep 
Spin Miniprep kit (Qiagen, Cat.No. 27104). The cell pellets were resuspended in 250 
μL of buffer P1 (with LyseBlue reagent added at a 1:1000 ratio to buffer P1). Then, to 
lyse the cells, 250 μL of buffer P2 was added to the resuspended cells and mixed 
thoroughly by inverting the tube 5-6 times until the mixture became completely blue. 
To stop the lysis reaction 350 μL of buffer N3 was added and mixed by inverting 5-6 
times until the solution became colourless. The solutions were then centrifuged at 
13,000 rpm for 10 minutes. The supernatant was applied to QIAprep spin columns by 
pipetting, centrifuged for 1 minute at maximum speed and flow-through was 
discarded. The spin columns were then washed with 500 μL of buffer PB, centrifuged 
and flow-through discarded. The columns were then washed with 750 μL of buffer PE 
and the spin columns were transferred into collection tubes. The columns were 
placed in fresh microfuge tubes and 50 μL of elution buffer was added and the let 
stand for 1 minute. The tubes were centrifuged at maximum speed for 1 minute to 
elute the plasmid DNA and the eluted DNA was measured using a Nano Drop.    
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2.2.11 Screening digests to confirm insert and sequencing  
The isolated plasmids (5 clones from each allergen) were subjected to a screeding 
restriction enzyme digestion to confirm insertion into pTrcHisA vector. The plasmids 
were digested according the method described in Section 2.2.7. OVM and OVT were 
digested with HindIII and XhoI while OVAL and LYS were digested with EcoRI and 
BamHI. The digested samples were then analysed by gel electrophoresis on 1% 
agarose gel following the procedure described in Section 2.2.5. Upon confirmation of 
insert, the clones were sequenced using pTrcHisA sequencing primers; Forward 5’-
GAGGTATATATTAATGTATCG-3’ and Reverse 5’- GATTTAATCTGTATCAGG-3’. The 
sequencing was done by the Micromon DNA sequencing facility at Monash University 
(Clayton, Victoria, Australia). The sequences were compared with published allergen 
sequences on IUIS/NCBI by conducting a nucleotide BLAST search.     
 
 
2.2.12 Pilot expressions - time course   
For expression of the proteins, overnight cultures of E. coli TOP10 colonies containing 
each allergen construct (2 clones for each allergen) were grown separately in LB 
media with ampicillin (please note that OVAL expression was done by an 
undergraduate student as part of a honours project and only one clone was 
expressed). The overnight cultures were then re-inoculated in 10 mL of fresh LB media 
with ampicilin and grown to mid-log phase (OD600 0.4-0.6). Mid-log phase was 
reached after approximately 2 hours post inoculation and was measured using a 
spectrophotometer with an optical density set at OD600. A 1 mL sample of each 
culture was collected and pelleted and frozen for later analysis. Expression was 
59 | P a g e  
 
Chapter 2 
induced with 100 μL of 100 mM /ƐŽƉƌŽƉǇůɴ-D-1-thiogalactopyranoside (IPTG) to give 
a final concentration of 1 mM and grown for six hours at 37°C with shaking. Samples 
were collected, pelleted and frozen every 1-hour for determination of optimum 
expression time.  
 
 
2.2.13 SDS-PAGE analysis  
Each frozen cell pellet collected at different time points was resuspended and lysed 
with 400 μL of Cell Lytic B cell lysis reagent for ~10 minutes. Samples collected at all 
the time points were used for the analysis except for OVAL for which only the samples 
collected at hours 0, 2, 4, 5 & 6 were used. The lysed cells were then centrifuged at 
13,000 rpm for 5 mins and the insoluble (pellet) and soluble (supernatant) fractions 
were separated. The insoluble fractions were resuspended in 100 μL of 2 x Tris-
Glycine SDS sample loading buffer (Life Technologies, Cat. No. LC2676). 9μL of these 
resuspended samples were combined with 1 μL of NuPAGE reducing agent (10x) (Life 
Technologies, Cat. No. NP0004). The soluble samples (4 μL) were combined with 5 μL 
loading buffer and 1 μL reducing agent. All samples were then heated at 85°C for 2 
minutes and loaded onto 4-20% gradient Novex Tris-Glycine gels (Life Technologies, 
Cat. No. EC60252BX5) along with the SeeBlue® Pre-stained protein standard (Life 
Technologies, Cat.No. LC5625). The gels were placed in a XCell II Blot™ Module (Life 
Technologies, Cat.No. EI0002) and tightened to create an inner and an outer chamber 
within the module.  The inner chamber was filled with Novex® Tris-Glycine SDS 
running buffer (1x) (Life Technologies, Cat.No. LC2675) until the chamber was 
overflown. The outer chamber was then half filled with running buffer and the anode 
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and cathode were connected. The gel was run for ~1.5 hours at 125 V (constant 
voltage). Upon completion of the gel run, the gels were washed in dH20 to remove 
running buffer. The gels were then stained in SimplyBlue™ SafeStain (Life 
Technologies, Cat.No. LC6060) for one hour on a platform rocker. The stain was 
washed with dH20 and the gels were incubated in fresh dH20 overnight at room 
temperature with rocking. Next day the gels were dried using Gel-Dry™ drying 
solution (Life Technologies, Cat.No. LC4025) and the dried gel images were captured 
by scanning with a white background.  
 
 
2.2.14 Western blot analysis  
SDS-PAGE, as described in Section 2.2.13, was repeated again for 1 clone from each 
allergen. (Please note that western blot for OVAL was conducted by an undergraduate 
student as part of an honours project). Upon completion, the proteins on the gels 
were transferred onto nitrocellulose membranes on a XCell II™ Blot Module 
according to manufacturer’s guidelines. Essentially, a transfer sandwich was made in 
the following order: 2x blotting pad-filter paper-gel-nitrocellulose membrane-filter 
paper-2x blotting pad. The sandwich was then assembled into the module and the 
inner chamber was filled with Novex® Tris-Glycine transfer buffer (1x) (Life 
Technologies, Cat.No. LC3675). After connecting the anode and the cathode, the 
transfer was conducted at 25 V for 2 hours. The proteins on the nitrocellulose 
membranes were detected using WesternBreeze® chromogenic detection kit (Life 
Technologies, Cat. No. WB7103). First, the membranes were blocked in 10 mL of 
blocking buffer for 1 hour, followed by rinsing with dH20 twice (5 minutes each time). 
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The membranes were then incubated with 10 mL of the primary antibody prepared 
in blocking buffer for 1 hour. Anti-Xpress mouse monoclonal antibody (Life 
Technologies, Cat. No. R910-25) was used as the primary antibody at a concentration 
of 0.5 μg/mL. The unbound antibody was then washed 4 times (5 minutes each time) 
with 20 mL of antibody wash. The membranes were incubated with 10 mL of provided 
secondary antibody (anti-mouse IgG-alkaline phosphatase conjugated) for 30 
minutes. The membranes were washed 5 times with antibody wash and rinsed 3 
times with dH20. The membranes were then incubated with 5 mL of chromogenic 
substrate (5-bromo-4-chloro-3-indolyl-phosphate (BCIP)/nitro blue tetrazolium 
(NBT)) until purple bands developed on the membrane. When bands appeared, the 
reaction was stopped by rinsing the membranes 3 times with dH20. The western blot 
was repeated twice using two other primary antibodies: Tetra-His antibody (0.2 
μg/mL) and Penta-His antibody (0.2 μg/mL). Images of all the developed blots were 
then captured on a Chemidoc.         
 
 
2.2.15 Expression of the proteins in E. coli Express Iq strain- time-course 
The pTrcHisA vectors containing each allergen were transformed into Express Iq 
chemically competent E. coli cells (New England BioLabs, Cat. No. C3037H), following 
manufacturer’s guidelines. Plasmids from the transformed clones were then isolated 
by mini-prep and were sequenced. Upon confirming the sequences, one clone from 
each allergen was subjected to a time-course expression to determine optimal 
expression time. An overnight culture for each allergen was prepared using a single 
colony. The next day, the overnight culture was used to inoculate 10 mL of fresh LB 
62 | P a g e  
 
Chapter 2 
media with ampicillin (50 μg/mL) and grown to mid-log phase at 37°C with shaking at 
250 rpm. 1 mL of the culture was centrifuged and pelleted to be used as the non-
induced control. Expression was induced by adding 36 μL of IPTG (0.4 mM final 
concentration) to the remaining 9 mL of mid-log phase culture and grown for 6 hours 
at 37°C with shaking. Every 1-hour, a 1 mL sample was collected and pelleted. All cell 
pellets were frozen at -20°C until further use.     
 
 
2.2.16 SDS-PAGE and western blot analysis of the expressed proteins 
Cell pellets collected (in Section 2.2.15) at time points 0, 2, 4, 5 & 6 were subjected 
to SDS-PAGE and western blot analysis following the method outlined in Sections 
2.2.13 and 2.2.14. For western blotting, only anti-Xpress antibody (0.5 μg/mL) was 
used as the primary antibody and the images were captured using a camera instead 
of Chemidoc.    
 
 
2.2.17 Mass-spectrometry analysis of the expressed proteins 
Another SDS-PAGE was conducted using the corresponding expression fraction 
(soluble or insoluble) and the optimum time point of each allergen. For OVM and 
OVAL the soluble fraction at 2 hours was used, and for OVT and LYS the insoluble 
fraction at 2 hours was used. Once the gel run was complete, 4 bands conforming to 
the correct size of each allergen were incised using sterile blades and subjected to 
mass spectrometry analysis (16 gel bands in total). The gel bands were in-gel-digested 
with trypsin and incubated overnight at 37°C to digest the proteins into peptides.  In-
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gel-digest samples were analysed on a LTQ Orbitrap Elite (Thermo Scientific) coupled 
to an Ultimate 3000 RSLC (rapid separation liquid chromatography) nanosystem 
(Dionex). The nano-RSLC system was equipped with an Acclaim Pepmap nano-trap 
ĐŽůƵŵŶĂŶĚĂŶĐĐůĂŝŵWĞƉŵĂƉĂŶĂůǇƚŝĐĂůĐŽůƵŵŶ͘ϮʅůŽĨƚŚĞƉĞƉƚŝĚĞŵŝǆ;ŝ͘Ğ͘ĞĂĐŚ
digested band) was loaded onto the trap column of 3% CH3CN containing 0.1% formic 
acid for 5 minutes before the enrichment column is switched in-line with the 
analytical column. The LTQ Orbitrap Elite mass spectrometer was operated in the 
data-dependent mode, whereby spectra were acquired first in positive mode 
followed by collision induced activation (CID). Ten of the most intense peptide ions 
ǁŝƚŚĐŚĂƌŐĞƐƚĂƚĞƐшϮǁĞƌĞŝƐŽůĂƚĞĚĂŶĚĨƌĂŐŵĞŶƚĞĚƵƐŝŶŐŶŽƌŵĂůŝǌĞĚĐŽůůŝƐŝŽŶĞŶĞƌŐǇ
of 35 and activation Q of 0.25 (CID).  Data analysis was carried out using Proteome 
Discoverer (Thermo Scientific version 1.4) with Mascot against the BIRDS database. 
Search parameters were precursor mass tolerance of 10 ppm, fragment mass 
tolerance of 0.6 Da (CID). Carbamidomethyl of cysteine was set as fixed modification 
and oxidised methionine as a variable modification.  Trypsin with maximum of 1 
missed cleavage was used as the cleavage enzyme.    
    
 
2.2.18 Purification of recombinant proteins 
Recombinant proteins expressed in both TOP10 and Express Iq E. coli strains were 
subjected to a number of protein purification procedures using Qiagen Ni-NTA based 
protein purification kits. However these did not yield satisfactory results, therefore 
were discontinued.      
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2.3 Results 
2.3.1 PCR amplification of the egg white allergen cDNA 
The mRNA isolated from chicken oviduct were used to PCR amplify egg white 
allergens (OVM, OVAL, OVT & LYS) using one-step PCR method. For Gal d 3, a long-
range PCR, that utilises the traditional two-step method, was used. The one-step PCR 
gel result showed a band for OVM at 800 bp (expected 630 bp), OVAL between 800-
2000 bp (expected 1158 bp), no band for OVT (expected 2115) and Gal d 4 at above 
400 bp (expected 441) (Figure 2.2). The long-range PCR conducted for OVT with and 
without Q-solution both produced bands at the expected range band, however the 
band of the sample without Q-solution was brighter and clearer than the sample with 
Q-solution (Figure 2.3).   
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Figure 2.2: One-step PCR of allergens. ůůĞƌŐĞŶƐǁĞƌĞ WZ ĂŵƉůŝĨŝĞĚ ƵƐŝŶŐŵZE
ŝƐŽůĂƚĞĚĨƌŽŵĂĐŚŝĐŬĞŶŽǀŝĚƵĐƚ͘dŚĞĐEƐǇŶƚŚĞƐŝƐĂŶĚƚŚĞWZĂŵƉlification was 
done in a single reaction tube in a one-step method. Allergen specific primers with 
ƌĞƐƚƌŝĐƚŝŽŶĞŶǌǇŵĞƐŝƚĞƐŝŶƐĞƌƚĞĚǁĞƌĞƵƐĞĚĨŽƌƚŚĞWZ͘ĂŶĚƐǁĞƌĞƉƌĞƐĞŶƚŝŶKsD
(627 bp), OVAL (1163 bp) & LYS (444 bp) lanes while OVT did not have a band at the 
expected range. dŚĞĂƌƌŽǁƐŝŶĚŝĐĂƚĞƚŚĞůŽĐĂƚŝŽŶŽĨƚŚĞƚŚƌĞĞWZƉƌŽĚƵĐƚƐŽŶƚŚĞŐĞů͘   
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Figure 2.3: Long-range PCR of OVT. This long-ƌĂŶŐĞWZŵĞƚŚŽĚǁĂƐĐŽŶĚƵĐƚĞĚǁŝƚŚ
and without the optimisation reagent Q-solution to amplify OVT, using specific 
primers with restriction enzymes. Both lanes showed a band at the expected size 
;ϮϭϯϳďƉͿ͕ǁŝƚŚƚŚĞWZǁŝƚŚŽƵƚY-solution showing the prominent band. The arrow 
ŝŶĚŝĐĂƚĞƐƚŚĞůŽĐĂƚŝŽŶŽĨƚŚĞWZƉƌŽĚƵĐƚŽŶƚŚĞŐĞů͘ 
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2.3.2 Cloning of the PCR amplified egg white allergens into pTrcHisA expression 
vector 
The gel-purified PCR products (allergens) and pTrcHisA vector were digested by 
restriction enzymes, which showed bands at the corresponding size when analysed 
by gel electrophoresis post-digestion (Figure 2.4). Undigested pTrcHisA vector 
appeared at a lower size when compared to the digested samples (Figure 2.4). The 
digested PCR products were then ligated into their respective digested pTrcHis 
vector. The ligations were transformed into E. coli TOP10 cells, plasmids isolated and 
were subjected to a screening digest. The screening digest results showed that 4/5 
OVM clones, 5/5 OVAL clones, 5/5 OVT clones and 4/5 LYS clones carried the insert 
(Figure 2.5). One clone carrying the insert from each allergen was then sequenced. 
When the obtained sequences were analysed on NCBI BLAST, all sequences showed 
шϵϴ % similarity to the published sequences: OVM 99 % (Figure 2.6), OVAL 99 % 
(Figure 2.7), OVT 98 % (Figure 2.8) and LYS 99 % (Figure 2.9). 
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Figure 2.4: Restriction enzyme digested PCR products and pTrcHisA vector. OVM & 
OVT were digested with XhoI & HindIII and OVAL & LYS were digested with BamHI and 
ĐŽZ/;Ϳ͘dǁŽůŽƚƐŽĨƉdƌĐ,ŝƐǀĞĐƚŽƌǁere also digested with the same restriction 
enzyme combinations; yŚŽ/Θ,ŝŶĚ///ĂŶĚĂŵ,/ΘĐŽZ/;Ϳ͘ 
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Figure 2.5: Screening digests of the allergen-pTrcHisA constructs to confirm insert. 
Isolated plasmids from five clones of each allergen-pTrcHisA constructs were digested 
with their respective restriction enzymes. The arrows show the inserts digested out of 
the allergen-ƉdƌĐ,ŝƐĐŽŶƐƚƌƵĐƚƐ͘KsD;Ϳ͕Ks>;Ϳ͕Ksd;ͿΘ>z^;Ϳ͘ 
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Figure 2.6: IUIS/NCBI BLAST search result conducted using the sequence obtained 
from OVM cDNA cloned into pTrcHisA. When the sequence of OVM (Query) was 
BLAST searched, Gallus gallus serine peptidase inhibitor SPINK7 (synonym for 
ŽǀŽŵƵĐŽŝĚͿŵZEǁĂƐŝĚĞŶƚŝĨŝĞĚ;^ďũĐƚͿ͘  
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Figure 2.7: IUIS/NCBI BLAST search result conducted using the sequence obtained 
from OVAL cDNA cloned into pTrcHisA. When the sequence of OVAL (Query) was 
>^dƐĞĂƌĐŚĞĚ͕'ĂůůƵƐŐĂůůƵƐŽǀĂůďƵŵŝŶŵZEǁĂƐŝĚĞŶƚŝĨŝĞĚ;^ďũĐƚͿ͘   
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*Figure 2.8: Continued on next page* 
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Figure 2.8: IUIS/NCBI BLAST search result conducted using the sequence obtained 
from OVT cDNA cloned into pTrcHisA. When the sequence of OVT (Query) was BLAST 
ƐĞĂƌĐŚĞĚ͕'ĂůůƵƐŐĂůůƵƐŽǀŽƚƌĂŶƐĨĞƌƌŝŶŵZEǁĂƐŝĚĞŶƚŝĨŝĞĚ;^ďũĐƚͿ͘   
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Figure 2.9: IUIS/NCBI BLAST search result conducted using the sequence obtained 
from LYS cDNA cloned into pTrcHisA. When the sequence of LYS (Query) was BLAST 
ƐĞĂƌĐŚĞĚ͕'ĂůůƵƐŐĂůůƵƐůǇƐŽǌǇŵĞŵZEǁĂƐŝĚĞŶƚŝĨŝĞĚ;^ďũĐƚͿ͘    
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2.3.3 Time-course expression, SDS-PAGE analysis and western blot analysis of 
allergens  
Expression of the allergen sequences in E. coli was induced with IPTG and samples 
were collected every one-hour for six hours. The samples collected at hours 0, 2, 4, 5 
& 6 were then analysed by SDS-PAGE and western blot. Two clones of each allergen 
was analysed by SDS-PAGE. The soluble fraction of OVM clone 1 showed an increasing 
pattern (increasing band intensity with time) at the expected molecular weight of 28 
kDa. The insoluble fraction of the same clone or the soluble and insoluble fraction of 
the second clone did not show a distinct pattern (Figure 2.10).  Both clones of OVT 
showed an increasing pattern of expression with time in both clones (Figure 2.11). 
LYS, however, did not show a distinct pattern of expression in either of the clones 
when analysed by SDS-PAGE (Figure 2.12).  
 
When OVM was analysed by western blot using 3 different antibodies, both soluble 
and insoluble fractions showed expression. The soluble fraction had clearer and 
distinct bands when compared to the inconsistent pattern of the insoluble fraction. 
In the soluble fraction of OVM, 5-hours band appeared to be clearer and darker than 
the other bands (Figure 2.13). Western blot of OVT showed that it was expressed only 
in the insoluble fraction, with multiple bands appearing throughout the blot, 
including one at the expected molecular weight (76 kDa) (Figure 2.14). Western blot 
of LYS showed that the expression is limited to the insoluble fraction at the expected 
molecular weight (14.7 kDa). The band at 5-hours appeared to be darker than the 
other bands (Figure 2.15).       
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As mentioned earlier, SDS-PAGE and western blot for OVAL was done by an 
undergraduate student as a part of an honours research project 179. The results 
obtained from that project are included in this chapter (Figure 2.16). The soluble 
fraction on the SDS-PAGE and western blot showed bands appearing at the expected 
molecular weight (45 kDa). The insoluble fraction in the western blot showed distinct 
bands, whereas the insoluble fraction in the SDS-PAGE did not show distinct bands.    
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Figure 2.10: SDS-PAGE analysis of two OVM clones after time-course expression. 
The cell pellets containing expressed OVM collected at different time intervals of the 
time-course were lysed and the insoluble and soluble fractions were separated. The 
insoluble fractions were resuspended in 100 μL of 2 x Tris-'ůǇĐŝŶĞ^^ƐĂŵƉůĞůŽĂĚŝŶŐ
buffer. 9μL of these resuspended samples were combined with 1 μL of NuPAGE 
reducing agent (10x). The soluble samples (4 μL) were combined with 5 μL loading 
buffer and 1 μL reducing agent. All samples were then heated at 85°C for 2 minutes 
and analysed on a 4-20% gradient Novex Tris-Glycine gel. A molecular weight marker 
was included in the first lane of both gels. The gels were stained in SimplyBlue™ 
SafeStain. (A)-clone 1, (B)-clone 2. The arrows and the boxes show the expected 
molecular weight of OVM and its location on the gel.  
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Figure 2.11: SDS-PAGE analysis of two OVT clones after time-course expression. The 
cell pellets containing expressed OVT collected at different time intervals of the time-
course were lysed and the insoluble and soluble fractions were separated. The 
insoluble fractions were resuspended in 100 μL of 2 x Tris-'ůǇĐŝŶĞ^^ƐĂŵƉůĞůŽĂĚŝŶŐ
buffer. 9μL of these resuspended samples were combined with 1 μL of NuPAGE 
reducing agent (10x). The soluble samples (4 μL) were combined with 5 μL loading 
buffer and 1 μL reducing agent. All samples were then heated at 85°C for 2 minutes 
and analysed on a 4-20% gradient Novex Tris-Glycine gel. A molecular weight marker 
was included in the first lane of both gels. The gels were stained in SimplyBlue™ 
SafeStain. (A)-clone 1, (B)-clone 2. The arrows and the boxes show the expected 
molecular weight of OVT and its location on the gel.   
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Figure 2.12: SDS-PAGE analysis of two LYS clones after time-course expression. The 
cell pellets containing expressed LYS collected at different time intervals of the time-
course were lysed and the insoluble and soluble fractions were separated. The 
insoluble fractions were resuspended in 100 μL of 2 x Tris-'ůǇĐŝŶĞ^^ƐĂŵƉůĞůŽĂĚŝŶŐ
buffer. 9μL of these resuspended samples were combined with 1 μL of NuPAGE 
reducing agent (10x). The soluble samples (4 μL) were combined with 5 μL loading 
buffer and 1 μL reducing agent. All samples were then heated at 85°C for 2 minutes 
and analysed on a 4-20% gradient Novex Tris-Glycine gel. A molecular weight marker 
was included in the first lane of both gels. The gels were stained in SimplyBlue™ 
SafeStain. (A)-clone 1, (B)-clone 2. The arrows and the boxes show the expected 
molecular weight of LYS and its location on the gel.   
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Figure 2.13: Western blot analysis of OVM time-course expression. Following 
expression of OVM in E. coli TOP10, cell pellets collected at hours 0, 2, 4, 5 & 6 were 
lysed and the insoluble and soluble fractions were separated. The samples (time 
intervals) of both samples were run on 4-20% gradient Novex Tris-Glycine gels and 
were transferred on to nitrocellulose membranes. The three membranes were 
incubated with three separate primary antibodies produced in mouse: Anti-Xpress (A), 
Tetra-His (B) & Penta-His (C) (arrows = expected size of OVM). The blots were 
incubated with anti-mouse IgG-alkaline phosphatase conjugate (as a secondary 
antibody) and the bands were detected using a chromogenic substrate (BCIP/NBT). 
Please note that the 6th hour of insoluble fraction is not included on the blot.   
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Figure 2.14: Western blot analysis of OVT time-course expression. Following 
expression of OVT in E. coli TOP10, cell pellets collected at hours 0, 2, 4, 5 & 6 were 
lysed and the insoluble and soluble fractions were separated. The samples (time 
intervals) of both samples were run on 4-20% gradient Novex Tris-Glycine gels and 
were transferred on to nitrocellulose membranes. The three membranes were 
incubated with three separate primary antibodies produced in mouse: Anti-Xpress (A), 
Tetra-His (B) & Penta-His (C) (arrows = expected size of OVT). The blots were 
incubated with anti-mouse IgG-alkaline phosphatase conjugate (as a secondary 
antibody) and the bands were detected using a chromogenic substrate (BCIP/NBT). 
Please note that the 6th hour of insoluble fraction is not included on the blot.
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Figure 2.15: Western blot analysis of LYS time-course expression. Following 
expression of LYS in E. coli TOP10, cell pellets collected at hours 0, 2, 4, 5 & 6 were 
lysed and the insoluble and soluble fractions were separated. The samples (time 
intervals) of both samples were run on 4-20% gradient Novex Tris-Glycine gels and 
were transferred on to nitrocellulose membranes. The three membranes were 
incubated with three separate primary antibodies produced in mouse: Anti-Xpress (A), 
Tetra-His (B) & Penta-His (C) (arrows = expected size of LYS). The blots were incubated 
with anti-mouse IgG-alkaline phosphatase conjugate (as a secondary antibody) and 
the bands were detected using a chromogenic substrate (BCIP/NBT). Please note that 
the 6th hour of insoluble fraction is not included on the blot. 
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Figure 2.16: SDS-PAGE and western blot of OVAL time-course expression. (A)- ^^-
PAGE of insoluble and soluble fractions of E. coli TOP10 after time-course expression. 
Fractions collected at 0, 2, 4, 5 & 6 hours were analysed on a 4-20% gradient Novex 
Tris-Glycine gel. (B)- Western blot analysis of the insoluble and soluble fractions of E. 
coli TOP10 after time-course expression. Fractions collected at 0, 1, 2, 3, 4, 5 & 6 were 
run on a 4-20% gradient Novex Tris-Glycine gel and transferred to a nitrocellulose 
membrane. The blot was incubated with monoclonal anti-ovalbumin antibody 
produced in mouse as the primary antibody and was then incubated with anti-mouse 
IgG-alkaline phosphatase conjugate as the secondary antibody. The bands on the blot 
were detected using a chromogenic substrate (BCIP/NBT). Figure and description 
adopted from: ŚĂŵŝŬĂĞ^ŝůǀĂϮϬϭϮ180.     
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2.3.4 Expression of allergens in Express Iq E. coli 
The allergen-pTrcHisA constructs were transformed into Express Iq E. coli cells and 
the transformed plasmids were sequenced. The sequencing showed that OVM and 
LYS were 100% similar to the E. coli TOP10 propagated plasmids while OVAL was 98% 
similar and OVT was 99% similar to the TOP10 sequences (sequencing results not 
shown). SDS-PAGE and western blot analysis of the expressed proteins showed that 
OVM and OVAL are expressed in both soluble and insoluble fractions while OVT and 
LYS were limited to the insoluble fraction (Figure 2.17). OVM showed, in the soluble 
fraction, no band at 0 hours, a dark band at 2 hours and from thereon diminishing 
bands with increasing time. The insoluble fraction of OVM showed a dark and large 
band at the expected range of 28 kDa along with multiple bands of different sizes for 
all time points, except 0 hours where there were no bands present.   OVAL showed a 
faint band at 0 hours with intensifying bands with time, in the soluble fraction. The 
insoluble fraction of OVAL showed no band at 0 hours and intensifying bands with 
increasing time. Both fractions of OVAL showed multiple bands at different sizes, 
including dark and large bands at the expected size of 45 kDa. OVT showed multiple 
bands for all time points in the insoluble fraction, including at the expected size of 76 
kDa, except for 0 hours where there were no bands. LYS showed a single band at the 
expected size of 14.7 kDa for all time points except 0 hours in the insoluble fraction, 
with 2 and 6 hours showing darker bands than 4 and 5 hours.              
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Figure 2.17: Expression of recombinant allergens in Express Iq E. coli to determine 
the optimum time point of expression and the fraction where the expressed proteins 
are found. The transformed Express Iq E. coli cells (for each allergen) were induced 
with IPTG and grown for 6 hours. Samples were collected and pelleted every 1-hour, 
including before IPTG induction (0 hours). The pellets representing the time points 0, 
2, 4, 5 and 6 were lysĞĚĂŶĚƚŚĞƐŽůƵďůĞĂŶĚŝŶƐŽůƵďůĞĨƌĂĐƚŝŽŶƐǁĞƌĞƌƵŶŽŶ^^ŐĞůƐ͘
The gels were then blotted onto nitrocellulose and incubated with Anti-Xpress 
antibody for detection purposes. The blots were then detected using a chromogenic 
substrate (BCIP/NBT). (A) OVM, ;ͿKs>͕;ͿKsd͕;Ϳ>z^͘ The arrows indicate the 
band of interest for each protein.      
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2.3.5 Mass spectrometry analysis of the expressed proteins   
A SDS-PAGE analysis was conducted using the expressed protein fractions. This gel 
allowed incision of 4 bands from the expected size range of each allergen that was 
subjected to mass spectrometry analysis (Figure 2.18). Each gel slice was numbered 
for identification purposes. The mass spectrometry analysis of the recombinant 
protein bands showed that OVAL, OVT and LYS are positively identified (Table 2.8). 
The analysis showed no indication of presence of OVM in the protein bands 1-4, that 
were incised from the gel run with OVM expressed E. coli extract. Bands 5-8 incised 
from the OVAL gel were identified as ovalbumin, 9-12 incised from OVT gel were 
identified as ovotransferrin, and bands 13-16 incised from LYS gel were identified as 
lysozyme (Table 2.8). 
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Figure 2.18: Chosen slices of gels for mass spectrometry analysis following SDS-
PAGE of all recombinant allergens. Four slices of gel were incised from the area of 
the gel each allergen is expressed. Each was numbered according to the figure and 
subjected to trypsin in-gel digestion and subsequent mass spectrometry analysis.   
 
Table 2.8: Mass spectrometry results of the recombinant allergens.  
Database Gel section
 
Identified 
protein name 
Protein 
score 
Sequence 
coverage (%) 
Birds 1 Ovomucoid - - 
Birds 2 Ovomucoid - - 
Birds 3 Ovomucoid - - 
Birds 4 Ovomucoid - - 
Birds 5 Ovalbumin 3248 70 
Birds 6 Ovalbumin 5495 76 
Birds 7 Ovalbumin 6341 90 
Birds 8 Ovalbumin 4909 82 
Birds 9 Ovotransferrin 708 53 
Birds 10 Ovotransferrin 668 48 
Birds 11 Ovotransferrin 621 50 
Birds 12 Ovotransferrin 879 48 
Birds 13 Lysozyme 298 48 
Birds 14 Lysozyme 223 38 
Birds 15 Lysozyme 292 54 
Birds 16 Lysozyme 183 29
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2.4 Discussion 
Egg white allergy is a widespread disorder mainly affecting children. The wide use of 
chicken eggs in various food and pharmaceutical products complicates avoidance of 
egg white, which is the only current management strategy available for egg allergic 
patients. However, strict avoidance of egg allergens may be very difficult to achieve 
due to its extensive use in processed foods and pharmaceutical products. Avoidance 
of eggs may also have nutritional disadvantages to the individual 83,181. Allergen 
specific-immunotherapy (SIT) is currently being pursued as a promising curative 
treatment for food allergy, including egg allergy. SIT involves the administration of an 
allergen starting at very small amounts and increasing to a higher maintenance 
dosing, to promote tolerance by the immune system 12. Egg allergic patients react to 
each allergen at different intensities; therefore, it will be important to administer the 
allergens separately in SIT to better manage adverse reactions. However, isolating 
egg white allergens without contamination from the remaining allergens is extremely 
difficult, time consuming and expensive. Production of recombinant variants of 
allergens is an effective alternative to natural allergens, since the allergen is produced 
independently of the others.  
 
E. coli is an excellent host organism for expression of recombinant proteins because 
it offers many advantages compared to other host systems including, but not limited 
to, easy propagation, production of large culture volumes and easy transformation 
of exogenous DNA 173,174. This chapter aimed at isolating the cDNA of the major egg 
white allergens, cloning them into an expression vector and expressing the 
recombinant proteins in E. coli.  
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Isolation of mRNA from an animal tissue can often be a problematic task due the 
tendency of mRNA, or RNA, to degrade easily. In this study, the oviduct was obtained 
immediately after the hen was euthanized, chopped in to small pieces and preserved 
in RNAlater reagent to avoid such degradation. This was crucial to avoid incorrect 
cDNA being produced. The success of the mRNA isolation was evident by the 
successful PCR amplification of the allergen cDNA. It was necessary to utilize a one-
step PCR method, in which cDNA synthesis and subsequent PCR is done in a single 
step, to amplify the cDNA because the conventional PCR using a separately prepared 
cDNA library did not yield any results for unknown reasons. The one-step PCR showed 
that OVM, OVAL and LYS were successfully amplified, evident by bands appearing at 
the expected sizes. OVT was not amplified in the one-step PCR possibly due to its 
larger size when compared to the other three allergens. However, this was easily 
overcome by using a long-range PCR method, which is designed to amplify large DNA 
fragments. In this long-range PCR, an optimisation reagent, Q-solution, was used in 
order to see if the quality and the quantity of the DNA could be improved, however 
the results indicated that amplification of OVT was better without the Q-solution.  
 
The successful insertion of the PCR products into the pTrcHisA expression vector was 
shown by the screening digests that were performed after the PCR products were 
inserted into the vector using restriction enzymes. A screening digest is often useful 
prior to sequencing to avoid unnecessary costs associated with sequencing. The 
sequencing results finally established that the correct allergen sequences were PCR 
amplified. The minute discrepancies in the obtained sequences and the published 
sequences can be attributed to PCR errors or sequencing errors, however, the extent 
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of these discrepancies were not deemed a problem for this study. It is important to 
point out that most of the published sequences of egg allergens are extracted from 
chickens in countries other than Australia. This study used DNA from a hen from 
Australia, therefore it is wise to suggest that the minute differences in the sequence 
may well be due to genetic changes that naturally exist between chickens from 
different continents.  
 
The proteins were expressed using pTrcHisA for a number of reasons. This vector is 
designed for efficient and high level expression of recombinant proteins using a trc 
(trp-lac) promoter 182. This vector also carries lac repressor gene lacIq which allows 
controlled induction of protein expression using IPTG, even in hosts with or without 
the lacIq gene 183. The proteins expressed using this vector are expressed as N-
terminal 6 x His tagged proteins, which allows detection using anti-His antibodies and 
purification using immobilized metal ions such as nickel, copper and cobalt in the 
presence of chelating agent such as nitrilotriacetic acid (NTA). In addition, this vector 
adds an Xpress epitope to the N-terminus, which allows detection of the expressed 
proteins using anti-Xpress antibodies. All of these features made this vector an 
excellent choice for the purpose of this study.              
 
A pilot time-course expression of the proteins was done to determine the optimum 
time E. coli TOP10 needs to express each protein without causing too much 
degradation. SDS-PAGE analysis provided a protein profile of all the proteins in the 
cell extracts, while the western blots assisted in detecting the protein of interest. 
Although some of the SDS-PAGE results showed a pattern in protein expression, 
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particularly in OVM and OVT, the gels provided inconclusive results due to the large 
number of other proteins that seemed to show similar expression patterns. However, 
the successive western blot results provided important information about how each 
protein is expressed in E. coli TOP10. OVM and OVAL were expressed as soluble and 
insoluble proteins while OVT and LYS were expressed strictly as insoluble proteins.  
 
When exogenous or endogenous proteins are overexpressed in E. coli, these proteins 
are often accumulated in inclusion bodies of the host cells. When disulphide bonded 
proteins are expressed in the cytosol of the cells, the reducing environment of the 
cytosol forces misfolding or unfolding of the proteins, thus causing aggregation of the 
protein as inclusion bodies 184,185. However, a fraction of the proteins containing 
disulphide bridges may sometimes be appropriately folded and end up as a soluble 
protein in E. coli 186. This provides a possible explanation to the expression of OVM 
and OVAL in both the soluble and insoluble fractions and the restriction of OVT and 
LYS to the insoluble fraction. Nevertheless, this may not be completely accurate as all 
four proteins were expressed under similar conditions, hence if overexpression was 
the sole cause, all proteins should have shown similar results. Biological functions of 
proteins or chemicals may cause changes in host systems, just as humans react to 
foreign bodies such as pathogens. Therefore, it’s wise to suggest that formation of 
inclusion bodies can possibly, or at least partly, be ascribed to the response of the 
host to the function of the proteins.  
 
Another noticeable feature of the SDS-PAGE and western blot results is the 
appearance of bands of different sizes in the insoluble fractions. This may well be due 
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to protein degradation. E. coli is known to contain mechanisms of degrading 
abnormal proteins 187,188, which may explain why OVM, OVAL and OVT showed 
breaking down of the protein by showing multiple bands. It is quite intriguing that 
LYS is not affected by protein degradation machinery, possibly because the 
antibacterial properties of LYS counteracts the cell mechanism to degrade it, which is 
an important characteristic for an antibacterial agent.  
 
Expression of non-degraded recombinant proteins in the soluble fraction of E. coli is 
often advantageous for downstream applications such as protein purification. 
Availability of soluble proteins eliminates the use of costly refolding experiments post 
purification. To reduce protein degradation and to potentially express OVT and LYS 
in the soluble fraction in this study, the allergen-vector constructs were transformed 
into Express Iq E. coli strain. This strain is derived from the highly versatile E. coli BL21 
strain and is designed for expression of toxic or unfavourable proteins 189. The 
subsequent SDS-PAGE and western blot analysis, following time-course expression 
using the freshly transformed cells, noticeably indicated a significant reduction in 
protein degradation, which was evident by appearance of less bands in the insoluble 
fractions of all four proteins in contrast to the results obtained using the TOP10 strain. 
OVT and LYS were not solubilized even in this strain, however the yield of OVM and 
OVAL were significantly increased in both fractions as shown by appearance of 
prominent bands.  
 
Expression of OVM resulted in an interesting pattern in the soluble fraction, in which 
the amount of soluble protein was higher at 2 hours than the subsequent hours. OVM 
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is a trypsin inhibitor and availability of high concentrations of this protein may be 
toxic for the host cells. It can be suggested that host defence machinery may have 
limited the expression of soluble, correctly folded and functional OVM with 
increasing time. This statement can be further supported by the expression of OVAL, 
which has increased with time, in contrast to OVM. OVAL is considered to be a 
storage protein with no known adverse effects or toxicity, which may explain why the 
host cells have allowed excessive production of soluble OVAL as evident by the 
presence of larger bands in the western blot. Unlike the OVM, OVT or LYS, OVAL has 
expressed more soluble protein than the insoluble proteins. This can be explained by 
the conformational structure of OVAL; it contains only one intrachain disulphide bond 
which is not essential for its native conformation 190. Disruption of this disulphide 
bond still preserves OVAL’s native-like form, although it makes the protein more 
susceptible to proteolytic digestion due to its fluctuating conformation 190. Therefore, 
expression of this protein in the reducing environment of the cell cytosol does not 
entirely affect its natural conformation, significantly reducing protein aggregation. 
The formation of cell aggregates, or inclusion bodies, in a lesser extent may well be 
due to the unstable conformation in a fraction of the expressed protein resulting in 
damaged proteins. This feature of OVAL, combined with its reputation as a neutral 
protein, has allowed expression of a higher amount of soluble protein.  
 
OVT was limited to the insoluble fraction, similar to the E. coli TOP10 cells, possibly 
due the instability caused by the deformation of disulphide bonds. It is known that 
disruption of a single disulphide bond of OVT makes it less stable compared to its 
native form, while altering its iron binding properties 191. LYS was also limited to the 
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insoluble fraction, however, with no protein degradation, similar to what was 
observed when expressed in E. coli TOP10. As aforementioned, LYS’s antibacterial 
properties may have prevented it from being degraded. However, how can the 
protein be limited to the insoluble fraction, which results from misfolding or 
unfolding of the protein, and still be functional? Native LYS has four disulphide bonds 
that are independent of one another 192. Reduced forms LYS is known to refold rapidly 
(<4 milliseconds) back to its native form, for which none of the disulphide bonds are 
indispensable 192,193. Therefore, it can be suggested that the reduced forms of LYS are 
aggregated as soon as the proteins are overexpressed in E. coli and later refolding 
protects the protein from host defences due to the protein’s retained stability and 
function as an antibacterial.                          
 
The mass spectrometry analysis, although successfully identified OVAL, OVT and LYS, 
failed to identify OVM. Trypsin in-gel digestion was used for the 
digestion/preparation of the gel slices. The trypsin inhibitory activity of OVM may 
have affected the results indicating that the recombinant protein is partially or fully 
functional. An ideal suggestion to confirm the identity of recombinant OVM would be 
to either use OVM specific antibodies or N-terminal amino acid sequencing. However, 
the appearance of the protein in Figure 2.17 near the molecular weight of 30 kDa 
corresponds to the expected molecular weight of 28 kDa of OVM. For this mass 
spectrometry analysis, it was decided to analyse four gel bands per protein from 
where the protein of interest is expressed on the gel. This was done to ensure that 
the correct band is identified. However, the results indicated that all four bands were 
representatives of each allergen, suggesting that the smaller bands may be degraded 
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proteins while the larger bands may be aggregates. It was only necessary to confirm 
that the expressed proteins are indeed the allergen of interest, therefore the result 
of this mass spectrometry analysis was sufficient for this study.  
 
Purification of the expressed recombinant proteins were attempted, however did not 
yield satisfactory results. Further purifications were not attempted due time and 
resource limitations. It was decided to use the crude E. coli extracts after protein 
expression for the successive chapters of this thesis. As a future direction, these 
recombinant proteins can be purified using a number of methods. All the proteins 
were expressed with N-terminal 6xHis-tags, therefore Ni-NTA affinity purification 
followed by high-performance liquid chromatography (HPLC) can be used to purify 
the proteins for downstream applications including animal based studies or clinical 
testing. A circular dichroism (CD) spectroscopy analysis of the purified recombinant 
allergens can be used to obtain detailed structural information, especially for OVM 
which was not identified by mass spectrometry in this study. The most important 
characteristic of the produced recombinant allergens is that they are not 
contaminated with other egg white proteins, which can potentially be used in SIT for 
patients allergic to a particular/specific egg white allergen. However, the 
allergenecity, or IgE reactivity, of these recombinant allergens must first be 
established and is addressed in Chapter 3 of this thesis.        
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2.5 Conclusion  
Allergy to chicken egg white is a disorder of the immune system mainly affecting 
children. Pure individual egg white allergens will be beneficial for treatment methods, 
such as immunotherapy, and diagnostics, such as skin prick tests. Recombinant 
protein production has been utilized to produce a range of other types of allergens. 
This study aimed at producing recombinant versions of the 4 major egg white 
allergens; OVM, OVAL, OVT and LYS. E. coli was used as the host system of choice due 
to the myriad of benefits it offers for recombinant protein production. The results 
showed that all four proteins were successfully expressed in E. coli. These proteins 
have the potential to be used in downstream applications and potentially be used in 
animal trials and clinical testing aimed at treating egg allergy.              
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recombinant allergens with natural 
eggwhite allergens 
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immunological analysis of IgE reactive recombinant egg white allergens 
expressed in E. coli. Molecular Immunology: 65: 104-112.  
(This publication includes findings from Chapter 2 & 3 of this thesis) 
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3.1 Introduction 
Food allergy is the major cause of conditions such as asthma, eczema and respiratory 
allergies in children 80. Egg allergy is no exception; it is second only to cow’s milk 
allergy in the spectrum of food allergies and it affects mainly children 51. It is also the 
most common allergy among children with atopic dermatitis 83,84. Egg allergy also 
affects adults 87, however in a smaller scale when compared to the number of 
affected children. Children with egg allergy normally grow out of the condition by 
school age 88,89, however, due to the severity of the condition which may cause life-
threatening anaphylaxis, it remains an immense problem in many societies around 
the world. 
 
The pathogenesis of egg allergy directly involves the intestinal immune system. The 
mucosal barrier of the intestine provides the first line of defence against potentially 
harmful or non-harmful environmental substances including allergens. The intestinal 
immune system often promotes immune-suppression instead of immune-promotion 
to avoid unnecessary harm to the individual 49. The digestive enzymes, proteases, bile 
salts and lipases also plays a key role against foreign substances by creating a harsh 
environment 52. However, all of these obstacles are overcome by egg white allergens 
in individuals with egg allergy; partly due to the rigidity of the egg allergens and partly 
due to abnormalities in the intestinal immune system 62. The abnormalities in the 
intestinal immune system may be due to genetic predisposition. In egg allergic 
patients, upon contact with an egg allergen, antigen presenting cells (APCs) found 
mainly in the lamina propia of the intestine present the allergen/antigen to T-cells. 
Differentiation of these T-cells causes antigen specific priming of B-cells to produce 
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excessive amounts of allergen specific IgE. The specific IgE molecules are directly 
responsible for the release of chemical mediators that cause clinical symptoms of egg 
allergy 2,20.     
 
Currently there is no permanent cure for egg allergy. The most advisable 
management method is strict dietary avoidance, however the occurrence of egg and 
traces of eggs in a range of food products, pharmaceuticals such as vaccines and other 
consumables makes it almost impossible to completely avoid egg allergens83. The 
most successful egg allergy treatment strategy in the clinic is allergen SIT. Being a 
food allergy, egg allergy is often treated with OIT, a type of SIT, and has been the 
most promising method. OIT aims to induce tolerance to an individual allergic to a 
particular food allergen by orally administering the allergen 149,194. Immunotherapy 
takes into account the role of IgE during the adverse immune reactions and aims to 
promote stepwise reduction in the production of allergen specific IgE, a process 
known as allergen desensitization 195. This immune rehabilitation process may have 
drawbacks, especially in highly sensitive individuals who may be prone to severe 
conditions such as anaphylaxis. 
 
During OIT, it is important to consider the allergic reactivity of each patient to specific 
allergens in the chicken egg. Egg allergy is mainly caused by the four main allergens 
in the egg white; ovomucoid (OVM), ovalbumin (OVAL), ovotransferrin (OVT) and 
lysozyme (LYS). Some patients may react to one allergen at higher intensities than to 
the other allergens. This complicates the process of OIT because natural allergen 
extracts used in OIT are often not pure, contaminated with other allergens. It is also 
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difficult to control the amount of natural egg allergens to be administered to the 
patient. Due the difficulties faced with natural allergens in OIT, production of 
recombinant allergens has been pursued as an excellent alternative for many 
allergies 160. Recombinant allergens are purer than their natural counterparts and 
free from contamination with other allergens and substances. These recombinant 
allergens can also be used in safer practice of diagnostic methods such as skin prick 
tests (SPT).  
 
This Chapter aimed at scrutinizing the IgE reactivity of recombinant OVM, OVAL, OVT 
and LYS produced in Chapter 2 of this thesis. These recombinant allergens were 
analysed for their IgE reactivity using egg allergic non-allergic patients’ sera from a 
well-defined Australian population. Initially, it was necessary to immunologically 
analyse natural egg white with each allergic sera sample. A pool of egg allergic sera 
was then made using the most reactive sera samples, which was then used to analyse 
the IgE reactivity of the recombinant allergens.    
     
                 
3.2 Methods 
3.2.1 Preparation of natural egg whites 
Commercially available caged and free-range eggs were purchased from a 
supermarket. Each type of egg was cracked and the contents were put into a sterile 
porcelain bowl. The egg yolks were carefully removed by sucking the yolks using an 
empty plastic bottle, ensuring the yolk is not damaged and completely removed. The 
protein concentration of each egg white was measured using a Nano Drop. 1 volume 
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of each egg white was then combined with 3 volumes of dH20 and the protein 
concentrations were measured again.  
 
 
3.2.2 SDS-PAGE of the natural egg whites to determine protein concentration 
10 μg and 20 μg of each egg white (caged and free-range) was then analysed by SDS-
PAGE. 1 μL (for 10 μg) and 2 μL (for 20 μg) of the egg white preparations were 
combined with 20 μL of 2 x Tris-Glycine SDS sample loading buffer (Life Technologies, 
Cat. No. LC2676). All samples were then heated at 85°C for 2 minutes and loaded 
onto 4-20% gradient Novex Tris-Glycine gels (Life Technologies, Cat. No. 
EC60252BX5). The gels were placed in a XCell II Blot™ Module (Life Technologies, 
Cat.No. EI0002) and tightened to create an inner and an outer chamber within the 
module.  The inner chamber was filled with Novex® Tris-Glycine SDS running buffer 
(1x) (Life Technologies, Cat.No. LC2675) until the chamber was overflown. The outer 
chamber was then half filled with running buffer and the anode and cathode were 
connected. The gel was run for ~1.5 hours at 125 V (constant voltage). Upon 
completion of the gel run, the gels were washed in dH20 to remove running buffer. 
The gels were then stained in SimplyBlue™ SafeStain (Life Technologies, Cat.No. 
LC6060) for one hour on a platform rocker. The stain was washed with dH20 and the 
gels were incubated in fresh dH20 overnight at room temperature with rocking. Next 
day the gels were dried using Gel-Dry™ drying solution (Life Technologies, Cat.No. 
LC4025) and the dried gel images were captured by scanning with a white 
background.  
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3.2.3 Western blot analysis of natural egg white to test for non-specific binding of 
secondary antibody 
A SDS-PAGE was conducted using 10 μg of each egg white which were run on two 
lanes next to each other. SeeBlue® Pre-stained protein standard (Life Technologies, 
Cat.No. LC5625) was also included in another lane. Upon completion, the proteins on 
the gels were transferred onto nitrocellulose membranes on a XCell II™ Blot Module. 
Essentially, a transfer sandwich was made in the following order: 2 x blotting pad-
filter paper-gel-nitrocellulose membrane-filter paper-2x blotting pad. The sandwich 
was then assembled into the module and the inner chamber was filled with Novex® 
Tris-Glycine transfer buffer (1x) (Life Technologies, Cat.No. LC3675). After connecting 
the anode and the cathode, the transfer was conducted at 25 V for 2 hours. The 
membrane was then stained in 10 mL of Ponceau S (Sigma-Aldrich, Cat.No. P7170) 
for 5 minutes and the stain was washed with dH2O. The membrane was visualised 
and then destained by washing the blot in 10 mL of 0.1M NaOH until the colour 
washed off. The blot was then washed 3-4 times with dH2O before proceeding to the 
next step.    
 
The proteins on the nitrocellulose membranes were detected using WesternBreeze® 
chromogenic detection kit (Life Technologies, Cat. No. WB7103). First, the membrane 
was blocked in 10 mL of blocking buffer (hammerstein casein solution in buffered 
saline- supplied in WesternBreeze® Chromogenic kit) for 1 hour, followed by rinsing 
with dH20 twice (5 minutes each time). The membrane was incubated with 10 mL of 
monoclonal anti-human IgE-alkaline phosphatase conjugated-antibody (Sigma-
Aldrich, Cat.No. A3076) at a concentration of 1:1000 for 1 hour with agitation. The 
104 | P a g e  
 
Chapter 3 
membrane was washed 5 times with prepared antibody wash and rinsed 3 times with 
dH20. The membrane was then incubated with 5 mL of chromogenic substrate (5-
bromo-4-chloro-3-indolyl-phosphate (BCIP)/nitro blue tetrazolium (NBT)) until 
purple bands developed on the membrane. When bands appeared, the reaction was 
stopped by rinsing the membrane 3 times with dH20. The developed blot was then 
captured on a Chemidoc.    
 
 
3.2.4 Immunological analysis of natural egg white against egg allergic patients’ 
sera 
Experimentation involving patients’ sera was conducted in compliance with the 
National Statement on Ethical Conduct in ,ƵŵĂŶZĞƐĞĂƌĐŚ;ϮϬϬϳͿǁŝƚŚĂƉƉƌŽǀĂůĨƌŽŵ
ĞĂŬŝŶ University Faculty of Science, Engineering and Built Environment Human Ethics 
Advisory Group (HEAG), with a project approval number of STEC-34-2013-
,EW>͘ 
 
Egg white from a freshly laid egg was separated from the egg yolk and 1 volume of 
the egg white was diluted with 3 volumes of dH20. 10 μg of the diluted egg white (per 
well) was run on 4-20% gradient Tris-Glycine gels and blotted on to nitrocellulose as 
previously discussed in Section 3.2.2 and Section 3.2.3. The Poceau S stained blots 
were then carefully cut into individual lane strips using sterile scissors, a total of 36 
strips were obtained of which 3 contained the molecular weight marker. The strips 
were then destained by washing with 0.1M NaOH to remove Ponceau S stain. Lastly, 
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the strips were blocked using the provided blocking buffer for 1 hour and the blocking 
buffer was washed twice with dH2O for two minutes. 
 
Allergic and non-allergic patients’ sera were obtained from the Murdoch Childrens 
Research Institute of the Royal Children’s Hospital (Melbourne, Australia): 25 egg 
allergic, 5 other allergies, and 10 non-allergic. 100μL of each allergic serum sample 
was diluted with 900 μL of blocking buffer. The nitrocellulose strips with immobilised 
egg white proteins were then incubated with each of the diluted serum sample 
overnight at 4°C (i.e. 1 strip per patient). Next, the strips were incubated with anti-
human IgE (alkaline phosphatase conjugated) secondary antibody produced in 
mouse. Three nitrocellulose strips were incubated with only the secondary antibody 
as negative controls.  The detection was carried out using the WesternBreeze® 
Chromogenic kit as previously mentioned in Section 3.2.3.  
 
 
3.2.5 Mass spectrometry analysis of the natural proteins 
The 4 bands that appeared to be the 4 allergens were incised from a freshly run gel 
with egg white and a mass spectrometry analysis was conducted to confirm the 
identity of the proteins. The gel bands were in-gel-digested with trypsin and 
incubated overnight at 37°C to digest the proteins into peptides.  In-gel-digest 
samples were analysed on a LTQ Orbitrap Elite (Thermo Scientific) coupled to an 
Ultimate 3000 RSLC nanosystem (Dionex), as described in section 2.2.17 of this thesis. 
Data analysis was carried out using Proteome Discoverer (Thermo Scientific version 
1.4) with Mascot against the BIRDS database. Search parameters were precursor 
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mass tolerance of 10 ppm, fragment mass tolerance of 0.6 Da (CID). 
Carbamidomethyl of cysteine was set as fixed modification and oxidised methionine 
as a variable modification.  Trypsin with maximum of 1 missed cleavage was used as 
the cleavage enzyme.    
 
 
3.2.6 Immunoassay of recombinant proteins against allergic patients’ sera 
The 4 recombinant egg white allergens produced in Chapter 2 were freshly expressed 
in E. coli and 5 mL cultures were pelleted after 2 hours post induction with IPTG. The 
cell pellets were lysed using Cell Lytic B and the fractions of E. coli that showed 
expression of each allergen were run on SDS-PAGE and blotted onto a nitrocellulose 
membrane. For OVM and OVAL, the soluble fraction was used and for OVT and LYS, 
the insoluble fraction was used. This was done in duplicate, one to be used with 
allergic sera and the other with non-allergic control sera. Another nitrocellulose blot 
was prepared by immobilising the soluble and insoluble fractions of E. coli extract (i.e. 
E. coli containing the pTrcHisA vector without an insert was IPTG induced for 2 hrs 
and soluble and insoluble fractions were collected). 
 
A pool of egg allergic patients’ sera was prepared by combining 50 μL sera of patients 
4, 5, 6 & 7 with 1800 μL of blocking buffer. The 2 mL allergic patients’ serum pool was 
first pre-incubated with the nitrocellulose membrane containing the E. coli extracts 
for 2 hrs at room temperature. Then one of the nitrocellulose membranes with the 
recombinant proteins was incubated with the same E. coli depleted serum pool 
overnight at 4°C with agitation. The remaining recombinant protein membrane was 
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incubated in a pool of non-allergic patients’ sera pool prepared by combining 50 μL 
of 10 non-allergic sera samples with 1500 μL blocking buffer. All the blots were then 
incubated with anti-human IgE-alkaline phosphatase conjugated- secondary 
antibody produced in mouse (1:1000), and detected using the chromogenic 
substrate, as described in Section 3.2.3.   
 
The above-mentioned western blot was repeated using anti-human-IgE-alkaline 
phosphatase conjugated-secondary antibody produced in goat (1:1000). In this case, 
an extra western blot was conducted using the recombinant proteins with anti-Xpress 
antibody as the primary antibody and anti-mouse IgG-alkaline phosphatase 
conjugated- antibody as the secondary antibody.     
 
 
3.3 Results 
3.3.1 Preparation of egg white 
Freshly laid caged and free-range egg whites were analysed by SDS-PAGE at two 
different concentrations; 10 μg and 20 μg. There was no visible difference in the 
protein profile of the two types of eggs. Lanes loaded with 10 μg of egg white showed 
clearer bands than the lanes loaded with 20 μg (Figure 3.1). The caged and free-range 
egg whites were then analysed by western blotting using anti-human-IgE antibody. 
There were no visible bands in the western blot at the beginning of chromogenic 
development. After 4.5 minutes of chromogenic substrate incubation, faint bands 
appeared at two different molecular weights (Figure 3.2).   
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Figure 3.1: SDS-PAGE of egg whites to determine the best amount to use for 
successive immunological analysis. Egg whites from freshly laid caged and free-
ranged eggs were separated from the egg yolks. The egg whites were diluted in 3 
volumes of dH20. 10 μg and 20 μg of each type of egg white was then analysed by 
^^-PAGE on a 4-20% gradient Tris-Glycine gel.  
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Figure 3.2: Western blot analysis of natural egg whites to detect possible non-
specific binding of anti-human-IgE antibody. 10 μg of prepared egg white from caged 
and free-range eggs were run on a 4-20% gradient Novex Tris-Glycine gel along with 
the SeeBlue® pre-stained protein standard (MW). Upon completion, the proteins on 
the gel was transferred onto a nitrocellulose membrane and the protein bands were 
visualised with Poceau S solution. After an image of the protein profile was captured, 
the blot was destained using 0.1 M NaOH and washed with dH20. The blot was then 
incubated with anti-human-IgE-alkaline phosphatase conjuaged-antibody and the 
blot was detected using a chromogenic substrate (BCIP/NBT).   
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3.3.2 Immunological analysis of natural egg white 
Prior to testing of the recombinant proteins, natural egg white was tested against a 
population of egg allergic and other allergic sera to test for IgE reactivity 
(allergenicity). The western blots conducted shows that 10 patients were allergic to 
OVM, 4 to OVAL, 14 to OVT and 18 to LYS (Figure 3.3 and Figure 3.4). A number of 
individuals showed reactivity to more than 1 allergen as depicted in Table 3.1. 
Patients who showed reactivity to all 4 allergens had higher egg specific serum IgE 
levels when compared to the others (Table 3.1). The mass spectrometry analysis 
conducted on the 4 bands, identified as the allergens, confirmed the identities of the 
proteins, except for OVM (Table 3.2). 
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Figure 3.3: Western blot analysis of chicken egg white against egg allergic patients’ 
sera. Natural egg whites were immobilized on nitrocellulose strips membranes and 
were incubated with egg allergic patients’ sera. The strips were then incubated with 
anti-human-IgE secondary antibody and bands were detected using a chromogenic 
substrate (BCIP/NBT). Control strips were incubated only with the secondary 
antibody. 
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Figure 3.4: Number of individuals allergic to each natural egg white allergen in an 
Australian population. This graph shows the number of patients allergic to each 
allergen as determined from the western blot analysis shown in Figure 3.3. 
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Table 3.1: The number of allergens each patient is allergic to (as extracted from the 
western blots on Figure 3.3) and their corresponding egg specific serum IgE levels.  
Patient Egg specific 
serum IgE 
level 
(IU/ml)* 
OVM OVAL OVT LYS Other allergies 
1 1.25 9 - 9 9 Peanut 
2 1.78 9 - 9 9 Peanut 
3 3.62 9 - 9 9 - 
4 28.8 9 9 9 9 - 
5 13.6 9 9 9 9 - 
6 9.26 9 - 9 9 - 
7 93.5 9 9 9 9 Peanut 
8 18.5 - - - 9 - 
9 13.2 9  9 9 Peanut 
10 16.5 9 - 9 9 - 
11 2.58 - - - - - 
12 2.21 - - - - - 
13 2.08 - 9 9 - Peanut 
14 6.89 9  9 9 Peanut 
15 4.13 - - - 9 Peanut 
16 1.72 - - - - - 
17 1.32 - - 9 - - 
18 1.21 - - - - Peanut 
19 8.63 - - - - - 
20 1.02 - - - - Peanut 
21 1.05 - - - - Peanut 
22** 0 - - - - Rye grass 
23** 0 - - - 9 Rye grass 
24** 0 - - - 9 Rye grass 
25 0.47 - - 9 9 Peanut & Rye grass 
26** 0 - - 9 9 Rye grass 
27 0.32 - - - 9 Peanut 
28 0.18 - - - 9 Peanut 
29** 0 - - - - Peanut 
30 1.19 - - - - Peanut 
 
Table 3.2 Mass spectrometry analysis of the natural egg white allergens. 
Database Gel section 
 
Identified protein name Protein 
score 
Sequence 
coverage (%) 
Birds OVM - - - 
Birds OVAL Ovalbumin 2840 76 
Birds OVT Ovotransferrin 4219 75 
Birds LYS Lysozyme 1087 72 
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3.3.3 Immunological analysis of recombinant egg white allergens 
The recombinant proteins were then blotted onto nitrocellulose membranes and 
tested against egg allergic sera and non-allergic sera as the primary antibodies and 
anti-human-IgE antibody produced in mouse as the secondary antibody. The allergic 
sera was first pre-incubated with E. coli extract, this blot did not appear to have any 
bands post incubation with secondary antibody and chromogenic development 
(Figure 3.5). The blot incubated with allergic sera had multiple bands appearing for 
all allergens at the expected molecular weights, except LYS. OVM had two bands, 
OVAL had a doublet band and OVT had a prominent band at the expected molecular 
weight with some faint smeared bands at lower molecular weights (Figure 3.5). The 
blot incubated with non-allergic sera had bands appearing for OVAL and OVT (Figure 
3.5).    
 
A second western blot was conducted using a different secondary antibody; anti-
human-IgE antibody produced in goat. Another western blot was simultaneously 
conducted using anti-Xpress antibody as the primary antibody and anti-mouse-IgG 
antibody as the secondary antibody. The western conducted with the anti-Xpress 
antibody showed multiple bands for all allergens at the expected molecular weights, 
with multiple bands appearing for OVM, OVAL and OVT. OVAL in this blot showed a 
large band at the expected molecular weight with an excessive number of bands of 
different molecular weights (Figure 3.6). The blot incubated with allergic patients’ 
sera showed bands for OVM, OVAL and OVT at the expected molecular weights, with 
multiple bands appearing at different molecular weights (Figure 3.6). The blot 
incubated with non-allergic patients’ sera did not have any bands (Figure 3.6).   
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Figure 3.5: Immunological analysis of recombinant proteins against allergic 
patients’ sera and non-allergic sera using secondary antibody produced in mouse. 
The allergic serum pool was pre-incubated with E. coli extract (A). Then two blots were 
prepared, one was incubated with the pre-incubated allergic sera pool (B) and the 
other was incubated with the non-allergic sera pool (C). All blots were then incubated 
with anti-human IgE secondary antibody produced in mouse and developed with a 
chromogenic substrate (BCIP/NBT). The arrows indicate the band of interest for each 
allergen.  
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Figure 3.6: Immunological analysis of recombinant proteins against allergic 
patients’ sera and non-allergic sera using secondary antibody produced in goat. The 
allergens were first detected using anti-Xpress antibody to re-affirm the expression of 
all proteins (A). Then two blots were prepared, one was incubated with an allergic 
sera pool pre-incubated with E. coli extract (B) and the other was incubated with a 
non-allergic sera pool (C). Blots (B) and (C) were then incubated with anti-human IgE 
secondary antibody produced in goat and developed with a chromogenic substrate 
(BCIP/NBT). The arrows indicate the band of interest for each allergen.  
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3.4 Discussion 
Hypersensitivity to chicken egg is a disorder of the immune system mainly affecting 
children. As for many other food allergies, strict avoidance of eggs is the most 
efficient management strategy. However, this approach is rather impractical due to 
the extensive use of eggs in a range of food products, vaccines and other 
consumables83. The existence of eggs or traces of eggs in these products increases 
the risk of accidental exposure of the patient’s immune system to egg allergens, 
possibly causing unwanted clinical symptoms such as itching, rashes, urticaria, 
vomiting, and in the worst case, immune reactions such as anaphylaxis. In such 
instances, use of epinephrine auto-injectors such the EpiPen may provide temporary 
relief, however severe reactions may not be relieved 151.  
 
Immunotherapy is the only curative method pursued by clinicians to treat many types 
of allergies, including egg allergies. Allergen SIT involves the administration of small 
doses of an allergen to the patient to induced tolerance to that particular allergen149. 
These allergens are administered subcutaneously, sublingually or orally. OIT is often 
used for treating food allergies in countries such as Australia and Europe. In this 
process, patients are orally given extracts of the relevant allergen with increasing 
doses 194. OIT is advantageous for food allergic treatment because it takes into 
account the normal route a food allergen enters the body; the gastrointestinal tract. 
However, there are drawbacks with OIT, and other types of immunotherapy, due to 
the unavailability of pure uncontaminated allergens. Recombinant protein 
production allows production of recombinant allergens with high purity independent 
of other allergens from the same source. This chapter analysed the IgE reactivity of 
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the recombinant egg white allergens produced in Chapter 2 of this thesis. The 
recombinant proteins were analysed using egg allergic and non-allergic patients’ 
sera.             
        
Prior to testing the produced recombinant allergens against allergic patients’ sera for 
IgE reactivity, it was necessary to test the obtained patient sera against natural egg 
white to choose the most allergic serum samples. The Western blot shown in Figure 
3.3 indicates that the obtained serum population did not react to all of the allergens 
at similar intensities, with some samples showing reactivity to only one allergen. This 
result suggests that egg allergy in Australian populations may mainly be due to 
allergic reactivity of OVT and LYS, although individuals allergic to OVM showed higher 
intensity of IgE reactivity. Patients that showed reactivity to all 4 allergens had higher 
egg specific serum IgE levels, suggesting a possible correlation between the high 
serum IgE levels and multi-reactivity to different allergens. However, this correlation 
cannot be confirmed without a larger number of samples to show statistical 
significance. It should be noted that some individuals who had egg specific serum IgE 
did not react to any of the allergens, which can be attributed to allergy to egg yolk in 
these patients, an aspect not addressed in this study. The blot also shows that OVM 
has appeared at a higher molecular weight when compared to the recombinant 
protein, possibly due to the heavy glycosylation of natural OVM in egg white 110. The 
mass spectrometry analysis showed that OVM was not identified, possibly due to the 
trypsin inhibitory activity of OVM. The gel slices were trypsin digested for mass 
spectrometry analysis, therefore OVM may have affected this process thus hindering 
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the result. The same result was also observed in Chapter 2 when the recombinant 
proteins were analysed by mass spectrometry analysis.  
 
The 4 serum samples that showed most IgE reactivity to natural egg white were then 
used to make a serum pool that showed reactivity to all 4 allergens, which was used 
to test the recombinant allergens for IgE reactivity. The results shown in Figure 3.5 
indicate that 3 of the 4 allergens were IgE reactive; with only LYS not showing 
reactivity. However, non-allergic sera blot also showed bands for OVAL and OVT 
indicating that the secondary antibody non-specifically binds to these two 
recombinant proteins. Therefore, it was decided to repeat the western blot using a 
secondary antibody produced in goat instead of mouse. The blot shows that OVM 
and OVT had more reactivity when compared to OVAL, consistent with the result seen 
in Figure 3.3 in which natural OVM and OVT were more allergenic to the 4 chosen 
serum samples. The serum pool was pre-incubated with E. coli extract to deplete the 
pool of any E. coli specific IgE, which could have given a false positive in the 
experimental blots. However, the results indicate that there were no E. coli specific 
IgE present in the serum pool. The successful use of crude extract shows that it is not 
vital to purify the natural egg proteins for preliminary IgE reactivity studies like the 
current study. In addition, the results also show that heating of the protein samples 
at 85°C for 2 minutes before SDS-PAGE does not appear to affect the IgE reactivity of 
the proteins. The blot conducted using anti-Xpress antibody confirmed that all 
proteins are expressed and present on the blot.  
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The western blots of the recombinant allergens showed the presence of multiple 
bands for OVM, OVAL and OVT. This is probably due to breakdown of the proteins 
during expression. Some of the breakdown proteins were IgE reactive; these may 
have been breakdown products containing IgE binding epitopes of the proteins. 
Regardless of the protein breakdown, all three proteins had a band at the expected 
molecular weight. As mentioned earlier, LYS was not found to be IgE reactive for an 
unexplainable reason. However, it can be suggested that competition from the other 
three allergens, in particular highly IgE reactive OVM and OVT, may have contributed 
to the diminished or loss of IgE reactivity of LYS. This may be overcome by conducting 
the western blot of the allergens separately and independently of one another.    
 
The production of IgE reactive recombinant counterparts of natural egg allergens 
opens doors for downstream applications, including SIT. IgE reactive OVM has been 
previously produced by Rupa and Mine 159, however the current study focuses on an 
Australian population, which has not been tested previously. Other research groups 
have expressed OVAL, OVT and LYS in various expression systems, however their IgE 
reactivity has not been tested simultaneously against egg allergic patients’ sera, or, 
poorly studied. The clinical significance of this study is the potential use of purified 
recombinant proteins for SIT and for diagnostic methods such as SPT. Currently, SPT 
utilizes whole egg extracts or components isolated from natural eggs for 
diagnosis196,197. The recombinant proteins produced in this study, due to the lack of 
contamination with other allergens, may be used in SPT to pinpoint which allergen a 
patient might be allergic to. Another important application of the produced 
recombinant proteins is OIT, a type of SIT, in which heat denatured proteins can be 
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administered orally to induce tolerance. OVM and OVT are known to contain 
conformational and linear IgE binding epitopes, making them IgE reactive even after 
heat denaturing, with OVT showing an increase in IgE reactivity after heat 
denaturing122,198. These properties make these two proteins ideal candidates for OIT. 
For patients allergic to more than one allergen, the recombinant proteins can be used 
in a step-wise manner in SIT to induce tolerance without causing an augmented 
immune response.   
 
 
3.5 Conclusion 
In summary, this study assessed the relative IgE reactivity of four recombinant egg 
white allergens in a well-defined Australian patient group. The patients’ sera were 
first tested against natural egg white, which revealed that the patient population is 
mostly affected by allergenecity to OVT and LYS while OVM showed higher reactivity. 
The immunoassays conducted to scrutinize the recombinant allergens showed that 
OVM, OVAL and OVT were IgE reactive while LYS was not IgE reactive. The availability 
of purified preparations of these IgE reactive recombinant allergens promises to 
contribute significantly to egg white allergy diagnostics and therapeutics in the 
future.      
 
 
122 | P a g e  
 
Chapter 4 
 
CHAPTER 4 
Hypoallergenic variant of the major 
egg white allergen ovomucoid 
produced by disruption of cysteine 
bridges 
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the major egg white allergen Gal d 1 produced by disruption of cysteine 
bridges: International Archives of Allergy and Immunology (submitted 
for review). 
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4.1 Introduction 
Hypersensitivity to chicken egg is caused by allergens present in the egg white and 
egg yolk. Among these, OVM (ovomucoid) is known to be the most allergenic and 
predominant allergen and it is found in the chicken egg white 109,110. This 28 kDa 
glycoprotein accounts for approximately 11% of the total egg white protein. The 
tertiary structure of OVM is composed of 186 amino acids which form three domains, 
with each domain containing approximately 60 amino acids. The tertiary structure is 
robustly supported by 9 intra-domain cysteine-cysteine disulphide bridges and 5 
oligosaccharide side chains. The function of OVM is known to be a trypsin inhibitor, 
however the trypsin inhibitory activity is limited to the second domain 109. 
Hypersensitivity to OVM occurs because of its ability to efficiently bind to IgE. It has 
8 IgE binding epitopes 110, of which some are linear while others are conformational. 
The highly IgE reactive epitopes present in the third domain make it the most 
allergenic domain of the three. The presence of linear IgE binding epitopes in OVM 
makes it resistant to conditions such as heat and/or proteolytic digestion 199. Since 
egg allergic patients are often allergic to cooked egg 200, it can be suggested that OVM 
plays a crucial role in cooked egg allergy due to its rigidity. These specific features of 
OVM make it the prime allergen when compared to other allergens in chicken egg 
and an ideal target for development of egg allergy treatment strategies.       
      
There is no long term cure for egg allergy. Strict avoidance of egg is the currently 
recommended management strategy, however avoidance is difficult and may cause 
malnutrition in children 201,202, especially in financially disadvantaged families where 
procurement of more expensive nutritional supplements or food that can replace 
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eggs may be difficult. It is also problematic to completely avoid eggs because of the 
presence of components or traces of egg in various food products, pharmaceutical 
products and vaccines 203,204. Allergen specific OIT offers a potential treatment 
strategy, not only for egg allergy but also for other type of food allergies. OIT 
essentially involves the gradual oral feeding of an allergen to the patient in order to 
induce tolerance 205,206. However, OIT can be perilous for some patients, primarily 
because of the high allergenicity of some allergens and the sensitivity of the patient, 
which may cause adverse conditions such as anaphylaxis that can even lead to death 
207-209. Adverse reactions to OIT are currently a potential barrier to clinical application 
210,211. Therefore, production of less allergenic versions, or hypoallergens, of allergens 
has been the focus of many research groups 212-214, since these hypoallergens can 
offer improved safety of OIT.  
 
Production of hypoallergenic OVM can be achieved by using mutagenesis as a tool in 
two different strategies; one, by mutating the sequences of the IgE binding epitopes, 
two, by targeting the secondary structure of the proteins. Drew et al (2004) 154 
successfully produced a hypoallergenic variant of the major latex allergen Hev b 6.10 
by disrupting the cysteine-cysteine bonds of the protein to reduce its IgE reactivity. 
In this study, it was aimed to produce a hypoallergenic variant of OVM by targeting 
cysteine-cysteine disulphide bridges using site-directed mutagenesis.       
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4.2 Methods 
4.2.1 Site-directed mutagenesis of OVM  
The cDNA of OVM was cloned into pTrcHisA expression vector as discussed in 
Dhanapala et al 2015 161. This construct was used for site-directed mutagenesis of 
nucleotides coding two cysteine residues, using QuickChange Lightning Multi Site-
Directed Mutagenesis kit (Agilent Technologies Cat. No. 210513). Two TGC triplicates 
coding for cysteine 192 and 210 (Figure 4.1) were targeted in order to disrupt two 
different cysteine-cysteine bridges located in domain III of OVM (Figure 4.2). The TGC 
codons were changed to GCC codons that code for alanine. Initially, mutagenic primer 
pairs were designed according to the mutagenesis kit guidelines. The two pairs were 
named PM7 and PM9, because the mutations were targeting the 7th and the 9th 
cysteine-cysteine bridges, respectively. The primers are as follows; 
PM7 forward 5'-GGCAACAAGTGCAACTTCGCCAATGCAGTCGTGGAAAG-3'  
PM7 reverse 5'-CTTTCCACGACTGCATTGGCGAAGTTGCACTTGTTGCC-3'  
PM9 forward 5'-ACTCTCACTTTAAGCCATTTTGGAAAAGCCTGAAAGCTTGGCTGT-3'  
PM9 reverse 5'-ACAGCCAAGCTTTCAGGCTTTTCCAAAATGGCTTAAAGTGAGAGT-3'  
 
The bolded and underlined GCC on forward primers show the mutations. To mutate 
the OVM cDNA in pTrcHisA vector, the above-mentioned primers and the cDNA 
constructs (as template DNA) were subjected to a polymerase chain reaction (PCR). 
The PCR reaction was set up according to Table 4.1. The PCR was then run according 
to the cycling parameters outlined in Table 4.2. Following the PCR, the reaction was 
digested with ƉŶI for 5 minutes at 37°C, to digest the non-mutated template DNA. 
Figure 4.3 outlines the site-directed mutagenesis process.       
126 | P a g e  
 
Chapter 4 
 
Figure 4.1: The nucleotide and amino acid sequence of OVM. The squared cysteine 
(C) residues at positions C192 and C210 are the targeted residues. These were 
replaced with alanine by mutating the nucleotides to GCC.   
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Figure 4.2: The secondary structure of OVM showing the total number of cysteine 
bridges. The two arrows show the two cysteine bridges that would be destroyed by 
the mutations shown in Figure 1. (Figure adapted from Kato et al 1987 109).  
 
 
 
 
 
 
 
 
 
128 | P a g e  
 
Chapter 4 
Table 4.1: Mutagenic PCR master mix components.        
Reaction component Volume used (μL) 
10x QuickChange Lightning Multi 
reaction buffer  
2.5  
Double-distilled H20  15.5 
Template DNA  1 (50 ng) 
Mutagenic primers 1 of each primer (100 ng of each 
primer) 
dNTP mix 1 
QuickChange Lightning Multi enzyme 
blend 
1 
Total 25 
 
 
Table 4.2: Mutagenic PCR conditions. 
Segment Cycles Temperature Time 
1 1 95°C 2 minutes 
2 30 95°C 20 seconds 
55°C 30 seconds 
65°C  3 minutes (30 
seconds/kb of 
plasmid length) 
3 1 65°C 5 
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Figure 4.3: An outline of the site-directed mutagenesis process. (Figure adapted 
from QuickChange Lightning Multi Site-ŝƌĞĐƚĞĚ DƵƚĂŐĞŶĞƐŝƐ Ŭŝƚ ŝŶƐƚƌƵĐƚŝŽŶƐ
manual).    
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4.2.2 Chemical transformation into E. coli 
The mutated plasmids were then transformed into XL10-Gold ultracompetent E. coli 
ĐĞůůƐ͘ƐƐĞŶƚŝĂůůǇ͕Ϯђ>ŽĨƚŚĞƉƌŽǀŝĚĞĚɴ-mercaptoethanol mix was added to 45 μL of 
XL10-Gold cells in an Eppendorf and incubated on ice for 10 minutes, with gentle 
swirling every 2 minutes.  Then, 1.5 μL of the ƉŶI-treated mutagenesis reaction was 
added to the E. coli cells, gently mixed and incubated on ice for 30 minutes. The mix 
was then heat-pulsed for exactly 30 seconds at 42°C on a heat block and incubated 
on ice for 2 minutes. The reaction was incubated with 0.5 mL of pre-heated LB media 
at 37°C for 1 hour at 250 rpm. The transformant was then spread-plated on LB agar 
with 50 μg/mL ampicillin and incubated overnight at 37°C. The next day, 6 clones 
were grown in fresh LB media with ampicillin and grown overnight. The cells in 
overnight cultures were pelleted by centrifuging at 13,000 rpm for 5 minutes and 
subjected to a mini-prep (Qiagen Cat. No. 27104) to isolate the plasmid constructs 
according to the method outlined in section 2.2.10. The isolated plasmids of the 6 
clones were sequenced to confirm the mutations. The sequences were aligned and 
compared with wild type OVM using the NCBI BLAST tool. The clones that had the 
correct sequence and the mutations were then transformed into Express Iq chemically 
competent E. coli cells (New England BioLabs, Cat.No.: C3037H) following 
manufacturer’s guidelines. The transformants were plated on LB agar with ampicillin 
and incubated overnight at 37°C. In addition to the mutant transformants plate, a 
sample of glycerol-stocked E. coli containing the wild-type ovomucoid construct was 
also plated on LB agar with ampicillin.        
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4.2.3 Time-course expression of mutant OVM to determine optimum expression 
time 
A single colony of the mutant OVM was grown overnight in LB media with 50 μg/mL 
ampicillin. The overnight culture was then subcultured in 10 mL of fresh LB media and 
grown to mid-log phase (OD600 0.4-0.6). A 1 mL sample of the cells was pelleted to be 
used as the unexpressed control (0 hour) of the time-course expression. Expression 
was then induced with 40 μL of IPTG and the cells were incubated for 6 hours at 37°C 
with shaking at 250 rpm. A 1 mL sample was collected every one hour for a 6 hour 
period. The pellets collected at time points 0, 2, 4, 5 and 6 were lysed using 400 μL of 
Cell Lytic B (Sigma Aldrich, Cat.No: B7435) lysis reagent and centrifuged at 13,000 
rpm for 5 minutes to separate the pellet (insoluble fraction) and the supernatant 
(soluble fraction). The two fractions were analysed by SDS-PAGE and western blot 
according to the methods described in Sections 2.2.13 and 2.2.14.    
   
 
4.2.4 Expression and immunoblotting of wild type and mutant OVM using three 
different detection antibodies 
The wild-type and mutant OVM were expressed in E. coli to their optimum time 
points as determined by the time-course expressions (wild-type OVM optimum time 
was determined in Chapter 2). Cells were pelleted and lysed using Cell Lytic B as 
previously described. The soluble fractions of both proteins were run on SDS-PAGE in 
equal amounts (15 μL), along with a molecular weight marker. A gap lane was left 
between the two proteins to avoid any cross-contamination between the two 
variants. The SDS gel was then transferred on to a nitrocellulose membrane to be 
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used for western blotting. A total of 5 nitrocellulose membranes were prepared this 
way, of which 2 would be used in the analysis described in Section 4.2.5. Three 
prepared nitrocellulose membranes were subjected to western blotting using 3 
different antibodies that can detect the expressed protein (e.g. anti-Xpress antibody, 
tetra-His antibody and penta-His antibody).  
 
 
4.2.5 Immunological analysis of wild type vs. mutant OVM using western blot 
Experimentation involving patients’ sera was conducted in compliance with the 
National Statement on Ethical Conduct in ,ƵŵĂŶZĞƐĞĂƌĐŚ;ϮϬϬϳͿǁŝƚŚĂƉƉƌŽǀĂůĨƌŽŵ
ĞĂŬŝŶ University Faculty of Science, Engineering and Built Environment Human Ethics 
Advisory Group (HEAG), with a project approval number of STEC-34-2013-
,EW>͘ 
 
The two remaining nitrocellulose membranes from Section 4.2.4 were used for 
immunoblotting using egg allergic and non-allergic patients’ sera to test for IgE 
reactivity. In Chapter 3, a pool of egg allergic patients’ sera and a pool of non-allergic 
patients’ sera for immunological analysis of recombinant egg white proteins were 
used. In this study, the same pooled serum preparations were used and incubated 
one membrane with allergic patients’ sera and the other with non-allergic patient’s 
sera, and incubated overnight at 4°C. The blots were then incubated with anti-human 
IgE (alkaline phosphatase conjugated) secondary antibody produced in goat at a 
dilution of 1:1000. The bands were detected using a chromogenic substrate as used 
in the western blots described in Section 2.2.14.      
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4.3 Results 
4.3.1 Mutagenesis of OVM  
Following site-directed mutagenesis to alter C192 and C210, 6 clones were 
sequenced to confirm the mutations. Five of the 6 clones had only one mutation 
present (Figure 4.4). One clone had both of the mutations at the expected locations 
of the sequence (Figure 4.5). When the wild-type OVM sequence was aligned with 
the mutant OVM sequence on NCBI BLAST, it was seen that the TGC codons (cysteine) 
for C192 and C210 had been changed to GCC, which in turn codes for alanine.  
 
4.3.2 Time-course expression of mutant OVM to determine optimum expression 
time 
The mutant OVM protein was expressed in E. coli following IPTG induction for 6 
hours, and pellets were collected every one hour, including one before IPTG 
induction. The pellets from time points 0, 2, 4, 5 and 6 were lysed and the soluble and 
insoluble fractions were analysed using SDS-PAGE and western blot. The results show 
that the optimum expression time point for mutant OVM is 5 hours (Figure 4.6), as 
compared to 2 hours for wild-type OVM (Figure 4.6). It can also be seen that the 
expression level of mutant OVM decreases after 5 hours.     
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Figure 4.4: Sequence alignment of wild-type OVM (query) and mutant OVM (Sbjct) 
showing only one mutation. The outlined region shows the mutation following site-
directed mutagenesis. The mutation is at C192, which changed the codon TGC to 
GCC.    
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Figure 4.5: Sequence alignment of wild-type OVM (query) and mutant OVM (Sbjct) 
showing both mutations. The two outlined regions show the two mutations following 
site-directed mutagenesis. The two mutations are at C192 and C210, which changed 
the codon TGC to GCC.    
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Figure 4.6: Time-course expression of the mutant OVM. The mutant OVM (B) was 
subjected to a time-course expression to determine its optimal expression time and 
conditions. This was then compared with the time-course expression of the wild-type 
OVM (A) as previously shown in Chapter 2. The arrows indicate the expected 
molecular weight of OVM.  
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4.3.3 Expression and immunoblotting of wild type and mutant OVM using three 
different detection antibodies 
The wild-type and mutant recombinant OVM proteins were expressed in LB till their 
respective optimum time points by inducing with IPTG. The proteins were analysed 
by SDS-PAGE and western blotting using three different antibodies (anti-Xpress, 
Tetra-His and Penta-His antibodies). The SDS-PAGE shows that similar amounts of 
both proteins are loaded on to the gel (Figure 4.7). The western blots show that there 
is a slightly higher amount of mutant protein present on the nitrocellulose membrane 
(Figure 4.7).    
 
 
4.3.4 Immunological analysis of wild type vs. mutant OVM using western blot 
Two nitrocellulose membranes were prepared using the same samples used for the 
blots shown in Figure 4.7. The two membranes were subjected to western blotting 
using egg allergic patients’ sera and non-allergic sera. The egg allergic patients’ sera 
blot shows reduced binding (lighter colouration) for the mutant OVM lane when 
compared to the wild-type OVM (Figure 4.8). The non-allergic sera blot showed no 
detectable bands in either of the lanes representing wild-type or mutant OVM (Figure 
4.8).   
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Figure 4.7: Immunoblot comparison of the wild-type and mutant OVM immobilized 
on nitrocellulose. Three western blots were conducted using His-tag specific 
antibodies (Tetra-His & Penta-His) and anti-Xpress antibody to compare the 
expression level of wild-type and mutant (PM7/9) OVM. The arrow indicates the 
expected molecular weight of OVM. 
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Figure 4.8: Immunological comparison of IgE reactivity of wild-type and mutant 
OVM. Western blots were conducted, with exactly the same amount of proteins 
loaded, with egg allergic and non-allergic patients’ sera. Anti-human IgE produced in 
goat was used as the secondary antibody. Non-allergic controls were used to test for 
any non-specific binding of secondary antibody. The blots show a loss of IgE reactivity 
in the mutant PM7/9. The arrows indicates the expected molecular weight of OVM. 
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4.4 Discussion 
Hypersensitivity to chicken egg white is mainly caused by 4 major egg white allergens. 
Of these, OVM is known to be the most allergenic protein. OVM is known to cause 
hypersensitivity in its natural or cooked form. This may primarily be due to its rigid 
tertiary structure that allows it to withstand harsh conditions such as heat and 
stomach/digestive acids. Due to the lack of an effective curative treatment, strict 
avoidance is currently the standard method of managing egg allergy. However, this 
strategy is not feasible due to the difficulty in achieving complete egg avoidance and 
the high nutritional value of eggs in a balanced diet, especially for children. Induction 
of tolerance to allergens is a well-established strategy for treatment of different types 
of allergies such as insect venom or pollen allergy. Immunotherapy, specifically OIT, 
which is a type of allergen SIT, has been explored for the induction of tolerance to 
food allergens. OIT involves feeding a patient increasing amounts of raw or cooked 
versions of the allergen source, in order to induce desensitization or long-lasting 
tolerance to the allergen 194. One barrier to implementation of OIT in the clinical 
setting is the high rate of adverse reactions necessitating discontinuation of therapy, 
which primarily involve immediate allergic reactions to the allergen 210,211.  
Recombinant versions of allergens offer an approach to reduce adverse reactions, 
thereby allowing improved effectiveness 160. These recombinant allergens are purer 
and free from contamination from other allergens of the food source, thus may also 
be useful for diagnosis of allergy (e.g. skin prick tests or immunoassay). Food allergies, 
including allergy to chicken egg, may sometimes cause severe reactions such as 
anaphylaxis. In such patients, use of natural or recombinant allergens for diagnosis 
or immunotherapy may be associated with unwanted allergic reactions. Therefore, 
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hypoallergenic, or less allergenic, versions of allergens would be useful in such 
patients with severe allergic reactions. Production of hypoallergenic variants has 
been rigorously pursued in allergy research. For example, the production of a 
hypoallergenic variant of the major latex allergen Hev b 6.01 by site-directed 
mutagenesis by Drew et al 2004 154, and development of a vaccine using 
hypoallergenic derivatives of the birch pollen allergen Bet V 1 by Niederberger et al 
2004 215. In this study, a hypoallergenic variant of the major egg white allergen OVM 
(OVM) that showed reduced IgE reactivity when compared to its wild-type 
counterpart was developed.  
 
For mutagenesis, it was decided to use alanine as a replacement for cysteine residues 
at C192 and C210 because it is the most common amino acid that does not have 
extreme electrostatic or steric effects on the conformation of the protein 216. The 
sequencing result of the 6 clones post mutagenesis showed that 5 clones had only 
one of the desired mutations present. The mutagenesis kit used in this study allowed 
introducing multiple mutations in a single reaction. Therefore, the low efficiency can 
be attributed to factors such as the quality of the template DNA or efficiency of the 
mutagenic primers. Nevertheless, one clone had both of the desired mutations at 
C192 and C210, replacing TGC codons (cysteine) with GCC (alanine). OVM secondary 
structure is made up of three tandem domains (I-III), with domain III showing high IgE 
reactivity 113. By targeting C192 and C210, it was aimed to destroy two cysteine-
cysteine disulphide bridges in domain III, thus altering its conformation. It was 
hypothesized that altering the conformation of domain III may have a significant 
effect on IgE reactivity of the whole protein.  
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The mutant OVM was successfully expressed in E. coli. A time-course expression was 
conducted to determine the optimum time point for expression of the mutant 
protein. It is known that the wild-type recombinant OVM was best expressed at 2 
hours post induction with IPTG 161. However, the expression pattern of the mutant 
protein was different to that of the wild-type, as shown in Figure 4. The mutant 
protein’s expression level increased with time up until 5 hours, as opposed to the 
wild-type protein’s which showed a reduction in expression after 2 hours. Similar to 
the wild-type, the mutant was highly expressed in the insoluble fraction, indicating 
that the expression of the protein causes formation of inclusion bodies in E. coli. 
Nonetheless, the amount expressed in the soluble fraction was sufficient for the 
remainder of this study.   
 
When analysing two proteins on an immunoblot to compare their reactivity for an 
antibody, it is essential to immobilize similar amounts of the two proteins. When 
comparing recombinant proteins, it is crucial that the proteins are purified to allow 
loading of similar amounts of proteins to a gel to be transferred on to a nitrocellulose 
membrane. In this study, purified recombinant versions of the wild-type or mutant 
OVM was not available due to time and resource constraints. Therefore, after 
inducing expression till the optimum time point of each variant, similar volumes of 
the crude E. coli extracts were loaded onto gels, transferred on to nitrocellulose and 
subjected to detection using different antibodies to confirm that both proteins are 
expressed and loaded at similar quantities. When analysed on SDS-PAGE and western 
blotted using anti-Xpress, Tetra-His and Penta-His antibodies, it was evident that 
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there was more of the mutant protein immobilized on the nitrocellulose membrane 
when compared to the wild-type protein. This was not a significant issue as the aim 
was to test the IgE reactivity of the mutant against the wild-type OVM.  It was only 
vital to ensure that the wild-type protein did not exceed the amount of mutant 
protein on the membrane. Following the aforementioned immunoassays, the two 
proteins were compared against each other for IgE reactivity using egg allergic 
patients’ sera. The blot in Figure 4.8 clearly shows that there is a significantly visible 
reduction of IgE reactivity in the mutant protein, although there is more of the 
mutant protein immobilized on the membrane. One may argue that the IgE in the 
sera may have attached/reacted to E. coli protein, however the results in Chapter 3 
shows that the IgE in the egg allergic sera used do not react to E. coli proteins 161. The 
membrane incubated with non-allergic sera showed no bands, indicating that the 
secondary antibody, anti-human IgE produced in goat, does not non-specifically bind 
to the recombinant proteins.   
 
This study shows that disruption of only 2 out of 9 cysteine-cysteine bridges in OVM 
by targeting C192 and C210, significantly reduces its reactivity to egg-specific IgE. The 
result also suggests that the structure of the protein plays a crucial role in its 
allergenicity. This mutant OVM has the potential to be used in safer egg OIT. This 
study provides preliminary results for future research involving production of 
hypoallergenic variants of egg allergens, in particular OVM. The result obtained from 
this study should be followed by further in vitro and in vivo experimentation. The 
foremost next step is purification of the protein from the soluble fraction of E. coli. 
The protein was expressed with a 6x histidine tag, therefore nickel affinity 
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purification techniques can be utilized for this purpose. The purified protein can then 
be used in B-cell and T-cell activation tests/assays. T-lymphocytes (T-cells) are known 
to be important in allergic desensitization 217,218, therefore it is imperative to test the 
ability of the hypoallergenic OVM produced in this study to stimulate T-cells. Animal 
models also play a pivotal role in food allergen research 219, therefore it should be 
suggested that the hypoallergenic OVM produced in this study should undergo 
animal model based experimentation prior to clinical testing.  
 
 
4.5 Conclusion 
Egg allergy is a wide spread disorder affecting mainly children. Natural and 
recombinant egg allergens are used in SIT. However, these have disadvantages when 
dealing with patients with high reactivity to the allergens. In this study, a 
hypoallergenic variant of the major egg white allergen OVM was produced by 
disrupting two cysteine-cysteine bridges using site-directed mutagenesis. This 
hypoallergenic variant, upon purification and further immunological analysis, may be 
used as an excellent constituent in future immunotherapy vaccines for egg allergy.     
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5.1 Introduction 
Hypersensitivity to chicken egg is a condition affecting mainly children 82. Currently, 
dietary avoidance and allergen SIT are pursued as egg allergy management strategies. 
Production of recombinant variants of egg allergens and production of hypoallergenic 
variants of the egg allergens has a been the focus of egg allergy research in order to 
assist in diagnostic methods such as skin prick tests (SPT) and treatment methods 
such as SIT 160. However, egg allergy research should not be limited to clinical 
improvements. The abundantly available knowledge and resources in advanced 
molecular and genetic techniques used in other medical research and life sciences 
may be utilised for tackling egg allergy from the root of the cause.  
 
Genetic manipulation and engineering have become successful strategies in 
producing disease free crops and animal products. A team in New Zealand has 
ĚĞǀĞůŽƉĞĚ Ă ƚƌĂŶƐŐĞŶŝĐ ĐĂůĨ ůĂĐŬŝŶŐ ƚŚĞ ŵŝůŬ ĂůůĞƌŐĞŶ ɴ-lactoglobulin using RNAi 
technology 46. dŚĞƉƌŽƚĞŝŶɴ-lactoglobulin causes mild to severe allergic reactions in 
individuals sensitised to this protein. Using RNAi technology, the research team 
ĚĞǀĞůŽƉĞĚ Ă ƚƌĂŶƐŐĞŶŝĐ ĐĂůĨ ƚŚĂƚ ůĂĐŬĞĚ ƚŚĞ ɴ-lactoglobulin protein in milk post 
hormonal induction. The lack of a highly effective treatment method for chicken egg 
allergy provides the opportunity to utilize similar techniques to produce eggs that 
lack the allergic components. It may be possible to simply knockdown the expression 
of the allergens in the chicken eggs using RNAi technology, however knockdown of 
the four allergens may have negative effects as these proteins comprises the majority 
of the egg white proteins and may reduce the reproductive viability and the 
nutritional value of the eggs. However, a simple knockdown or knockout of certain 
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allergens may be possible due to the presence of functionally similar homologous 
proteins in the egg white. It is also imperative to study the importance of these 
proteins to the developing eggs, which can also be scrutinized by knocking down/out 
the individual genes.    
 
Fire et al220 first published work on RNAi in Caenorhabditis elegans (C.elegans) which 
earned them a Nobel Prize in 2006. This mechanism targets exogenous double-
stranded RNA (dsRNA), which may be an evolutionarily significant mechanism to 
target pathogens such as viruses. RNAi may also be involved in regulation of gene 
expression, in which excessive translation of mRNA coding a specific protein is 
inhibited.  A ribonuclease known as DICER cleaves dsRNA into small non-coding RNAs; 
microRNA (miRNA) or small interfering RNA (siRNA). These small non-coding RNAs 
then associates with RNA-induced silencing complex (RISC) to initiate targeting and 
degradation of exogenous dsRNA220-222. The use of RNAi for human advantage 
essentially involves “fooling” of the host defence mechanisms. miRNAs or siRNAs 
complementary to mRNA of a targeted gene can be introduced to the host to 
promote silencing or knockdown of the targeted gene expression 46,222,223. This 
method can be effectively used for knockdown of allergen genes in chickens to either 
study the importance of the proteins or to produce hypoallergenic eggs.        
 
RNAi is not the only option for the development of hypoallergenic chicken eggs. The 
advancement of techniques such as CRISPR-Cas9 (clustered regularly interspaced 
short palindromic repeats-Cas 9)167 based genome editing may also allow precision 
engineering of the chicken genome to edit/change the IgE binding epitopes to 
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produce transgenic hens capable of producing hypoallergenic eggs. This method can 
also be used for functional analysis of the allergens by targeted gene knockouts. 
CRISPR-Cas9 mechanism is used against exogenous DNA elements in bacteria and 
archaea as a part of their adaptive immune system.  Cas9 is a small RNAs guided 
nuclease which allows genome editing through double-stranded breaks in the 
targeted gene loci. Non-homologous end joining (NHEJ) or homology-directed repair 
(HDR), both DNA damage repair pathways, typically repairs the site cleaved by Cas9. 
NHEJ caused by Cas9 can be harvested to efficiently introduce insertion/deletion 
(indels) mutations, which can cause a frameshift in the mRNA reading frame, thus 
resulting in a premature termination of translation. On the other hand, HDR can be 
utilized to introduce point mutations or to insert specific sequences to the targeted 
gene loci via recombination using donor DNA templates that are supplied 
exogenously. NHEJ may be a useful tool in knocking out allergen genes in the chicken 
genome, while HDR can be used to mutate IgE binding epitopes of the allergens or to 
introduce sequences for a hypoallergenic variant of the selected allergen into the 
genome167,224.     
 
Egg white allergy is caused by allergens present in both the egg white and yolk. Of 
these egg white allergens are considered to be the predominant allergens due to 
their high IgE reactivity, abundance and structural stability. These allergens are 
namely ovomucoid (Gal d 1), ovalbumin (Gal d 2), ovotransferrin (Gal d 3) and 
lysozyme (Gal d 4)97,98. Ovomucoid, hereafter referred to as OVM, is the most 
allergenic and the most structurally stable allergen of all. The rigid properties of OVM 
protect it and its IgE binding properties from cooking and the harsh environment in 
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the gut, therefore playing a crucial role in egg hypersensitivity caused by both raw 
and cooked egg94,112. These properties make OVM an excellent target for production 
of hypoallergenic chicken eggs.  
 
In this chapter, it was aimed to investigate genome engineering strategies to 
knockout and knockdown OVM. The first aim of this chapter was to utilize CRISPR-
Cas9 to knockout OVM in chicken DF-1 fibroblast cells. The second aim was to utilize 
RNAi to knockdown OVM in chicken to study the feasibility of a complete knockout 
in chicken.              
 
 
5.2 Methods 
Animal experimentation/sampling was conducted under protocol AEC1496, approved 
ďǇƚŚĞƵƐƚƌĂůŝĂŶŶŝŵĂů,ĞĂůƚŚ>ĂďŽƌĂƚŽƌǇ;^/ZK-AAHL) Animal Ethics Committee 
and in accordance with the Australian code of practice for the care and use of animals 
for scientific purposes. 
 
Please note that all experiments in this chapter utilized Promega restriction enzymes 
as opposed to New England Biolabs enzymes used in previous chapters. 
 
 
5.2.1 CRISPR-Cas9 knockout of OVM in DF-1 cells 
For all CRISPR-Cas9 related experimental procedures, a protocol by Ran et al 2013224 
was used as a reference.  
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5.2.1.1 Preparation of small guide RNA (sgRNA) expression constructs 
DNA sequence of exon 1 of OVM gene, located on chromosome 13 (NCBI accession 
number: NC_006100), was used to design two small guide RNAs (sgRNAs). The exon 
1 sequence shown below was submitted to an online CRISPR Design Tool 
(http://tools.genome-engineering.org) and two sgRNAs with the highest quality 
score and the lowest number of off-targets in genes were chosen.  
 
OVM exon 1: 
ATGGCCATGGCAGGCGTCTTCGTGCTGTTCTCTTTCGTGCTTTGTGGCTTCCTCCCAG    
 
ƐŐZEϭ:  
CAGCACGAAGACGCCTGCCA (quality score: 87, off-targets in genes: 0) 
ƐŐZEϮ:  
CTGTTCTCTTTCGTGCTTTG (quality score: 75, off-targets in genes: 0) 
 
The sgRNAs were then custom made, with a top strand and a bottom strand (reverse 
complement) for each sgRNA. Both strands had additional nucleic acids in addition to 
the sgRNA sequence, as shown below; 
 
ƐŐZE-top: CACCGNNNNNNNNNNNNN (EĚĞŶŽƚĞƐƚŚĞƐŐZEƐĞƋƵĞŶĐĞ) 
ƐŐZE-bottom: AAACNNNNNNNNNNNNNC (N denotes the reverse complemented 
ƐŐZEƐĞƋƵĞŶĐĞ)  
 
Phosphorylation and annealing of the top and bottom strands of sgRNAs and the 
subsequent ligation into the pSpCas9 (BB)-2A-GFP vector were done according the 
protocols on Ran et al 2013224.  
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5.2.1.2 Transformation of sgRNA-pSpCas9 (BB)-2A-GFP constructs into E.coli 
The sgRNA-pSpCas9 (BB)-2A-GFP constructs were transformed into electro-
competent DH5-ɲ ͘ĐŽůŝ ĐĞůůƐ ƵƐŝŶŐ ĞůĞĐƚƌŽƉŽƌĂƚŝŽŶ͘ dŚĞ ƌĞĂĐƚŝŽŶƐǁĞƌĞ ƐĞƚ ƵƉ ŝŶ
microfuge tubes on ice as follows; 
30 μL of 10% glycerol 
7 μL of electro-competent E.coli 
2 μL of sgRNA- pSpCas9 (BB)-2A-GFP construct   
 
The reactions were transferred into chilled electrode gap cuvettes and were pulsed 
in an E.coli pulser at 2.25 kV with electrical capacitance set at 25 μF and electrical 
ƌĞƐŝƐƚĂŶĐĞ ƐĞƚ Ăƚ ϮϬϬ ɏ͘ dŚĞ ƚƌĂŶƐĨŽƌŵĂŶƚƐ ǁĞƌĞ ƚŚĞŶ ƉůĂƚĞĚ ŽŶ > ĂŐĂƌ ǁŝƚŚ
ampicillin (100 μg/mL) and incubated overnight at 37°C. The following day, a single 
colony representing each sgRNA was grown overnight in LB media with ampicillin. 
Plasmids were isolated from these cultures following the mini-prep procedure 
outlined in section 2.2.10 of this thesis. The insertion of sgRNA in to pSpCas9 (BB)-
2A-GFP was confirmed by sequencing with a U6 promoter forward primer:  5’-
GAGGGCCTATTTCCCATGATTCC-3’.      
  
 
5.2.1.3 Cell culture of DF-1 cells and transfections with sgRNA  
Chicken fibroblast cells, DF-1 (ATCC Cat.No. CRL-12203), were cultured in a Corning® 
75 cm2 cell culture flask in Dulbecco’s modified eagle’s serum media (DMEM) 
containing 10 % fetal calf serum (FCS), 1% HEPES (4-2-hydroxyethyl-1-
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piperazineethanesulfonic acid), 5.6% sodium bicarbonate, 2 mM L-glutamine and 100 
μg/mL of each of penicillin and streptomycin antibiotics. After 3 days, the cells in the 
flask were washed with phosphate buffered saline (PBS-pH 7.4) and were separated 
from the flask wall and collected by incubating with 2 mL Trypsin for 5 minutes. The 
cells were then counted using a haemocytometer. The cells were then re-cultured in 
DMEM in a 24-well plate (100, 000 cells per well) according to the plate plan on Table 
5.1 and were grown to 90% confluency (approximately 15 hours). The cells were then 
transfected with the sgRNA constructs in triplicates as shown in Table 1. For 
transfection of each well 500 ng of sgRNA construct was combined with 100 μL of 
Opti-MEM® (Life Technologies Cat.No. 51985091) and incubated at room 
temperature for 5 minutes. At the same time, 2 μL of Lipofectamine® 2000 was 
combined with 100 μL of Opti-MEM® and incubated for 5 minutes. The two reactions 
were then combined in a single tube and incubated for 20 minutes at room 
temperature. The total reaction was then added to the well to transfect the cells. 
Please note that before transfections, fresh DMEM were added to each well 
containing the cultured cells. The transfected cells were grown for approximately 36 
hours and transfection efficiency was confirmed by observing under fluorescence 
microscopy (Leica DMLB) to detect green fluorescence protein (GFP).    
 
 
Table 5.1: Plate plan of DF-1 cells to be transfected with sgRNA constructs.  
Un-
transfected 
Un-
transfected 
Un-
transfected 
sgRNA1 sgRNA1 sgRNA1 
sgRNA2 sgRNA2 sgRNA2 - - - 
- - - - - - 
154 | P a g e  
 
Chapter 5 
- - - - - - 
      
 
 
5.2.1.4 Enrichment of GFP positive cells by FACS 
Fluorescent-activated cell sorting (FACS) media was prepared by filtering phenol red-
free DMEM through a 0.22 μM filter to remove antibiotics. The cells in the transfected 
wells were dissociated from the wells using trypsin and were collected in 15 mL 
Falcon tubes. The cells were centrifuged at 1350 rpm (200 g) for 5 minutes. The cells 
were resuspended in 200 μL of FACS media and the cells were filtered through a mesh 
cap into a strainer tube. The cells expressing GFP were then sorted in a FACSCalibur 
(BD-Biosciences) flow cytometer. The sorted cells were cultured in DMEM in a 24-
well plate and were allowed to expand for 2 weeks. DMEM were changed every 3 
days by removing 100 μL of old media and adding 100 μL of fresh media.  
 
 
5.2.1.5 Functional analysis of sgRNA by SURVEYOR assay 
Genomic DNA from the sorted and cultured cells from section 5.2.14 were isolated 
using a Blood & Cell Culture DNA Mini kit (Qiagen, Cat. No. 69581) following 
manufacturer’s instructions (two samples prepared: sgRNA1 and sgRNA2). Mutations 
caused by sgRNAs were detected using a SURVEYOR® Mutation Detection kit 
(Transgenomic® Cat.No. 706020). Initially, a forward and a reverse primer were 
designed to amplify the targeted region of OVM exon 1 by the two sgRNAs: 
 
Forward: 5’-CGCGGACCTCAATAAATATTACCAGCCT-3’ 
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Reverse: 5’-CGCCCACCTCGTTATGGCCTTGT-3’ 
  
  
A gradient PCR was conducted in a thermocycler using GoTaq® Green Master Mix 
(Promega Cat.No. M712) according to the reaction and PCR conditions shown in Table 
5.2 to determine optimum PCR conditions. For this purpose genomic DNA from 
sgRNA1 sample was used as template and the PCR products were analysed by agarose 
gel electrophoresis as described in section 2.2.5. Then another PCR was conducted 
using the determined optimum temperature to amplify the targeted regions from 
genomic DNA of sgRNA1, sgRNA2 and wild-type samples. 5μL of each PCR product 
was analysed by gel electrophoresis. The sgRNA PCR product (test) and wild-type PCR 
product (reference) were then hybridized to form heteroduplexes and 
homoduplexes. Essentially, 5μL of PCR products of sgRNA1 & wild-type, sgRNA2 & 
wild-type, and wild-type & wild-type (reference) were separately mixed in PCR tubes 
and were hybridized in a thermocycler with the conditions outlined in Table 5.3. The 
hybridized samples were then digested with SURVEYOR nuclease according the 
following reaction; 
 400 ng of hybridized DNA  
 0.15 M MgCl2 
 1 μL SURVEYOR Enhancer S  
 1 μL SURVEYOR Nuclease S 
 
 
The reactions were gently mixed by pipetting and incubated at 42°C for 6 minutes. 
The SURVEYOR nuclease treated samples were then analysed on a 1% agarose gel.  
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Table 5.2: Reaction and PCR conditions using GoTaq® Green Master Mix. 
Reaction Mix 
Component Volume Final concentration 
GoTaq® Green Master 
Mix 
25 μL 1 x 
Forward primer 1 μL 1 μM 
Reverse primer 1 μL 1 μM 
Genomic DNA template 1 μL 100 ng 
dH20 22 μL - 
Total 50 μL - 
 
PCR conditions 
Step Temperature Time 
Denaturation 95°C 2 minutes 
Annealing (Gradient) 54°C, 55.7°C, 56.8°C, 
58.1°C, 60.7°C, 61.9°C, 
62.9°C, 63.6°C 
30 seconds 
Extension 72°C 1 minute 
Final extension 72°C 5 minutes 
Refrigeration 4°C - 
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Table 5.3: DNA hybridization conditions for a thermocycler.  
Temperature Time 
95°C 10 minutes 
95°C to 85°C (-2.0°C/s) 
85°C 1 minute 
85°C to 75°C (-0.3°C/s) 
75°C 1 minute 
75°C to 65°C (-0.3°C/s) 
65°C 1 minute 
65°C to 55°C (-0.3°C/s) 
55°C 1 minute 
55°C to 45°C (-0.3°C/s) 
 45°C 1 minute 
45°C to 35°C (-0.3°C/s) 
35°C 1 minute 
35°C to 25°C (-0.3°C/s) 
25°C 1 minute 
4°C - 
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5.2.2 RNAi knockdown of ovomucoid 
5.2.2.1 shRNA design 
Two small interfering RNA molecules (siRNAs) targeting chicken ovomucoid gene 
were designed using the Dharmacon siRNA design tool. They were 18-19 nucleotides 
in length with a total GC content of less than 50%. To generate effective shRNAs, 
siRNA sequences were further screened using the criteria previously outlined by 
Taxman et al 2010 225. Briefly, potential siRNAs were scored for the stability of the 
duplex formed between nucleotides 6 – 11 on the sense and 14 – 9 on the antisense 
strands. Those siRNAs with a central ĚƵƉůĞǆѐG of > -12.9 kcal /mol were discarded. 
ѐG scores were calculated as described in Freier et al 1986 226 (Figure 5.1). The chosen 
two sense siRNA sequences are as follows; 
ƐŝZEϭ – GAACCAATATCAGCAAAGA (19 nucleotides) 
ƐŝZEϮ – GATGTATTGGTTTGCAAC (18 nucleotides) 
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Figure 5.1: Screening of siRNA selected by Dharmacon algorithm for suitability. The 
ŚŝŐŚůŝŐŚƚĞĚƐŝZEƐǁĞƌĞĐŚŽƐĞŶĂƐƚŚĞƐĞŵĞƚĂůůƚŚĞƌĞƋƵŝƌĞŵĞŶƚƐĂŶĚŚĂĚĂŚŝŐŚĞƌ
score than other candidates. Please note that only 19/50 candidates are shown here.  
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5.2.2.2 U6 promoter driven RNAi knockdown of OVM in DF-1 cells using the 
shRNAs   
In this section, the chosen siRNAs were used in a cell culture based experiment to 
knockdown OVM. 
 
5.2.2.2.1 Preparation of shRNA driven by chicken U6 promoter.  
The two siRNAs designed in section 5.2.2.1 were then used to produce two short 
hairpin RNA (shRNA) expression constructs via a one-step PCR method; 
ƐŚZEϭ (named shOvm1)- 
CTCGAGTTCCAAAAAAGAACCAATATCAGCAAAGATCTCTTGAATTCTTTGCTGATATTGG
TTCAAACCCCAGTGTCTCTCGGA 
 
ƐŚZEϮ (named shOvm2)- 
CTCGAGTTCCAAAAAAGATGTATTGGTTTGCAACATCTCTTGAATGTTGCAAACCAATACA
TCAAACCCCAGTGTCTCTCGGA 
 
 
The shRNA sequences shown above essentially have the following components in the 
given order: Terminator-^ĞŶƐĞƐŝZE;bolded)-Loop-ŶƚŝƐĞŶƐĞƐŝZE;bolded)-Part 
of chicken U6-4 promoter. The reverse sequence of the two shRNAs were custom 
made as oligos and were used in a PCR reaction to combine the hairpin to a chicken 
U6 promoter. The PCR was carried out as a gradient PCR using GoTaq® Green Master 
Mix (see section 5.2.1.5) with the following temperatures: 59.1°C, 62.6°C, 64.3°C, 
66.1°C, 69.4°C and 72°C. The desired PCR products of each shRNA (+ U6-4 promoter) 
were gel purified according the method described in section 2.2.6. The gel purified 
PCR products were then ligated into pGEM®-T Easy (Promega Cat.No. A1360) which 
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does not require restriction enzyme (RE) digestion prior to insertion. The ligations 
were then transformed into electro-competent E.coli as described in section 5.2.1.2. 
These cells were propagated and plasmids were isolated by mini-prep as described in 
section 2.2.10. To confirm the insertion of shRNAs (including U6 promoter), the 
plasmids were digested with EcoRI (this site is present either side of the multiple 
cloning site of pGEM®-T Easy) and analysed by agarose gel electrophoresis. Vectors 
containing the insert were then sequenced to confirm sequence validity of shRNAs 
and U6 promoter using the pUC/M13 forward sequencing primer: 5’-
CGCCAGGGTTTTCCCAGTCACGAC-3’. The constructed vectors were named pU6-
4shOvm1 and pU6-4shOvm2.      
 
 
5.2.2.2.2 Insertion of OVM target region into pEGFP_C vector 
The next task was to insert the region of OVM targeted by the shRNA into pEGFP_C 
vector which expresses proteins with a C-terminal fusion to green fluorescence 
protein (GFP). Initially, two primers were designed with a RE added to each primer; 
 
 Forward-5’ CGCAGATCTGCTGAGGTGGACTGCAGT-3’ RE site: BglII 
 Reverse-5’-CGCAAGCTTTCAGCATTTTCCAAAATG-3’ RE site: HindIII 
 
 
A PCR was conducted using the above primers to amplify the targeted OVM region 
from OVM cDNA inserted into pTrcHisA vector used in Chapters 2 & 3. Then the PCR 
product was ligated into pGEM®-T Easy vector using T4 DNA ligase as previously 
discussed in section 2.2.8 and the ligation was transformed into electro-competent 
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E.coli. Vectors were re-isolated from 10 transformant clones by mini-prep and the 
vectors were subjected to a screening digest with EcoRI to confirm successful 
insertion. Six clones bearing the insert were then sequenced to confirm the validity 
of the sequences. The obtained sequences were searched on NCBI/BLAST to confirm 
it matches with the sequence of OVM. A sample of pGEM®-T Easy containing the 
correct insert was digested with REs BglII and HindIII with the relevant buffers to cut 
out the OVM fragment. A sample of pEGFP_C was also digested with the same 
enzymes. The digested pGEM®-T Easy and pEGFP_C vector were run on a 1% agarose 
gel and the bands of interest were gel purified. The OVM fragment was then ligated 
into pEGFP_C with T4 DNA ligase. The ligation was transformed into electro-
competent E.coli, propagated and plasmids were isolated by mini-prep. The 
constructed plasmid was named pEGFP_C_OVM.  
 
 
5.2.2.2.3 Cell culture and transfection  
DF-1 chicken fibroblast cells were cultured in a 75 cm2 flask as described in section 
5.2.1.3. The cells were then subcultured into a 24-well plate as shown in Table 5.4. 
The cells were grown to 80% confluency and were co-transfected with 
pEGFP_C_OVM containing the targeted OVM sequence and pU6-4shOvm1 or pU6-
4shOvm2 containing the shRNA. The transfections were done as described in section 
5.2.1.3, however 500 ng of pEGFP_C_OVM and 500 ng of pU6-4shOvm1 or pU6-
4shOvm2 (total of 1 μg) were transfected. As a control, some cells were left 
untransfected. In addition to the untransfected cells, two negative controls were 
done: pEGFP_C_OVM only and pEGFP_C_OVM + Irrelevant shRNA. The positive 
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control cells were transfected with shEGFP which specifically targets EGFP in 
pEGFP_C_OVM vector. All the cells were then grown for 48 hours, visualised under 
fluorescence microscopy, and measured for mean fluorescence intensity using FACS. 
The mean fluorescence intensities of each treatment were then blotted against each 
other in a bar graph.  
 Table 5.4: Plate plan of DF-1 cells to be transfected with shRNA constructs  
 
 
 
5.2.2.3 Preparation of mini-Tol2 transposon and microinjection into chicken 
embryos  
In this section, the same siRNAs used in section 5.2.2.2 were used to design two 
hairpin microRNAs (miRNA) mimicking natural mir-30 miRNA structure to target OVM 
in chicken.  
 
 
Untransfected Untransfected Untransfected pEGFP_C_OVM 
Only 
pEGFP_C_OVM 
Only 
pEGFP_C_OVM 
Only 
pEGFP_C_OVM 
+ Irrelevant 
shRNA 
pEGFP_C_OVM 
+ Irrelevant 
shRNA 
pEGFP_C_OVM 
+ Irrelevant 
shRNA 
pEGFP_C_OVM 
+ shEGFP 
pEGFP_C_OVM 
+ shEGFP 
pEGFP_C_OVM 
+ shEGFP 
pEGFP_C_OVM 
+  pU6-
4shOvm1 
pEGFP_C_OVM 
+  pU6-
4shOvm1 
pEGFP_C_OVM 
+  pU6-
4shOvm1 
pEGFP_C_OVM 
+  pU6-
4shOvm2 
pEGFP_C_OVM 
+  pU6-
4shOvm2 
pEGFP_C_OVM 
+  pU6-
4shOvm2 
- - - - - - 
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5.2.2.3.1 miRNA design 
The two siRNAs designed using the Dharmacon tool were inserted into the native 
structure of gene expression regulatory microRNA known as miR-30. The native 
structure of miR-30 is as follows; 
 
A UC G GAAGC 
GCG CUGUAAACAUCC  GACUGGAAGCU U     A
CGU GACGUUUGUAGG  CUGACUUUCGG G     G
C -- G UAGAC
 
 
The two strands highlighted in red and blue were replaced with the sequences of the 
two siRNAs. The top strand highlighted in red is the sense strand and the bottom 
strand highlighted in blue is the anti-sense strand of the relevant siRNA. Once the 
siRNA were inserted into the miR-30 structure, they were named miOvm1 and 
miOvm2; 
 
miOvm1: 
A GU G GAAGC 
GCG GAACCAAUAUCA  GCAAAGAGCCU U     A
CGU CUUGGUUAUAGU CGUUUCUCGGG G     G
C -- G UAGAC 
 
 
miOvm2: 
A AG G GAAGC 
GCG AUGUAUUGGUUU  GCAACAGGACU U     A
CGU UACAUAACCAAA CGUUGUCCUGG G     G
C -- G UAGAC 
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Please note that for miOvm1 a GC was added at the 3’ end of the siRNA to make the 
two strands 22 bp long and miOvm2 was added with a GGA at the 3’ end. The miRNA 
structure was then predicted using ViennaRNA (University of Vienna) online tool to 
confirm the structure. The miRNAs were then custom made as oligonucleotides. The 
oligos were synthesised as two separate strands; a sense sequence (forward) and an 
antisense sequence (reverse). To the forward sequence of each miRNA, a BamHI 
overhang (GATC) was added to the 5’ end and a KpnI overhang (GTAC) was added to 
the 3’end. The synthesised oligonucleotides are as follows;  
 
miOvm1 Forward (RE sites bolded and italicized in black): 
GATCGCGAGAACCAATATCAGTGCAAAGAGCCTGTGAAGCAGCAGATGGGGGCTCTTTG
CTGATATTGGTTCCTGCGTAC 
 
miOvm1 Reverse: 
GCAGGAACCAATATCAGCAAAGAGCCCCCATCTGCTGCTTCACAGGCTCTTTGCACTGAT
ATTGGTTCTCGC 
 
 
miOvm2 Forward (RE sites bolded and italicized in black): 
GATCGCGAATGTATTGGTTTAGGCAACAGGACTGTGAAGCAGCAGATGGGGTCCTGTTG
CAAACCAATACATCTGCGTAC 
 
miOvm2 Reverse:  
GCAGATGTATTGGTTTGCAACAGGACCCCATCTGCTGCTTCACAGTCCTGTTGCCTAAACC
AATACATTCGC 
 
Please note that the sense strand is denoted by red and antisense strand is denoted 
by blue.  
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The oligonucleotides of each miRNA (forward and reverse) were then annealed to 
each other by combining 2 μg of each oligonucleotide with 46 μL of annealing buffer 
and incubating at 90°C for 3 minutes. The reaction was then cooled down to room 
temperature and 5 μL of each reaction was diluted in 45 μL of dH20.  
 
 
5.2.2.3.2 Construction of mini-Tol2 transposon for micro-injection 
The next step was to construct a vector harbouring the mini-Tol2 transposon for 
delivery of the designed miRNAs into chick embryos (Figure 5.2). As the first step, It 
was necessary to insert the miRNAs into intron 5 of PANK1 (pantothenate kinase 1) 
gene (hereafter referred to as Intron) to effectively induce RNAi mechanism. The 
Intron has been previously inserted in to a pEGFP_N1 vector, which has the sequence 
needed for expression of GFP (eGFP). This vector was known as pEGFP_N1Intron. 
Insertion of the Intron has divided the eGFP sequence in to 2 sections flanking the 
inserted Intron. To insert the miRNAs into Intron in pEGFP_N1Intron vector, the 
available vector was digested with REs BamHI and KpnI by incubating the following 
reaction at 37°C for 3 hours; 
 1 μL BamHI 
 1 μL KpnI 
 2 μL MC buffer  
 1 μg (1 μL) of pEGFP_N1Intron plasmid 
 15 μL of dH20 to make up to 20 μL    
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Figure 5.2: Construction of the vector harbouring mini-Tol2 transposon for delivery 
of miRNAs targeting OVM in to chicken embryos. The first task was to insert “eGFP-
Intron-ŵŝZE-Intron-eGFP” fragment from pEGFP_NiOvm1 or pEGFP_NiOvm2 vector 
into the base vector pT2-009 which harbours the sequence of mini-Tol2 transposon 
;dŽůϮ>,ΘdŽůϮZ,ĂƐƐŚŽǁŶŝŶƚŚĞĨŝŐƵƌĞͿĂŶĚƉ''^ƉƌŽŵŽƚĞƌ. The second task 
ǁĂƐƚŽWZĂŵƉůŝĨǇWŽůǇĨƌĂŐŵĞŶƚĨƌŽŵƉ'&W_N1Intron vector and insert in to pT2-
009 downstream of second eGFP fragment. The final vector was named Tol2Ovm1 or 
Tol2Ovm2.   
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The digested and undigested sample (control) were run on a 1% agarose and the 
digested sample was gel purified. This purified sample was then used in a ligation 
reaction with the diluted miRNAs from section 5.2.2.3.1. Please note that the 
ligations for miOvm1 and miOvm2 were done separately according to the following 
reaction; 
 1 μL of the diluted annealed oligonucleotides (miOvm1 OR miOvm2) 
 1 μL of Ligase buffer 
 1 μL T4 DNA ligase 
 100 ng (5 μL) of BamHI and KpnI digested pEGFP_N1Intron 
 2 μL of dH20 to make up to 10 μL  
 
A control ligation was also performed with only 5 μL of digested pEGFP_N1Intron and 
5 μL of dH20. All reactions were incubated at 4°C overnight. The ligations were then 
transformed into elctro-competent E.coli and were propagated. The transformants 
were plated on LB agar with kanamycin (50 μg/mL) and incubated overnight at 37°C. 
8 colonies representing each miRNA were grown overnight in LB media with 
kanamycin and plasmids were isolated by mini-prep. 5 samples of each construct 
were then sequenced to confirm the insertion of miRNA into pEGFP. The constructed 
vectors were named pEGFP_NiOvm1 and pEGFP_NiOvm2.  
 
The next task was to cut out the “eGFP-Intron-miRNA-Intron-eGFP” fragment from 
pEGFP_NiOvm1 and pEGFP_NiOvm2 and insert it into pT2-009 vector which encodes 
the mini-Tol2 transposon and pCAGGS promoter. For this purpose the constructed 
pEGFP_NiOvm1 and pEGFP_NiOvm2 vectors were digested with REs NotI and XhoI to 
separate the “eGFP-Intron-miRNA-Intron-eGFP” from the pEGFP_N1 vector 
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backbone. The reaction was further digested with FspI to digest the pEGFP_N1Intron 
backbone to smaller fragments. The digests were then analysed by gel 
electrophoresis, and the fragment of interest was gel purified. Parallel to this, two 
samples of pT2-009 plasmid were digested with REs NotI and XhoI. One sample was 
digested with high fidelity NotI while the other was digested with standard NotI for 
quality testing purposes. The digested and undigested pT2-009 were also analysed by 
gel electrophoresis and the gel band of interest was gel purified. The gel purified 
“eGFP-Intron-miRNA-Intron-eGFP” fragments (containing miOvm1 & miOvm2) and 
the RE digested pT2-009 were then ligated separately using T4 DNA ligase. The 
ligations were transformed into electro-competent E.coli and propagated. Plasmids 
were isolated from 6 transformant clones of each miRNA and were subjected to a 
screening digest using NotI and XhoI to confirm insert.    
 
The final task of this section was to insert a PolyA signal to the pT2-009 vector, 
downstream of the already inserted “eGFP-Intron-miRNA-Intron-eGFP” fragment. 
The PolyA sequence was PCR amplified from pEGFP_N1Intron vector by gradient PCR 
according to the method and conditions described in section 5.2.1.5 and Table 5.2. 
The gradient temperatures used were: 50.2°C, 54.9°C, 59.5°C and 62°C. The primers 
used for this PCR were; 
 
PolyA Forward- 5’-ACTGCGGCCGCGACTCTAGATCA-3’ 
Poly A Reverse- 5’-ACTGAATTCACGCTTACAATTTACGC-3’ 
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The PCR product was then ligated into pGEM®-T Easy vector as described in section 
5.2.2.2.1 and were subjected to a screening digest using EcoRI to confirm insert. To 
confirm the validity of the sequence, a single clone with the insert was sequenced 
using pUC/M13 forward sequencing primer: 5’-CGCCAGGGTTTTCCCAGTCACGAC-3’. 
Afterwards, the constructed pT2-009 (containing miOvm1 or miOvm2) and pGEM®-T 
Easy containing PolyA were digested with NotI. The digests were analysed by gel 
electrophoresis and the required bands were gel purified. The purified PolyA was 
then ligated into the pT2-009 harbouring miOvm1 and miOvm2 using T4 DNA ligase. 
The final vectors were named Tol2Ovm1 and Tol2Ovm2. These vectors were 
transformed in to electro-competent E.coli and were propagated. The transformants 
were plated on LB agar with ampicillin and one clone representing each of Tol2Ovm1 
and Tol2Ovm2 were sequenced to confirm the final product.  
 
 
5.2.2.3.3 Micro-injection of mini-Tol2-miRNA constructs into chick embryos 
E.coli harbouring the constructed mini-Tol2-miRNA vectors (Tol2Ovm1 and 
Tol2Ovm2) were grown in LB media with ampicillin. Plasmids were then isolated using 
a Qiagen Plasmid Maxi kit (Qiagen, Cat. No. 12163) following manufacturer’s 
guidelines. Then, 0.6 μg of Tol2Ovm1 or Tol2Ovm2 was combined with 1.2 μg of pT2-
002a plasmid (which codes for transposase) and 45 μL of OptiPro™ (Life Technologies, 
Cat.No. 12309-019) serum free media (SFM) and incubated at room temperature for 
5 minutes. At the same time, 3 μL Lipofectamine™ 2000 and 45 μL of OptiPro™ SFM 
were combined and incubated at room temperature for 5 minutes. Afterwards, both 
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mixes were combined and incubated at room temperature for 20 minutes. This final 
mixture is the transfection complex. 
   
For micro-injections, 100 fertilized eggs (50 for Tol2Ovm1 and 50 for Tol2Ovm2) were 
obtained from specific pathogen free (SPF) hens. These eggs were incubated to 2.5 
days (15-16 Hamburger-Hamilton stages). A small opening was made on the pointy 
end of each recipient egg by carefully crack opening the shell with a sterile metal 
forceps. The embryos were observed under a microscope for viability and 1-2 μL of 
the transfection complex was micro-injected into the dorsal aorta of the embryo. The 
opening on the shell was then re-sealed with 2 layers of sterile paraffin film and the 
eggs were returned to the incubator. Of the dedicated 50 eggs for each mini-Tol2-
miRNA construct, 29 eggs were micro-injected and 21 were discarded for Tol2Ovm1, 
while 36 eggs were micro-injected and 14 were discarded for Tol2Ovm2. The 
discarded eggs were due to incorrect staging of eggs, infertility of eggs or early death 
of embryos.            
 
 
5.2.2.3.4 Gonad assays of micro-injected embryos     
At 14 days of embryonic development of the micro-injected eggs, 5 eggs of each mini-
Tol2-miRNA construct were subjected to gonad assays. The gonads of the embryos 
were dissected out of the body and were placed on a glass microscopy slide. The 
gonads were then visualised under green fluorescence microscopy. The remainder of 
the eggs that were not opened for gonad assays were incubated till hatching and the 
172 | P a g e  
 
Chapter 5 
hatchlings were grown to sexual maturity. Chicks injected with Tol2Ovm1 were 
named M1 chicks and the chicks injected with Tol2Ovm2 were named M2 chicks.  
 
 
5.2.2.3.5 Semen screening by qPCR 
The hatched chicks were grown to sexual maturity and semen samples from roosters 
were obtained to screen for the presence of mini-Tol2-miRNA (miOvm1 or miOvm2) 
transgene. DNA from the semen samples were extracted using a Qiagen DNeasy 
Blood and Tissue Kit (Qiagen, Cat. No. 69506) according to manufacturer’s guidelines. 
The isolated genomic DNA was diluted 1/100 in sterile nuclease free dH20 and was 
subjected to quantitative PCR (qPCR) on a Mastercylcer® Ep Realplex (Eppendorf) 
following manufacturer’s guidelines. The qPCR reaction mix was prepared according 
to Table 5.5. Two reactions were set up for each DNA sample; experimental reaction 
using specific mini-Tol2 primers (Forward primer: 5’ CAGTCAAAAAGTACTTATTTTTTG 
GAGATCACT 3’; Reverse primer: 5’ GGGCATCAGCGCAATTCA ATT 3’) and a detection 
probe (5’ ATAGCAAGGGAAAATAG 3’); control reaction using primers specific for a 
genomic control region (Forward primer 5’ GATGGGAAAACCCTGAACCTC 3’; Reverse 
primer 5’ CAACCTGCTAGAGAAGATGAGAAGAG 3’) and a detection probe (5’ 
CTGCACTGAATGGAC 3’). The qPCR was carried out according to the conditions 
outlined in Table 5.6. Each rooster was tested at least twice and was classified 
positive if a CT (cycle threshold) value of less than 36 was obtained for experimental 
reactions. A CT of less than 32 for control reactions was used to indicate the presence 
of sufficient DNA in the sample tested. The relative levels of integrated mini-Tol2-
173 | P a g e  
 
Chapter 5 
miRNA DNA in semen were calculated by comparing the mean CT values from 
genomic and mini-Tol2 qPCR from semen samples of each bird.    
    
 
Table 5.5 qPCR reaction for semen screening 
Component Volume 
Taqman 2x universal 
master mix 
10 μL 
20x FAM labelled assay 
mix 
1 μL 
Forward primer 1 μL 
Reverse primer 1 μL 
Genomic DNA template 9 μL 
   
 
Table 5.6 qPCR reaction conditions for semen screening 
Step Temperature  Time 
Denaturation 95°C 10 minutes 
Step 1 95°C 15 seconds 
Step 2 60°C 1 minute  
Repeat step 1 & 2 45 times 
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5.3 Results 
5.3.1 CRISPR knockout of ovomucoid in DF-1 cells 
Two sgRNAs targeting exon 1 of OVM were designed. The chosen sgRNAs had the 
highest quality score and no off-targets in other genes of the chicken genome. The 
two sgRNAs (each sgRNA had a top and a bottom strand) were then cloned into 
pSpCas9 (BB)-2A-GFP vector. The sequencing results show that both sgRNAs has been 
successfully inserted into the vector (Figure 5.3). Confluent DF-1 cells were then 
transfected with the constructed pSpCas9 (BB)-2A-GFP containing the sgRNAs. When 
observed under bright-field microscopy, there were no visible differences between 
the cells of each treatment (Figure 5.4). When observed under green fluorescence, 
the un-transfected cells did not show any green colour while the sgRNA1 and sgRNA2 
transfected cells had green fluorescing cells (Figure 5.4). The green fluorescence cells 
in the transfected populations were then sorted using FACS.  
 
Genomic DNA was isolated from the sorted and expanded cells, which was subjected 
to SURVEYOR analysis. The gradient PCR conducted to determine the best annealing 
temperature of the primers designed to amplify the targeted genomic region showed 
clear bands at ~500 bp for all the temperatures, with 55.7°C yielding the most 
prominent band (Figure 5.5). PCR to amplify the targeted genomic sequence from 
wild-type cells, with the determined optimum annealing temperature, yielded a clear 
band at ~500 bp (Figure 5.5). Appearance of bands at ~500 bp indicates successful 
amplification of the targeted DNA from genomic DNA. 
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The PCR amplified targeted DNA from cells treated with sgRNA (sgRNA1 & sgRNA2) 
were the hybridized with DNA from wild-type cells.  The hybridized DNA were then 
digested with SURVEYOR nuclease. Gel electrophoresis of the digested products 
showed one band at ~500 bp for all treatments, indicating no mutations are present 
(Figure 5.5).           
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Figure 5.3: Sequence of sgRNA1 and sgRNA2 inserted into pSpCas9 (BB)-2A-GFP 
vector. dŚĞƐĞƋƵĞŶĐĞŽĨƚŚĞƚŽƉƐƚƌĂŶĚŽĨƐŐZEϭŝƐƐŚŽǁŶin (A), while the bottom 
strand is shown in ;Ϳ͘dŽƉƐƚƌĂŶĚŽĨ ƐŐZNA2 is shown in (C) and bottom strand is 
shown in ;Ϳ͘dŚĞƐĞƋƵĞŶĐĞŚŝŐŚůŝŐŚƚĞĚĂŶĚďŽůĚĞĚŝŶred ĂƌĞƚŚĞƐŐZEƐĞƋƵĞŶĐĞƐ͘
WůĞĂƐĞŶŽƚĞƚŚĂƚĨŽƌƚŚĞƐĞƋƵĞŶĐĞƐƐŚŽǁŶĨŽƌƚŚĞďŽƚƚŽŵƐƚƌĂŶĚƐŽĨďŽƚŚƐŐZEƐ͕ƚŚĞ
obtained sequence was reverse complemented.  
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Figure 5.4: Fluorescence microscopy of DF-1 cells transfected with pSpCas9 (BB)-2A-
GFP containing sgRNAs.  &Žƌ ĞĂĐŚ ĞǆƉĞƌŝŵĞŶƚĂů ƚƌĞĂƚŵĞŶƚ͕ ϱϬϬ ŶŐ ŽĨ ƐŐZE
combined with Lipofectamine® 2000 was added to the well. As a control, some cells 
were left un-transfected. 
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Figure 5.5: SURVEYOR analysis to detect mutations. 'ƌĂĚŝĞŶƚ WZ ŽĨ the target 
ƌĞŐŝŽŶĚŽŶĞƵƐŝŶŐŐĞŶŽŵŝĐEŝƐŽůĂƚĞĚĨƌŽŵĐĞůůƐƚĂƌŐĞƚĞĚďǇƐŐZEϭƚŽĚĞƚĞƌŵŝŶĞ
ƚŚĞ ŽƉƚŝŵƵŵ WZ ĐŽŶĚŝƚŝŽŶƐ ;Ϳ͘ WZ͕ ǁŝƚŚ ƚŚĞ ĚĞƚĞƌŵŝŶĞĚ ŽƉƚŝŵƵŵ ĂŶŶĞĂůŝŶŐ
temperature, ŽĨƚŚĞƚĂƌŐĞƚƌĞŐŝŽŶŽĨŐĞŶŽŵŝĐEŝƐŽůĂƚĞĚĨƌŽŵǁŝůĚ-type cells (B). 
WZŽĨƚĂƌŐĞƚƌĞŐŝŽŶŽĨŐĞŶŽŵŝĐEŽĨƐŐZEϭŚǇďƌŝĚŝǌĞĚǁŝƚŚǁŝůĚ-ƚǇƉĞ͕ƐŐZEϮ
hybridized with wild-type and wild-type only reference ĂĨƚĞƌĚŝŐĞƐƚŝŽŶǁŝƚŚ^ hZszKZ
nuclease (C).   
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5.3.2 RNAi knockdown of ovomucoid 
Two siRNAs targeting OVM were designed using the Dharmacon algorithm. The 
sequences of these siRNAs were then used in cell-based and animal (chicken) based 
experimentation to knockdown OVM. For the reader’s convenience, a flowchart of 
the major steps taken in these experiments is provided below in Figure 5.6.   
 
 
Figure 5.6: Flowchart outlining the major steps taken to study RNAi knockdown of 
OVM  
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5.3.2.1 Knockdown of ovomucoid in DF-1 cells  
The two siRNAs that target OVM mRNA were used to design shRNAs (shOvm1 & 
shOvm2) driven by the chicken U6-4 promoter. The gradient PCR conducted using the 
reverse complemented sequences of shOvm1 and shOvm2, to combine the shRNAs 
with the U6 promoter, showed a band at ~300 bp for all temperatures (except for 
72°C for shOvm2 where there was no band). For shOvm1 66.1°C yielded the most 
prominent band and for shOvm2 62.6°C yielded the most prominent band (Figure 
5.7). Primer dimers (smaller band) were also visible in all lanes. The U6 + shRNA PCR 
products were then ligated into pGEM®-T Easy vector (pU6-4shOvm1 & pU6-
4shOvm2). The screening digests showed that 5/6 clones of pU6-4shOvm1 contained 
the insert and 6/6 clones of pU6-4shOvm2 contained the insert (Figure 5.7). The 
sequencing result confirmed that both the sequence of U6 promoter and shRNA had 
been combined and inserted in to pGEM®-T Easy (Figure 5.8).  
  
The next task was to insert OVM mRNA sequence targeted by the two shRNAs in to 
pEGFP_C vector. The PCR conducted to amplify the OVM sequence showed a 
prominent band at ~500 bp (Figure 5.9). Primer dimers were also visible. The PCR 
product was then ligated into pGEM®-T Easy and the screening digest conducted post 
ligation showed a band at ~600 bp (insert) in 9/10 clones in addition to a larger band 
at ~7000 bp (vector backbone) in all clones (Figure 5.9). Sequencing and NCBI/BLAST 
confirmed that DNA sequence of interest was successfully amplified from OVM cDNA 
(Figure 5.10). The OVM fragment was then cut out of pGEM®-T Easy and inserted in 
to pEGFP by RE digestion and ligation (Figure 5.9).       
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Figure 5.7: Construction of shRNAs driven by a U6 promoter. A reverse 
complemenƚĞĚƐĞƋƵĞŶĐĞŽĨĞĂĐŚƐŚZEǁĂƐƵƐĞĚĂƐĂƉƌŝŵĞƌƚŽĂŵƉůŝĨǇƚŚĞƐĞƋƵĞŶĐĞ
of chicken U6 promoter from a donor ǀĞĐƚŽƌ;Ϳ͘ŐƌĂĚŝĞŶƚWZǁĂƐĐŽŶĚƵĐƚĞĚƚŽ
amplify the U6-4 promoter using the shOvm1 and shOvm2 primers (B). The desired 
WZƉƌŽĚƵĐƚŝƐƐŚŽǁŶďǇĂŶĂƌƌŽǁ͘ dŚĞWZĂŵƉůŝĨŝĞĚhϲ-4 нƐŚZEĐŽŶƐƚƌƵĐƚƐǁĞƌĞ
then ligated into pGEM®-T Easy vector (pU6-4shOvm1 & pU6-4shOvm2). Plasmids 
from 6 transformant clones of each of pU6-4shOvm1 and pU6-4shOvm2 were 
ƐƵďũĞĐƚĞĚƚŽĂƐĐƌĞĞŶŝŶŐĚŝŐĞƐƚƵƐŝŶŐĐŽZ/ƚŽĐŽŶĨŝƌŵŝŶƐĞƌƚ;Ϳ͘dŚĞĂƌƌŽǁƐŚŽǁƐƚŚĞ
hϲнƐŚZEĨƌĂŐŵĞŶƚĚŝŐĞƐƚĞĚŽƵƚŽĨƚŚĞǀĞĐƚŽƌďǇĐŽZ/͘ 
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Figure 5.8: Sequence results of the U6 + shRNA after insertion in pGEM®-T Easy. The 
known sequence of chicken U6-4 promoter is shown in (A). The reverse sequence of 
shOvm1 is shown in (B) and shOvm2 in (C). Sequencing result for pU6-4shOvm1 is 
ƐŚŽǁŶŝŶ;ͿĂŶĚpU6-4shOvm2 is shown in (E). The chicken U6-4 sequence is shown 
in red ĂŶĚƐŚZEƐĞƋƵĞŶĐĞƐĂƌĞƐŚŽǁŶŝŶblue. 
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Figure 5.9: Insertion of OVM target region in to pEGFP_C. The region of OVM 
ƚĂƌŐĞƚĞĚďǇƚŚĞƚǁŽƐŚZEƐǁĂƐĂŵƉůŝĨŝĞĚĨƌŽŵKsDĐE;Ϳ͘dŚĞWZ product was 
then ligated in to pGEM®-T Easy vector. The ligated vector was transformed in to E.coli 
and vectors isolated from 10 transformant clones were subjected to a screening digest 
ƵƐŝŶŐĐŽZ/ƚŽĐŽŶĨŝƌŵŝŶƐĞƌƚ;Ϳ͘ The arrow shows the insert digesteĚŽƵƚďǇĐŽZ/͘ A 
clone with the correct insert was digested with BgIII and HindIII (C). At the same time, 
Ɖ'&Wͺ ǀĞĐƚŽƌǁĂƐ ĚŝŐĞƐƚĞĚǁŝƚŚ Őů// ĂŶĚ,ŝŶĚ/// ;Ϳ͘ dŚĞ ĚŝŐĞƐƚĞĚKsD ƚĂƌŐĞƚ
sequence was ligated in to digesƚĞĚƉ'&WͺƵƐŝŶŐdϰE ůŝŐĂƐĞ ƚŽƉƌoduce the 
pEGFP_C_OVM vector.  
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Figure 5.10: PCR amplified OVM target region. The sequence highlighted in red was 
WZ ĂŵƉůŝĨŝĞĚ ĨƌŽŵ KsD ĐE͘ dŚĞ ĂŵƉůŝĨŝĞĚ ƐĞƋƵĞŶĐĞ ǁĂƐ ƚŚen inserted into 
pEGFP_C vector to produce the pEGFP_C_OVM vector.    
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Confluent DF-1 cells were then transfected with pEGFP_C_OVM containing targeted 
OVM and pU6-4shOvm1 or pU6-4shOvm2 harbouring the U6-4 driven shRNAs, along 
with negative and positive controls. Some cells were left untransfected as an 
additional negative control. The transfected cells were observed under fluorescence 
microscopy 48 hours post transfection. Under bright-field, cell of all treatments 
looked normal and no discrepancies were visible (Figure 5.11). Under green 
fluorescence light, no cells were visible in the untransfected sample, while the others 
had cells emitting green fluorescence. Cells transfected with pEGFP_C_OVM only and 
pEGFP_C_OVM + Irrelevant shRNA showed more green fluorescing cells when 
compared to cells transfected with pEGFP_C_OVM + shEGFP, pEGFP_C_OVM + pU6-
4shOvm1 or pEGFP_C_OVM + pU6-4shOvm2 (Figure 5.11).  
 
The mean fluorescence intensity (MFI) of untransfected and transfected cells were 
measured by FACS. pEGFP_C_OVM + shEGFP, pEGFP_C_OVM + pU6-4shOvm1 and 
pEGFP_C_OVM + pU6-4shOvm2 treated cells had a lower MFI than pEGFP_C_OVM 
only and pEGFP_C_OVM + Irrelevant shRNA treated cells (Table 5.7 and Figure 5.12). 
pEGFP_C_OVM + pU6-4shOvm1 and pEGFP_C_OVM + pU6-4shOvm2 treated cells 
had a lower MFI than the positive control pEGFP_C_OVM + shEGFP. Untransfected 
cells had little or no MFI.  
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Figure 5.11: RNAi Knockdown of OVM in DF-1 cells. Confluent &-1 cells were co-
transfected with pEGFP_C_OVM containing the targeted OVM fused to GFP and pU6-
4shOvm1 or pU6-4shOvm1 containing shZEƐ͘ &Žƌ ĞĂĐŚ ƚƌĞĂƚŵĞŶƚ͕ ϱϬϬ ŶŐ ŽĨ
pEGFP_C_OVM and 500 ng of ǀĞĐƚŽƌƐ ĐŽŶƚĂŝŶŝŶŐ ƐŚZE (total of 1 μg) were 
transfected. The cells were then grown for 48 hours, visualised under fluorescence 
microscopy. In addition to the un-transfected cells, two negative controls were done: 
pEGFP_C_OVM only and pEGFP_C_OVM н/ƌƌĞůĞǀĂŶƚƐŚZE͘dŚĞƉŽƐŝƚŝǀĞĐŽŶƚƌŽůĐĞůůƐ
were transfected with shEGFP which specifically targets EGFP in pEGFP_C_OVM 
vector.  
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Figure 5.12: Mean fluorescence intensity of DF-cells treated with shRNAs measured 
by FACS. Untrasfected and transfected cells were collected 2 days after transfections 
by dissociating from the wells with trypsin. The cells were prepared in FACS media and 
fluorescence intensity was measured. The negative control with pEGFP_C + Irrelevant 
ƐŚZEǁĂƐ ƵƐĞĚ ĂƐ ϭϬϬйŵĞĂŶ ĨůƵŽƌĞƐĐĞŶĐĞ ŝŶƚĞŶƐŝƚǇ ĨŽƌ ĐŽŵƉĂƌŝƐŽŶ ǁŝƚŚ ŽƚŚĞƌ
treatments.  
 
 
Table 5.7 Mean fluorescence intensities (MFI) of DF-1 cells treated with shRNAs.   
Treatment MFI 
Untransfected 43 
pEGFP_C_OVM Only 35, 344 
pEGFP_C_OVM + Irrelevant shRNA 31, 530 
pEGFP_C_OVM + shEGFP 18, 698 
pEGFP_C_OVM + pU6-4shOvm1 13, 038 
pEGFP_C_OVM + pU6-4shOvm2 11, 098 
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5.3.2.2 RNAi knockdown of ovomucoid in chicken 
In vitro analysis showed that both shRNAs would efficiently silence OVM-GFP fusion, 
therefore the next step was to use the same siRNA sequences, used to design the 
aforementioned shRNAs, to design two miRNAs mimicking the structure of miR-30. 
When the sequences of two miRNAs (miOvm1 & miOvm2) were submitted to 
ViennaRNA online tool, the expected structure was predicted (Figure 5.13). The two 
miRNAs were then successfully inserted into the Intron (intron 5 of PANK1 gene) 
within pEGFP_N1Intron plasmid by RE digestion (Figure 5.14). Sequencing further 
confirmed the successful insertion of the miRNAs (Figure 5.14).    
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Figure 5.13: Predicted secondary structure of the two miRNAs. The secondary 
ƐƚƌƵĐƚƵƌĞǁĂƐ ƉƌĞĚŝĐƚĞĚ ďǇ ƐƵďŵŝƚƚŝŶŐ ƚŚĞŵŝZE ƐĞƋƵĞŶĐĞƐ ƚŽ sŝĞŶŶĂZE ŽŶůŝŶĞ
tool. (A) miOvm1, (B) miOvm2. 
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Figure 5.14: Insertion of miRNAs in to the Intron contained in the pEGFP_N1Intron 
vector. pEGFP_N1Intron plasmid containing the PANK1 Intron was digested with KpnI 
and BamHI (A). These two sites are located ŝŶƚŚĞŝŶƚƌŽŶǁŚĞƌĞƚŚĞŵŝZEǁĂƐƚŽďĞ
ŝŶƐĞƌƚĞĚ͘ dŚĞ ĂŶŶĞĂůĞĚ ŵŝZEƐ ĚŝĚ Ŷot need to be digested because they were 
ĚĞƐŝŐŶĞĚǁŝƚŚŽǀĞƌŚĂŶŐZƐĞƋƵĞŶĐĞƐĂƚƚŚĞĞŶĚƐ͘dŚĞŵŝZEƐǁĞƌĞůŝŐĂƚĞĚŝŶƚŽƚŚĞ
ǀĞĐƚŽƌ ƵƐŝŶŐ dϰ E ůŝŐĂƐĞ͘ dŚĞ ůŝŐĂƚĞĚ ƉůĂƐŵŝĚƐ ǁĞƌĞ ƐĞƋƵĞŶĐĞĚ ƚŽ ĐŽŶĨŝƌŵ ƚŚĞ
insert: (B) pEGFP_NiOvm1, (C) pEGFP_NiOvm2. The insert is highlighted in red in (B) 
& (C).   
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The next task was to insert the “eGFP-Intron-miRNA-Intron-eGFP” fragment into pT2-
009 vector which encodes the mini-Tol2 transposon. Triple RE digestion of 
pEGFP_NiOvm1 and pEGFP_NiOvm1 containing “eGFP-Intron-miRNA-Intron-eGFP” 
resulted in 4 bands on the agarose gel and the double digest resulted in 2 bands 
(Figure 5.15). pT2-009 was also digested with REs; the sample digested with standard 
NotI yielded a prominent band than the sample digested with high fidelity NotI 
(Figure 5.15). The screening digest conducted upon ligation of “eGFP-Intron-miRNA-
Intron-eGFP” in to pT2-009 confirmed 1/6 clones of pT2-009 containing miOvm1 had 
the insert while 3/6 clones of pT2-009 containing miOvm2 had the insert.  
 
It was then necessary to insert PolyA into pT2-009, downstream of “eGFP-Intron-
miRNA-Intron-eGFP” fragment. Gradient PCR conducted to amplify PolyA from 
pEGFP_N1Intron resulted in prominent bands at ~200 bp in all temperatures (Figure 
5.16). Primer dimers were also visible in this gel. The PCR product was then inserted 
into pGEM®-T Easy and the screening digest confirmed successful insertion in all 
digested clones by showing a band at ~200 bp (Figure 5.16). Sequencing and 
subsequent NCBI/BLAST search showed that the amplified sequence is 100% similar 
to the known PolyA sequence (Figure 5.17). The PolyA was then successfully digested 
out of pGEM®-T Easy and inserted in to RE digested pT2-009 to produce Tol2Ovm1 
and Tol2Ovm2 (Figure 5.16).     
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Figure 5.15: Insertion of “eGFP-Intron-Hairpin-Intron-eGFP” fragment from 
pEGFP_NiOvm1 & pEGFP_NiOvm2 into pT2-009.  The “eGFP-Intron-Hairpin-Intron-
eGFP” fragments from pEGFP_NiOvm1 & pEGFP_NiOvm2 were ŝƐŽůĂƚĞĚ ďǇ Z
digestion (A). The band shown by the arrow in triple digest was gel purified and used. 
Then pT2-ϬϬϵǁĂƐĚŝŐĞƐƚĞĚǁŝƚŚZƐ;Ϳ͘ After ligation of the “eGFP-Intron-Hairpin-
Intron-eGFP” in to pT2-009, a screening digest was performed to confirm insertion (C). 
6 clones of pT2-009 containing miOvm1 and 6 clones of pT2-009 containing miOvm2 
were subjected to this screening digest. The arrows on (C) shows the insert (“eGFP-
Intron-Hairpin-Intron-eGFP”) which harbours either miOvm1 or miOvm2.      
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Figure 5.16: Insertion of PolyA into pT2-009.  ŐƌĂĚŝĞŶƚ WZ ǁĂƐ ĐŽŶĚƵĐƚĞĚ ƚŽ
amplify the PolyA sequence from pEGFP_N1Intron (A). ƌƌŽǁ ŝŶĚŝĐĂƚĞƐ ƚŚĞ WZ
product of interest. dŚĞWZƉƌŽĚƵĐƚǁĂƐŐĞůƉƵƌŝĨŝĞĚĂŶĚĐůŽŶĞĚŝŶƚŽƉ'DΠ-T Easy 
vector. Eight clones of transformant pGEM®-T Easy were subjected to a screening 
ĚŝŐĞƐƚǁŝƚŚĐŽZ/ƚo confirm insertion of PolyA (B). Then PolyA was cut out of pGEM®-
T Easy by digesting with NotI and was gel purified (C). Arrow indicates the PolyA insert 
cut out of pGEM®-T Easy. The pT2-009 vectors ĐŽŶƚĂŝŶŝŶŐƚŚĞŵŝZEƐ (miOvm1 or 
miOvm2) were also digested with NotI to allow insertion of the NotI digested PolyA 
;Ϳ͘ dŚĞ ďĂŶĚƐ ŝŶĚŝĐĂƚĞĚ ďǇ ƚŚĞ ĂƌƌŽǁ ŝŶ ;Ϳ ǁĞƌĞ ŐĞů ƉƵƌŝĨŝĞĚ ĂŶĚ ƵƐĞĚ ĨŽƌ ƚŚĞ
ligations with the insert (PolyA). The final vectors were named Tol2Ovm1 and 
Tol2Ovm2.  
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Figure 5.17: Comparison of PCR amplified PolyA sequence with the known PolyA 
sequence on NCBI/BLAST. Query: obtained sequence after cloning and sequencing, 
Sbjct: known PolyA sequence.  
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Constructed Tol2Ovm1 and Tol2Ovm2 along with pT2-002a which encodes 
transposase were successfully micro-injected in to 2.5 days old chicken embryos 
(Figure 5.18). Ten eggs at 15 days (5 for each of Tol2Ovm1 and Tol2Ovm2) were then 
subjected to gonad assays. Of the 5 Tol2Ovm1 injected embryos, 3 were female and 
2 were male, whereas of the Tol2Ovm2 injected embryos, 2 were female and 3 were 
male. Gonads from all eggs were observed under bright-field and fluorescence 
microscopy.  When observed under fluorescence, all gonads had large numbers of 
cells emitting green fluorescence (Figure 5.19 & Figure 5.20). Please note that only 
selected male gonads are shown in this chapter (Please refer to the Appendix A for 
images of all gonads).    
 
Of the remaining eggs that were incubated for hatching 9 chicks hatched and they 
were named according to the corresponding mini-Tol2-miRNA construct they were 
injected with; M1 & M2. Of the hatched chicks, there were 3 M1 males, 1 M1 female, 
3 M2 males and 2 M2 females. 2 M1 males, 2 M2 males and 1 M2 female survived to 
sexual maturity. One M1 male bird was subjected to semen screening by qPCR to 
confirm the presence of mini-Tol2-miRNA (miOvm1) transgene. The qPCR yielded a 
CT (cycle threshold) value of 31 for mini-Tol2-miRNA and 26 for genomic DNA. This 
predicts that 0.605% of this rooster’s sperm carries the mini-Tol2-miRNA transgene, 
which translates to ~1.5% of G1 chicks being fully transgenic, as determined by 
previous experiments done at CSIRO-AAHL. Please note that semen collection from 
the remaining roosters has been difficult, therefore semen screening results of these 
roosters were not available at the time of submission of this thesis.       
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Figure 5.18: Micro-injection of Tol2Ovm1 and Tol2Ovm2 in to chicken embryo. These 
images show the micro-injection of Tol2Ovm1 or Tol2Ovm2 along with pT2-002a 
transposase in to a 2.5 days old chicken embryo. For the purpose of this image, the 
injected material contained a dye, Bromophenol blue, showing distribution of the 
material throughout the embryo as shown in the images above.   
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Figure 5.19: Gonad analysis of embryos micro-injected with Tol2Ovm1 and pT2-
002a. The gonads were observed under bright-field and green fluorescence light at 
x40 and x100 magnification. Both gonads of each bird were observed. Only male 
gonads are shown in this figure.     
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Figure 5.20: Gonad analysis of embryos micro-injected with Tol2Ovm2 and pT2-
002a. The gonads were observed under bright-field and green fluorescence light at 
x40 and x100 magnification. Both gonads of each bird were observed. Only male 
gonads are shown in this figure.     
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5.4 Discussion  
Chicken egg allergy is a common disorder affecting mainly children worldwide. Like 
in many other food allergies, the most efficient way of egg allergy management is 
strict dietary avoidance. Dietary avoidance of eggs may however result in 
malnutrition in developing/growing children, as eggs contain essential vitamins and 
minerals. Complicating the situation further, eggs or traces of eggs are present in a 
range of food products and vaccines, making it difficult to completely avoid eggs. SIT 
is currently being pursued as the only curative treatment strategy for egg allergy and 
other food allergies. Production of recombinant variants and hypoallergenic variants 
of egg and other food allergens has been the focus of many researchers, which may 
be useful in well-controlled SIT and diagnostic techniques such as SPT. However, even 
SIT has limitations. The success of SIT primarily depends on the sensitivity of the 
patient to a given allergen. Administration of allergens may sometimes result in 
undesirable adverse reactions such as anaphylaxis, which has the potential to lead to 
death.  
 
The lack of highly effective egg allergy management strategies leads to the utilization 
of unconventional strategies to answer questions in egg allergy. Almost all research 
on egg allergy has overlooked tackling egg allergy at the root of the cause, away from 
the human immune system, the allergen source itself. It may well be possible to 
change the allergenic properties of chicken egg into a hypoallergenic form using well 
established methods and techniques used elsewhere in biological/biomedical 
research, including RNAi and CRISPR-Cas9. Ovomucoid (OVM) is the most allergenic 
protein in the chicken egg white. It is structurally rigid and contains multiple IgE 
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binding epitopes, allowing it to retain is allergenic properties even after heating 
(cooking) and/or proteolytic digestion. Therefore, in this study, OVM was chosen as 
a candidate for knockout and knockdown studies.  
 
It was hypothesized that knockout/knockdown of OVM may not have adverse effects 
on the chicken or the developing eggs due to the presence of a natural homologue 
present in the egg white known as ovoinhibitor (OVH). Both OVM and OVH are serine 
protease inhibitors characterized by three well-conserved intra-domain disulphide 
bridges known as the Kazal domain227,228. OVM expression is limited to the egg white, 
whereas OVH is expressed in almost all components of the egg. It is poorly 
understood why OVM, being functionally similar to OVH yet less potent, has evolved 
as a separate protein in the egg white. It can be suggested that OVM evolved, in wild 
birds, to provide extra protection against trypsin during egg formation inside the 
oviduct or against bacterial proteases exogenously introduced to the egg. Today, 
commercial egg laying hens are raised in highly controlled and cleaner environments 
and therefore face foreign pathogens in a lesser extent when compared to their wild 
counterparts. Therefore, in this study, it was suggested that knockdown or knockout 
of OVM may not have a significant effects in chickens’ development or health.  
 
CRISPR-Cas9 based precision genome engineering has been utilized as a potent tool 
in many disciplines across biological and biomedical sciences. One of the goals of this 
chapter was to design two guide RNAs (sgRNAs) capable of knocking out OVM in DF-
1 chicken fibroblast cells. Although there is no preferred region of the coding 
sequence of a gene to be targeted for a simple gene knockout, exon 1 of OVM gene 
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in chromosome 13 was chosen as a starting point for this experiment. It is essential 
to choose sgRNAs with a high score given by the online CRISPR design tool to increase 
chances of efficient gene knockouts, therefore, for this study, the sgRNAs with the 
highest scores were selected. When DF-1 cells were transfected with the pSpCas9 
(BB)-2A-GFP carrying either of the sgRNA, some cells produced green fluorescence. 
This was an indication that the pSpCas9 (BB)-2A-GFP has been successfully 
transfected into these cells. The cells were FACS sorted and re-cultured to produce a 
fully transfected cell population, allowing isolation of only targeted genomic DNA. 
The DNA samples isolated from cells targeted with sgRNAs were hybridized with wild-
type DNA to produce heterocomplexes, which allows SURVEYOR nuclease to detect 
mismatches and subsequent digestion of the DNA strand. However, the gel analysis 
of SURVEYOR nuclease digested heteroduplexes did not yield multiple bands 
indicating a failed knockout of OVM gene by either of the sgRNAs. It is unclear why 
the two sgRNAs, having high scores, failed to mutate the targeted gene. The next step 
would be to design new sgRNAs to target other exons of the OVM gene to scrutinize 
a gene knockout. This was not attempted in this study due to time limitations.       
 
Parallel to the CRISPR-Cas9 knockout of OVM in DF-1 cells, a RNAi knockdown study 
was also conducted. The aim of this study was to design two miRNAs capable of 
knocking down OVM in chickens. As the foremost step, 50 candidate siRNAs were 
designed using the Dharmacon tool and an algorithm was used to choose the best 
two siRNAs targeting the OVM mRNA sequence. It was then necessary to study the 
efficacy of these two siRNAs at knocking down OVM. Wise et al 2007229 describes a 
mechanism of RNAi using shRNAs driven by a chicken U6 promoter in DF-1 cells. A 
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similar approach was followed in this study, in which the two designed siRNAs were 
inserted into a known hairpin structure to produce two shRNAs driven by the chicken 
U6-4 promoter. pGEM®-T Easy was the vector of choice for expression of the shRNAs 
because this work did not require directional cloning as the shRNAs were fused to 
their own U6-4 promoters. Upon ligation of the U6-4 promoter + shRNAs in to 
pGEM®-T Easy (which were named pU6-4shOvm1 & pU6-4shOvm2), a screening 
digest was done for selected clones to confirm that the insert had been successfully 
ligated. Next, the targeted OVM was cloned into pEGFP_C vector, which expresses 
GFP with a C-terminal fusion of the inserted sequence/protein. It was expected that 
if either or both of the shRNAs targeted OVM, a reduction of GFP expression will be 
observed in transfected DF-1 cells. PCR amplification of the targeted OVM fragment 
from OVM cDNA was successful as evident by the screening digest and the 
sequencing results. It was not necessary to perform another screening digests after 
inserting the PCR product from pGEM®-T Easy into pEGFP_C vector because 
directional cloning using two different REs was used.  
 
The pEGFP_C containing the targeted OVM fragment, which was named 
pEGFP_C_OVM, was co-transfected with the pU6-4shOvm1 or pU6-4shOVM2 into 
DF-1 cells. As expected, both U6-4shOvm1 and pU6-4shOVM2 showed significant 
knockdown of GFP, indicating the two shRNAs are efficiently targeting OVM via RNAi. 
The observation of healthy and similar cell populations under bright-field microscopy 
in all treatments, including controls, shows that the study was well controlled with 
minimal or no external influence. The untransfected cells did not yield any GFP signal, 
indicating that the cells used for this study was completely free of GFP. The 
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pEGFP_C_OVM only transfected cells showed the highest GFP expression as this 
sample did not have any shRNAs targeting the GFP sequence. The cells transfected 
with pEGFP_C_OVM and an irrelevant shRNA however showed slightly less GFP 
expression when compared to pEGFP_C_OVM only control. This can be attributed to 
the total amount of DNA affecting the transfection efficiency, therefore 
pEGFP_C_OVM + irrelevant shRNA was used as the true negative control. The positive 
control (pEGFP_C_OVM + shEGFP) contained shRNA capable of targeting the GFP 
sequence in pEGFP_C_OVM. As expected, this control showed significant knockdown 
of GFP when compared to the negative control. It should be noted that pU6-4shOvm1 
and pU6-4shOVM2 transfected cells showed higher knockdown of GFP signals when 
compared to the positive control. This was not expected because similar amounts of 
DNA were added to both the positive control and the experimental cells. This may 
possibly be due the ability of the designed hairpins to target OVM more efficiently 
when compared to shEGFP targeting the GFP sequence. The result of this experiment 
showed that either of the two chosen siRNAs may be adequate to silence OVM in 
chicken by RNAi, however both were used for the follow up experiments. 
 
The chicken U6-4 promoter is a Polymerase III type promoter229 which, although 
known to be effective in vitro, may be toxic in vivo possibly due to the excessive 
expression of shRNAs saturating and impeding the RNAi mechanisms230. Therefore 
the two siRNAs, used as shRNAs in the earlier experiment, were then used to produce 
miRNAs mimicking the structure of miR-30. It was hypothesized that hitch-hiking the 
miR-30 like miRNAs into the PANK1 Intron will allow a more natural, promoter-less, 
expression of the siRNAs in vivo. MicroRNAs (miRNAs) are short (~22 nucleotides) 
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molecules that function as regulators of gene expression and mRNA stabilizers. These 
molecules, expressed in multicellular organisms, leave the nucleus as ~60 nucleotide 
molecules known as pre-miRNAs. At the cytoplasm, the pre-miRNAs are further 
cleaved by the enzyme Dicer to produce the mature miRNA (~22 nucleotides). The 
mature miRNAs can then recognize and bind to the 3’ end of the untranslated region 
(UTR) of target mRNAs using the RNA-induced silencing complex (RISC) to induce 
mRNA regulation including inhibition or degradation231-233. The model miRNA chosen 
for this study, miR-30, is from a family of miRNAs involved in transcriptional 
regulation and can be used for expression of siRNAs231,234.   
 
When the structure of the two miRNAs in this experiment, miOvm1 and miOvm2, 
were predicted using ViennaRNA online tool, the structures were similar to that of 
miR-30. The miRNAs were then inserted into the PANK1 Intron that had already been 
cloned in to a pEGFP_N1Intron plasmid by directional cloning. The sequencing result 
further confirmed that the miRNAs were successfully cloned into the Intron. The 
“eGFP-Intron-Hairpin-Intron-eGFP” from pEGFP_N1Intron was then digested out by 
a triple RE digest. It was necessary to conduct a triple digest because the 
pEGFP_N1Intron backbone and “eGFP-Intron-Hairpin-Intron-eGFP” were of similar 
sizes and would have been difficult to separate by gel electrophoresis. The RE FspI 
simply cleaved the pEGFP_N1Intron backbone into two smaller fragments. The 
“eGFP-Intron-Hairpin-Intron-eGFP” was then successfully inserted into pT2-009 
vector by directional cloning. The PolyA sequence was added in to the pT2-009, 
downstream of “eGFP-Intron-Hairpin-Intron-eGFP” fragment, as it is essential for 
gene expression. A gradient PCR was done to amplify the PolyA sequence from pEGFP 
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to choose the best PCR conditions, however all temperatures were successful. When 
the obtained sequence was compared to the known sequence of PolyA, a 100% 
similarity was observed. The insertion of PolyA into pT2-009 transposon concluded 
the construction of the vectors for delivery of miRNAs in to the chicken embryos, 
which were named Tol2Ovm1 and Tol2Ovm2.  
 
The constructed Tol2Ovm1 and Tol2Ovm2 plasmids were microinjected into 2.5 days 
old chicken embryos. Each of these vectors, which encodes a transposon and miRNA, 
was delivered along with pT2-002a which encodes a transposase. The Tol2Ovm1 or 
Tol2Ovm2 and pT2-002a carry the mini-Tol2 transposon and transposase 
respectively, which allow transposition of at least 10, 000 bp of DNA fragments into 
a targeted host235. This was the best option for the insertion of “eGFP-Intron-Hairpin-
Intron-eGFP” cassette, which is >4000 bp in size, into the genome of cells in the 
micro-injected embryos. Following micro-injections, gonads were observed from 
embryos at day 14. The presence of large numbers of GFP positive cells in all observed 
gonads indicates that miRNAs are being effectively processed by RNAi mechanisms, 
thus fusing the two fragments of eGFP to produce GFP. This indicates that successful 
transposition has occurred, followed by expression, intron splicing and miRNA 
processing. Essentially, the results of this experiment show that the two miRNAs may 
successfully knockdown OVM in transgenic chicken (G1 generation). 
 
The remainder of the embryos were allowed to hatch and the chicks were raised to 
sexual maturity. This generation is the G0 generation. The next step was to screen 
sperm samples from adult males for the presence of the transgene. Results from one 
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M1 male bird indicates that ~1.5% G1 offspring from this rooster will be fully 
transgenic. In addition, the presence of the mini-Tol2-miRNA transgene in sperm cells 
indicates that primordial germ cells (PGCs) has been transfected when the 
transfection complex was microinjected into the embryos. This rooster, and other 
remaining roosters upon semen screening, can be mated with wild-type females to 
produce transgenic chicks that will have knocked-down OVM levels. From this point, 
important observations can be made about the importance of OVM for the 
developing chicken. The level of OVM knockdown can be measured while measuring 
the expression levels of OVH, in comparison to wild-type chicks. If significant 
knockdown of OVM is achieved, it may even be possible to tests eggs from the G1 
generation against egg allergic patients’ sera for IgE reactivity. Although not 
completely hypoallergenic, egg white with reduced OVM may play a crucial role in 
egg allergy treatment methods such as immunotherapy and diagnostic methods such 
as skin prick tests for highly reactive patients.  
 
The current results of this study demonstrate that RNAi may be used as an important 
tool to knockdown allergenic proteins in the chicken egg. The impending results of 
this study will provide much more important information on feasibility of knocking 
out OVM from the chicken genome to produce significantly hypoallergenic chicken 
eggs using CRISPR-Cas9, or, other techniques such as TALENs (transcription activator-
like effector nuclease) and ZFN (zinc finger nuclease) based genome engineering. 
These techniques, along with the understanding of IgE binding epitopes of egg 
allergens, may also allow precision genome engineering to alter the IgE binding 
epitopes of all the allergens to produce a chicken lineage capable of laying 
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hypoallergenic chicken eggs. Such achievement in egg allergy may in fact cause a 
paradigm shift in food allergy research as a whole.  
 
 
5.5 Conclusion 
Egg allergy is a wide-spread disorder mainly affecting children.  Currently, strict 
dietary avoidance and immunotherapy are pursued as the most effective 
management and treatment strategies.  Traditionally, egg and other food allergy 
research has been focussing mainly on improving the immune system of the patients. 
Tackling the problem at the root of the cause has been overlooked by many, 
especially at a time when genetic engineering is being efficiently used to answer 
important questions in biomedical science, environmental science and agriculture. In 
this study, a knockout of the most important egg white allergen OVM was attempted 
in DF-1 chicken fibroblast cells, with no satisfactory results. As a second approach, 
RNAi knockdown of OVM was attempted using two siRNAs. The DF-1 cell culture 
based experiment showed that the two siRNAs can efficiently knockdown a GFP-OVM 
fusion, suggesting that OVM would be efficiently silenced in vivo. The subsequent 
delivery of the siRNAs, in the form of miRNAs, in to chicken embryos showed 
successful transgene integration and that the designed miRNAs are being effectively 
processed by RNAi mechanisms, promising the development of OVM knocked-down 
transgenic hens. This was further supported by the semen screening result of one 
male bird, which indicated that ~1.5% of G1 chicks will be fully transgenic with 
knocked-down OVM. The current results and results from follow up studies will 
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provide important information necessary for development of hypoallergenic chicken 
eggs using genome engineering strategies.          
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6.1 Discussion  
The chicken egg has been a part of the human diet for centuries. It is virtually a part 
of daily diets in non-vegan individuals due to its wide-range use. In the culinary world 
alone, eggs are used in food products including, but not limited to, cakes, 
hamburgers, stocks, battered foods, pasta, mayonnaise, breads, and custard or on its 
own in forms such as omelettes. This wide use is primarily due to the high availability, 
affordability and nutritional value of eggs. Inclusion of chicken egg provides many 
health benefits, especially for growing children, due to the presence of proteins, a 
mix of fats, minerals/elements such as magnesium, iron, calcium and potassium, and 
vitamins such as thiamin (B1), riboflavin (B2), vitamins B6, B12, D and E, folate and 
biotin, just to name a few.   Other food products may also carry traces of eggs carried 
on by food production machinery or utensils. Apart from these, traces of eggs are 
also found in pharmaceutical products including vaccines such as influenza. The 
allantoic or amniotic fluids of fertilized eggs are known to be effective and cheap for 
culturing of viruses required for production of vaccines. Isolation of egg-cultured 
viruses often causes carry-over of traces of egg proteins into the final product.  
However, not all individuals can enjoy the above-mentioned benefits from eggs or 
egg products. Today, 0.5-2.5% of children are affected by hypersensitivity to the 
chicken egg. With no permeant cure available, strict dietary avoidance is the best egg 
allergy management strategy. The wide use of eggs in a range of aforementioned 
products however, complicates strict avoidance and increases the chances of 
accidental exposure, which may result in adverse allergic reactions such as 
anaphylaxis. Eggs are cheap and readily available in both developed and 
underdeveloped societies. Therefore, strict avoidance of eggs may be nutritionally 
212 | P a g e  
 
Chapter 6 
disadvantageous for egg allergic children coming from financially disadvantaged 
families. Apart from dietary avoidance, egg allergen SIT is currently being pursued as 
a therapeutic measure. SIT includes OIT, a widely used method for treating food 
allergies, which involves oral administration of small amounts of the allergen to the 
individual in a dose-increasing manner to induce immunological tolerance.  
 
Currently, crude egg extracts or allergens isolated from natural egg white are used in 
OIT to treat egg allergy and this poses some complications. Crude egg extracts contain 
a mix of proteins, including a mix of allergens. This increases the risk of unwanted 
immune responses when administered to patients during OIT, especially in highly egg 
allergic patients. These extracts are also used in diagnostic methods such as skin prick 
testing (SPT), which may also cause severe allergic reactions during diagnosis. The 
presence of multiple allergens in the extract also undermines the recognition of 
causative egg allergen during diagnosis. The crude allergen extracts may also contain 
contaminant proteins and other elements which may impede proper diagnosis or 
treatment of egg allergy. Allergens isolated from natural egg white may contain 
traces of other egg allergens which can cause unwanted immune responses. The high 
occurrence of egg allergy and absence of highly effective treatment and management 
methods laid the foundation for the development of the hypotheses and aims of this 
thesis.  There were three main aims for this project: production of IgE reactive 
recombinant versions of 4 major egg white allergens; production of a hypoallergenic 
variant of the major egg white allergen ovomucoid; and investigation of genetic 
engineering approaches to produce hypoallergenic chicken eggs.   
 
213 | P a g e  
 
Chapter 6 
IgE reactive recombinant variants of allergens have been used in SIT for treatment of 
a number of allergies. Individual recombinant allergens are purer and less (or not) 
contaminated with other proteins or materials when compared to their natural 
counterparts, thus offering an excellent option for SIT including OIT. In egg allergy, 
the use of recombinant proteins for OIT is beneficial because of the shortcomings of 
the allergens extracted from natural egg white, which can trigger unwanted immune 
responses. For highly sensitive individuals, the separate recombinant proteins can be 
administered separately to better manage the desensitization process. The 
recombinant proteins can also be used in SPT which may help accurately identify 
which allergen a patient is allergic to, without causing unwanted immune reactions 
that may be caused by all the allergens/traces of other allergens present in natural 
egg white extracts.  
 
Chapter 2 of this thesis focussed on production of recombinant variants of the major 
egg white allergens: ovomucoid (OVM), ovalbumin (OVAL), ovotransferrin (OVT) and 
lysozyme (LYS). cDNA of all four allergens were successfully isolated from an oviduct 
of an egg laying hen. The cDNA were expressed in pTrcHisA vector, which fuses a 
6xHis tag and an Xpress epitope to the expressed protein which allows identification 
and purification of the proteins. The recombinant proteins were first expressed in E. 
coli TOP10 strain, however breaking down of the proteins was visible when analysed 
by SDS-PAGE and western blotting. Therefore, it was decided to express the protein 
in more versatile E. coli Express Iq strain. The results evidently showed an 
improvement of protein expression by showing less degradation when compared to 
the proteins expressed in E. coli TOP10. Although detection by anti-His antibodies 
214 | P a g e  
 
Chapter 6 
and anti-Xpress antibody assisted in confirming the correct protein has been 
expressed, it was decided to further analyse the proteins by mass-spectrometry, 
which also confirmed the identity of the proteins, except for OVM. It can be 
suggested that the trypsin inhibitory activity of OVM may have disrupted the in-gel 
trypsin digestion of the proteins in preparation for mass spectrometry analysis, thus 
causing the failure to successfully identify OVM. However, earlier detection by 
different antibodies at the correct molecular weight and cDNA sequencing result was 
sufficient to conclude that OVM in fact has been successfully expressed.  
 
The formation of inclusion bodies during protein expression in E. coli restricted the 
expression of OVT and LYS to the insoluble fraction, while OVM and OVAL were found 
in both soluble and insoluble fraction. This was not considered an issue for this 
experiment because it was decided to use crude E. coli extract with the expressed 
proteins for downstream applications. Ni-NTA based protein purification was 
attempted, however the purified proteins did not show high purity when analysed by 
SDS-PAGE. Follow-up nickel-affinity chromatography or size exclusion 
chromatography is necessary to isolate the expressed protein with high purity, 
however, this was not attempted due to time and resource constraints.   
 
In Chapter 3, the recombinant proteins produced in Chapter 2 were further studied 
for their IgE reactivity using allergic patients’ sera. The immunological analysis of 
allergic patients’ sera against natural egg white suggested that egg allergy in 
Australian populations may be due to hypersensitivity to OVT and LYS. The result also 
preserved the status of OVM being the most reactive egg allergen by showing dark 
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bands of intense IgE binding in the western immunoblots for the patients that were 
allergic to OVM. However, a much larger sera population is needed to draw any 
conclusions. When the recombinant proteins were tested against a pool of egg 
allergic patients’ sera OVM, OVAL and OVT were found to be IgE reactive while LYS 
did not show any reactivity. The most probable explanation for the absence of IgE 
reactivity of LYS is competition by the other allergens during incubation with the sera. 
This may be overcome by testing each recombinant allergen with egg allergic sera 
independent of one another, nonetheless this was not attempted due to the 
unavailability of sufficient amounts of blood sera. The produced IgE reactive OVM, 
OVAL and OVT, due to the lack of contamination from other allergens or each other, 
has the potential to be used in OIT and SPT upon purification and further animal 
based and clinical experimentation. Purified preparations of these recombinant 
proteins may carry trace amounts of E. coli proteins, however this should not present 
a problem as E. coli is part of human gut microbiota. 
 
As mentioned earlier, IgE reactive recombinant allergens may improve OIT. However, 
highly sensitive patients may still excessively react to these recombinant proteins 
during OIT, potentially causing life-threatening conditions such as anaphylaxis. OIT is 
of course done in a clinical setting under the watchful eyes of healthcare 
professionals, but hypersensitivity overreactions sometimes may still lead to 
unfavourable situations and can be costly. In such instances the use of less allergenic, 
or hypoallergenic, variants of allergens may prove to be extremely beneficial. 
Hypoallergens have been previously produced in studies involving allergies caused by 
allergens from different sources. These include, but not limited to, the production of 
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a hypoallergenic variant of the latex allergen Hev b 6.01 by Drew et al 2004154, 
production of a vaccine using hypoallergenic derivatives of the birch pollen allergen 
Bet v 1 by Niederberger et al 2004 215, pre-clinical testing of a vaccine developed with 
a combination of hypoallergenic dust mite allergens Der p 1 and Der p 2  by Wai et al 
2012 212 and, more recently, pre-clinical characterization of hypoallergenic carp 
allergen Cyp c 1 (paravalbumin) by Zuidmeer-Jongejan et al 2015 236. There is 
however lack of studies conducted on production of hypoallergenic recombinant 
variants of egg allergens with the focus been given to development of hypoallergenic 
natural egg white by different treatment methods such as heating, enzymatic 
digestion, radiation and ethanol precipitation237,238. These preparations may still be 
less versatile than recombinant hypoallergens due to contamination from other 
allergens present in the egg white. 
 
Chapter 4 of this thesis addressed production of a hypoallergenic variant of the 
dominant egg white allergen OVM. There are 9 cysteine-cysteine disulphide bridges 
in OVM 109, giving it structural stability even in the presence of heat and proteases. It 
has both linear and conformational IgE binding epitopes which, combined with 
structural stability, manages to retain its IgE reactivity thus potentially contributing 
to cooked egg allergic reactions 94,110,112. The presence of conformational epitopes in 
OVM highlights the possibility of making structural changes to reduce IgE reactivity. 
This was exploited in this chapter by mutating 2 cysteine-cysteine disulphide bridges 
using site-directed mutagenesis, similar to the development of Hev b 6.01 by Drew 
et al 2004154. It was decided to target 2 disulphide bridges as a starting point and 
mutate more bridges if necessary. However, the disruption of just two disulphide 
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bridges significantly reduced IgE reactivity, as shown by the immunoblotting 
conducted using egg allergic patients’ sera. It should be noted that the observed 
reduction in IgE binding to the mutant was in comparison to the recombinant wild-
type protein which was loaded on to the gel (and transferred on to nitrocellulose) at 
a higher concentration than the mutant, which essentially indicated a significant 
reduction of IgE reactivity. This hypoallergenic variant of OVM too has the potential 
to be used in OIT following animal and clinical trials. Nevertheless, unlike wild-type 
recombinant allergens, this hypoallergen cannot be used in diagnostic approaches 
such as SPT because of potential misdiagnosis of less sensitive patients.            
 
The recombinant allergens and hypoallergenic OVM produced in Chapters 2-4 
essentially may assist in improving the patient’s immune system against the allergen, 
which is the ultimate goal of OIT. Some research has also been conducted on 
disrupting the allergic cascade by reducing the activity of cytokines, such as IL-4 and 
IL-13, involved in allergic reactions239, which is again targeting the patient’s immune 
system. In the vast arena of egg allergy research, there is a lack of, more likely an 
absence of, research focussing on the root of the course which is the chicken itself. 
Methods such as RNAi and CRISPR-Cas9 are widely used in a range of research to 
answer questions in biomedicine and agriculture. A prime example of these is the 
developmeŶƚŽĨĂĐĂůĨƉƌŽĚƵĐŝŶŐŵŝůŬůĂĐŬŝŶŐɴ-lactoglobulin using RNAi by Jabed et 
al 2012 46. These methods have the potential to be used in egg allergy research.     
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Chapter 5 of this thesis aimed at using CRISPR-Cas9 to knockout OVM in a chicken 
fibroblast cell line and using RNAi to knockdown OVM in the chicken. OVM was 
chosen as the targeted allergen due to its dominance as an allergen over the other 
egg white allergens. The CRISPR-Cas9 driven knockout however did not yield 
satisfactory results due to unknown reasons. In this experiment, only exon 1 of OVM 
genomic DNA was targeted by two small guide RNAs (sgRNAs). It can be suggested 
that sgRNAs targeting different exons of the gene should be scrutinized to potentially 
and effectively knockout the gene.  
 
RNAi knockdown of OVM in the chicken, on the other hand, provided satisfactory 
preliminary data that may be useful in studying the importance of OVM for the 
developing chick and for egg laying. This experiment aimed to produce two short 
hairpin RNAs (shRNAs) capable of knocking down OVM expression. When the two 
shRNAs were tested in a chicken fibroblast cell line, it was evident that both shRNAs 
were effective at significantly knocking down OVM through RNAi. These shRNAs were 
then microinjected, in the form of micro RNAs (miRNAs), into chicken embryos in 
order to produce OVM knocked-down transgenic chickens. Preliminary gonad assays 
showed that both miRNA constructs are being targeted by the host RNAi machinery, 
thus indicating that OVM will be knocked-down to a certain extent in the transgenic 
chicken. Follow up semen screening of a male from the G0 generation male chickens 
predicted that ~1.5% of the G1 offspring will be transgenic and may have OVM 
knocked-down as a result.     
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The knockdown of OVM via RNAi will provide information about the importance of 
the protein for the chicken, however transgenic G1 generation hens and their eggs 
are necessary for further analysis and to draw conclusions. Only male birds from the 
G0 generation were selected because their semen will be used to produce the G1 
transgenic generation. Thus far, the selected males (2 representing each miRNA) 
seem healthy, somewhat providing assurance towards the production of the 
transgenic generation. Although a hypoallergenic egg was not decisively produced 
within the time-frame of this project, the RNAi knockdown data highlights the 
potential of genetic manipulation/engineering in egg allergy research, opening a 
brand-new frontier in the fight against this wide-spread condition.     
 
It is poorly understood why the human immune system recognizes some proteins in 
the egg as allergens and the others not. This is true for not just egg allergy, but also 
for other types of allergies. It is widely suggested that genetic predisposition and 
environmental factors may cause allergy240-242, however it is still unclear why any 
changes in the immune system can consider certain substances as allergens. For 
instance, cancer patients carry mutations in their genome that cause unfavourable 
conditions such as reduction in tumour suppression243. Any such mutations are not 
known to be responsible for allergies which may cause the immune system to 
recognize harmless environmental substances as harmful ones. It is suggested that a 
gene responsible for the skin barrier disease ichthyosis vulgaris, known as filaggrin 
(FLG), may play a crucial role in allergic contact dermatitis244, yet again it is not 
conclusive.  
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The lack of understanding of the exact biological cause of allergy has led to extensive 
scrutiny of the immune response and the properties of allergens. Current broad 
understanding of the changes that occur in innate and adaptive immunity during 
allergic reactions has permitted the development and effective utilization of methods 
such as SIT to treat allergies245-247. The understanding of the properties and IgE 
reactive epitopes of different allergens has allowed production of recombinant 
allergens and hypoallergens, which in turn target improvement of immunotherapy 
and allergy diagnosis. The scarcity of such recombinant allergens and hypoallergens 
for egg allergy treatment and diagnosis was addressed in this thesis, leading to the 
successful production of IgE reactive OVM, OVAL, OVT and LYS and a hypoallergenic 
variant of OVM. 
 
As mentioned earlier, genetic engineering tools such as RNAi and CRISPR were used 
in this PhD project as a novel frontier in egg allergy research. These techniques should 
not be limited to egg allergy research as they have substantial potential to be used in 
other food allergies such as peanuts, tree nuts, wheat, soy and seafood. Allergens 
involved in these food allergies are widely-studied248-252 and therefore genetic 
engineering may be useful in developing transgenic crops and animals without such 
allergenic traits. Such advanced techniques may not however be useful in other 
allergies such as house dust mites and grass pollen, simply because it is impossible to 
replace all dust mites and grasses in the environment. However, it is wise to state 
that tackling of food allergies alone can improve quality of life of many individuals 
while reducing the burden on medical industries and governments by saving millions-
billions of dollars spent annually on food allergy management. Being the second most 
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common food allergy in children and affecting 0.5-2.5% of children worldwide, a cure 
or a solution for egg allergy sure will be a significant contributing factor for such 
improvement of health and wellbeing of the society.      
 
 
6.2 Future perspectives 
The IgE reactive allergens and OVM hypoallergen produced in this study can be 
further studied using B-cell and T-cell activity assays. For successful immunotherapy 
using these recombinant proteins it is important to validate their ability to retain T-
cell reactivity, a feature necessary for immunotherapy253. In addition, the 
hypollergenic OVM protein should be able to demonstrate reduced B-cell reactivity 
while retaining T-cell reactivity. To conduct either of the above mentioned tests, it is 
important to purify the protein from E. coli extract.  All proteins were expressed with 
a 6xHis tag therefore nickel-affinity resin based purification can be used for initial 
purification, followed by nickel-affinity chromatography for a highly pure product. 
Size-exclusion and ion-exchange chromatography may also be used for purification 
of such proteins. It will also be interesting to study the efficacy of these recombinant 
proteins at desensitization using sensitized animal models such as mice or sheep. 
These animal models, especially mice, are widely used in biomedical research and can 
be easily sensitized using wild-type allergens 254. The animal testing can then be 
followed by clinical testing prior to be used in a regular basis for egg allergic patient 
treatment.     
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In the future, the transgenic hens that will be produced from the G0 generation of 
chickens produced in this project can be studied for the level of expression of OVM 
and possible upregulation/downregulation of other proteins. Their eggs can also be 
tested for their IgE reactivity with egg allergic patients’ sera, in comparison to wild-
type eggs. If the chickens seem healthy and are capable of laying eggs after 
knockdown of OVM, a total knockout of the gene may be attainable using methods 
such as CRISPR-Cas9, ZFN or TALENs. A successful knockout of OVM will allow 
production of a significantly hypoallergenic chicken egg that may be used for 
immunotherapy and even human consumption for patients allergic only to OVM. If 
total knockout of OVM is not feasible, the hypoallergenic variant produced in this 
study can be knocked-in using the same genome engineering methods.  
 
An alternative for knockdown or knockout of the allergens is changing the known 
sequences of IgE binding epitopes of the egg allergens using precision genome 
engineering methods such as CRISPR-Cas9. This can be implemented for addressing 
highly abundant allergens such as OVAL because a knockdown or a knockout of such 
proteins may prove detrimental to the chicken or the egg while reducing the quality 
of the eggs. It will also be fascinating to scrutinize cross-species gene swapping to 
produce hypoallergenic eggs. For instance, the human lysozyme sequence can 
possibly be knocked-in in place of the chicken lysozyme in the chicken genome as 
human lysozyme is similar to its chicken counterpart in molecular size, have similar 
functions and, most importantly, humans will not be allergic to human proteins. 
However, such cross-species genetic engineering should carefully address the ethical 
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nature of the research to avoid negativity about such research in the society. A final 
hypoallergenic egg should then be studied using animal models and clinical testing.       
 
 
6.3 Conclusion 
Hypersensitivity to the chicken egg is a wide-spread condition affecting mainly 
children. It affects 0.5-2.5% of children world-wide and 8.9% in Australia. Currently, 
avoidance of eggs or egg-related products are pursued as the most effective 
management strategy. However, this is extremely difficult and places a massive 
burden on affected family simply because of the abundance of egg-related food and 
pharmaceutical products. As a treatment method, immunotherapy is widely used in 
food allergies, including egg allergy. This too has limitations due to the unavailability 
of pure individual egg allergens and unwanted immune responses caused by the use 
of crude egg extracts or contaminated individual natural allergens for 
immunotherapy. The research conducted in this PhD project successfully produced 
IgE reactive versions of egg white allergens. In addition, a hypoallergenic variant of 
the major egg white allergen OVM was also produced. All of these proteins qualify to 
be used in pre-clinical and clinical testing following B-cell and T-cell activity testing. 
As a separate avenue for tackling egg allergy, this PhD project also scrutinized the 
used of genetic engineering to produce hypoallergenic chicken eggs. RNAi was used 
to deliver an OVM knockdown mechanism to developing chicken embryos, whose 
gonads demonstrated successful delivery and potential activity of the RNAi 
machinery. At the conclusion of this project, the parental generation (G0) of male 
birds seem healthy and predicted 1.5% transgenesis in the next generation (G1). The 
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G1 generation will provide important information required for use of precision 
genome engineering to develop hypoallergenic chicken eggs. In conclusion, this 
project provided useful results, reagents and novel information necessary for the 
development of a solution to treat chicken egg white allergy.                                                                
  
-The End- 
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Figure A1: Gonads of Tol2Ovm1 micro-injected Male 1 under bright-field and 
fluorescence microscopy.  
 
 
  
Figure A2: Gonads of Tol2Ovm1 micro-injected Male 2 under bright-field and 
fluorescence microscopy.  
 
 
 
 Figure A3: Gonads of Tol2Ovm1 micro-injected Female 1 under bright-field and 
fluorescence microscopy. 
 
 
 
  
Figure A4: Gonads of Tol2Ovm1 micro-injected Female 2 under bright-field and 
fluorescence microscopy. 
 
 
 
 
  
Figure A5: Gonads of Tol2Ovm1 micro-injected Female 3 under bright-field and 
fluorescence microscopy.  
 
 
  
Figure A6: Gonads of Tol2Ovm2 micro-injected Male 1 under bright-field and 
fluorescence microscopy.  
 
 
 
 
 
  
Figure A7: Gonads of Tol2Ovm2 micro-injected Male 2 under bright-field and 
fluorescence microscopy.  
 
 
  
Figure A8: Gonads of Tol2Ovm2 micro-injected Male 3 under bright-field and 
fluorescence microscopy. 
 
 
  
Figure A9: Gonads of Tol2Ovm2 micro-injected Female 1 under bright-field and 
fluorescence microscopy.  
 
 
  
Figure A10: Gonads of Tol2Ovm2 micro-injected Female 2 under bright-field and 
fluorescence microscopy. 
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Hypersensitivity  to the  chicken  egg is a widespread  disorder  mainly  affecting  1–2% of  children  worldwide.
It is  the  second  most  common  food  allergy  in  children,  next  to cow’s milk allergy. Egg allergy  is  mainly
caused by  hypersensitivity  to four allergens found  in  the  egg  white;  ovomucoid,  ovalbumin,  ovotrans-
ferrin and  lysozyme. However, some  research  suggests  the involvement  of  allergens  exclusively  found
in the  egg  yolk  such as chicken  serum  albumin  and  YGP42,  which  may  play a  crucial  role in  the  overall
reaction. In  egg allergic  individuals,  these  allergens  cause  conditions such  as itching,  atopic dermatitis,
bronchial asthma, vomiting,  rhinitis,  conjunctivitis,  laryngeal  oedema  and  chronic urticaria, and anaphy-
laxis. Currently  there  is  no permanent cure  for egg allergy.  Upon  positive  diagnosis for  egg  allergy,  strict
dietary avoidance  of  eggs  and  products containing  traces  of  eggs is the  most effective  way  of  avoiding
future hypersensitivity  reactions. However, it  is  difﬁcult  to  fully avoid eggs  since  they  are  found  in  a  range
of processed  food products.  An understanding  of  the  mechanisms of  allergic  reactions,  egg  allergens  and
their prevalence,  egg allergy  diagnosis  and  current  treatment  strategies  are important for future  studies.
This review addresses  these  topics  and  discusses both  egg white  and egg  yolk  allergy  as a  whole.
© 2015 Elsevier  Ltd. All rights reserved.
1. Allergy
Allergy is a symptomatic and an abnormal overreaction by the
immune system to innocuous environmental substances, such as
grass pollen and eggs, known as allergens. Allergens are a  type of
antigen, which trigger a complex immune response upon contact
with the immune system. Allergy is classiﬁed as a type 1  hyper-
sensitivity reaction because of the immediate and inﬂammatory
immune response that is characterised by the excessive produc-
tion  of the antibody Immunoglobulin E (IgE). An allergic response
involves two reaction phases based on the contact of the aller-
gen  with the immune system; primary and secondary response.
The primary response (upon initial contact with allergen), sti-
mulates the generation of IgE by T-lymphocytes. The secondary
Abbreviations: OIT, oral immunotherapy; SIT, speciﬁc immunotherapy; SPT, skin
prick test.
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response (upon secondary contact with the same allergen) results
in the degranulation of mast cells (mastocytes) and basophils
(basophil granulocytes). The mediators (e.g. histamine) released by
the degranulation process elicit clinical allergic symptoms such as
bronchoconstriction, sneezing, rashes, itching or  life threatening
conditions such as anaphylaxis, just to name a few (Janeway and
Traverse, 1994; Kay, 2001).
2.  Allergic response
2.1. Allergic sensitisation
Upon contact with the immune system, an allergen is engulfed
and processed by antigen presenting cells (APCs) and presented to
naïve T-helper cells (Th0). This causes Th0 cells to differentiate into
T-helper type 2 (Th2) cells in the presence of cytokines including
Interleukin-4 (IL-4). Th2 cells then further secrete IL-4, IL-5 and IL-
13,  which induce B-cell differentiation into plasma cells secreting
IgE.  The IgE antibodies subsequently bind to the high afﬁnity FcRI
receptors on mast cells and basophils, thus sensitizing the immune
system to the allergen (Kay, 2001) (Fig. 1).
http://dx.doi.org/10.1016/j.molimm.2015.04.016
0161-5890/© 2015 Elsevier Ltd. All rights reserved.
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Fig. 1. Illustration of the allergic reaction. This  ﬁgure outlines the steps of an allergic reaction. Once the initially encountered allergen is processed and presented by APCs
to  the Th0 cells, the Th0 cells differentiate into Th2 cells in allergic individuals. These Th2 cells then further secrete IL-4, IL-5 and IL-13,  triggering B-cell differentiation
into plasma cells. Subsequently, these plasma cells proliferate and produce excessive amounts of allergen speciﬁc IgE, which bind to the  FcRI receptors on mast cells and
basophils, thus sensitizing the immune system to the allergen. Upon secondary encounter of the immune system with the same allergen, the allergen binds to  multiple IgE
held on mast cells and basophils. Cross linking of the  FcRI  receptors, as a result of interaction between a single allergen and multiple IgE molecules, triggers the  release of
mediators including histamine, causing an allergic inﬂammation.
2.2. Allergic reaction
Upon secondary exposure to the same allergen (unprocessed by
APCs), the allergen binds to the membrane bound IgE molecules
on  mast cells and basophils. Cross-linking of FcRI occurs when
multiple IgE molecules interact with the same intact allergen,
triggering degranulation of mast cells and basophils, consequently
releasing granule-derived vasoactive chemicals such as histamine,
serine protease tryptase, lipid mediators such as leukotrienes,
prostaglandins and platelet activating factor, chemokines and
cytokines IL-4, IL-5 and IL-13 (Fig. 1). These mediators cause
allergic symptoms such as airway smooth muscle constriction
(bronchoconstriction), mucus hypersecretion, mucus cell metapla-
sia, redness, rashes, sneezing and anaphylaxis (Kay, 2001).
3.  Food allergy
Food allergy is one of the major allergies in today’s society.
In  a double-blind placebo controlled food challenge study con-
ducted by Allan Bock et al. (1988),  80% of the subject children were
found to develop hypersensitivity symptoms to food allergens. In
the  developed world, 10% of children are affected by food aller-
gies, while emerging or  developing nations has a prevalence of 7%
(Prescott et al., 2013).  Occurrence of food allergy, like other atopic
diseases, is rising and remains a  problem throughout the world.
It is a major cause of anaphylaxis, especially by nuts, and treated
worldwide in emergency departments and hospitals, incurring a
massive ﬁnancial burden on the governments and the public (Bock
et  al., 2001; Hugh, 2004). Food hypersensitivities include abnor-
mal  overreactions caused by intolerance to food (non-allergic) and
allergic responses caused by an antigen in the food. Intolerance to
food is due to some physiological abnormality, such as the lack of
lactase which causes intolerance to lactose, whereas the allergic
food reactions are mediated by IgE or non-IgE immune responses
(Hugh, 2004). Food allergies arise through the interaction between
the intestinal immune system and food allergens present in the
food  that we consume on a  daily basis. Allergenic foods include,
but not limited to, eggs, peanuts, ﬁsh and milk. Antigens (allergens)
present in these foods are responsible for IgE mediated hypersen-
sitivity reactions. For example, people allergic to milk react to the
milk whey protein allergen -lactoglobulin (Jabed et al., 2012) and
patients allergic to egg may  be due to the egg white protein ovomu-
coid  (Ando et  al., 2008).  Most of  these allergens are glycoproteins
that can withstand heat, acids and proteases (Hugh, 2004),  this
explains why most allergenic foods remain allergenic even after
cooking or processing.
4. Egg allergy
Hypersensitivity to the chicken (Gallus gallus) egg is a
widespread disorder mainly affecting children, with a recent meta-
analysis suggesting a  prevalence of 0.5–2.5% of children (Rona et al.,
2007). It is the second most common food allergy next to cow’s
milk allergy and it is the most common allergy among children
with atopic dermatitis (Caubet and Wang, 2011; Langeland, 1985;
Sampson, 1983). According to an Australian study conducted by
the Murdoch Children’s Research Institute (MCRI), 8.9% of infants
are allergic to eggs (Osborne et al., 2011). However, egg allergy
is not limited to children, with cases that have been reported of
adult onsets (Unsel et al., 2013). Children allergic to egg generally
grow out of the condition by school age (Boyano-Martínez et al.,
2002; Venter et al., 2008).  Hypersensitivity to allergens present
in  the eggs causes conditions such as itching, atopic dermatitis,
bronchial asthma, vomiting, angio-oedema, rhinitis, conjunctivi-
tis, laryngeal oedema, chronic urticaria and allergic eosinophilic
gastroenteritis (Eigenmann, 2000; Fremont et  al., 1997; Jaffe et  al.,
1994; Quirce et al., 2001). Egg allergic patients produce IgE speciﬁc
to sequential (linear) and conformational epitopes of egg allergens.
However some sequential epitopes recognised by persistent egg
allergic patients are not recognised by  patients with transient egg
allergy (Järvinen et al., 2007). This suggests a  difference in severity
of  allergic reaction between persistent and transient egg allergic
patients. Anaphylaxis may  also occur in some individuals, how-
ever this depends on the processing of the egg. This may  be due
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the reduction in IgE reactivity in heated egg, possibly due to the
disruption of conformational IgE binding epitopes in the egg aller-
gens. It has also been found that eggs heated on its own are more IgE
reactive when compared to eggs heated in the presence of another
substance such as wheat (Bloom et  al., 2014; Watanabe et al., 2014).
This suggests that an egg allergic patient may  show less reactivity
to  food items such as cakes or  mufﬁns than to fried or  baked egg.
The prevalence of egg allergy and the aforementioned conditions
highlight the importance of egg allergy research. An understand-
ing of the different egg allergens, egg allergy diagnosis methods
and treatment methods are imperative for future research.
5.  Allergy to egg white
Egg allergy is  mainly caused by 4 of the many different proteins
that make up the egg white (Leduc et al., 1999; Rupa and Mine,
2003). However, these may  not be the only allergenic egg white
proteins, particularly in the wake of new discovery of a  large num-
ber  of other proteins in the egg white (Mann and Mann, 2011).
These allergens are namely ovomucoid, ovalbumin, ovotransferrin
and lysozyme, with ovomucoid being the most allergenic of the
four and ovalbumin being the most abundant (Fig. 2). A  few studies
have identiﬁed egg yolk allergens, such as chicken serum albumin
and YGB 42 (Fig. 2).  The four aforementioned egg white allergens
are  produced by tubular gland cells which comprise the majority
of  the magnum portion of the chicken oviduct(Kohler et al., 1968;
Palmiter et al., 1970).  Induction of expression of these allergens are
highly dependent on estrogens and this has been demonstrated in
studies involving chicks in which upon administration of  estrogens
the tubular gland cells started producing the allergenic proteins
(Kohler et al., 1969; Oka and Schimke, 1969; Palmiter and Wrenn,
1971). Egg allergy can be caused by consumption of raw or  cooked
eggs, however a study conducted by Lemon-Mulé et al. (2008)
indicates that majority of the egg allergy patients are tolerant to
heated eggs, although the allergenicity of proteins are not exclu-
sively dependent on their resistance to heat and enzymes (Astwood
et al., 1996). The same study shows that continued exposure to the
heated egg is associated with immunological changes similar to
the changes observed in developing tolerance to raw eggs. These
immunological changes include increasing IgG4 levels and a  reduc-
tion in wheal sizes in egg white speciﬁc skin prick testing (SPT). IgA
and  IgA2 may  also be of importance in developing tolerance to egg
white (Konstantinou et al., 2014). However, more studies involv-
ing a larger number of subject individuals are necessary to conﬁrm
the effects of heating on egg white allergens, resulting IgE reactiv-
ity  and other immunological changes in patients. Given that the
structure of the proteins may  play a  crucial role in IgE binding and
eliciting an allergic response, an understanding of the structure and
function of each of the four allergens is  essential for future studies.
6.  Allergens in the egg white
6.1. Ovomucoid (Gal d  1)
Ovomucoid is  the most allergenic and the dominant allergen
found in the chicken egg white. Constituting 11% of the total egg
white, ovomucoid is  a  trypsin inhibitory glycoprotein with a  molec-
ular weight of 28 kDa (Kato et al., 1987; Mine and Zhang, 2002a).  It
is  comprised of 186 amino acids arranged in three tandem domains,
each approximately 60 amino acids in length, containing nine intra-
domain disulﬁde bonds and ﬁve carbohydrate side chains. The
trypsin inhibitory activity is limited to the second domain, in which
a  putative reactive site is present for trypsin inhibition (Abdou et al.,
2013; Kato et al., 1987). The arrangement of the three domains
is  also similar to the pancreatic trypsin inhibitor. Previous studies
have indicated that allergenicity or  IgE binding capacity of ovomu-
coid  is not considerably affected by heat and proteinase activity
(Järvinen et al., 2007; Konishi et al., 1985).  This suggests that the
structure of the IgE binding epitopes of ovomucoid is  mainly lin-
ear, however there are some conformational epitopes present in
all  domains (Mine and Zhang, 2002a). This suggests that cooking of
eggs may  have little or no effect on the allergenicity of  ovomucoid.
In addition, the third domain of ovomucoid shows more IgE binding
activity  when compared to the other two domains (Zhang and  Mine,
1998).  It can be suggested that the third domain would be an ideal
target for studies focusing on the production of hypoallergenic vari-
ants of ovomucoid that may  be used for treatment strategies such
as immunotherapy.
6.2. Ovalbumin (Gal d 2)
Ovalbumin is  the most abundant (58%) protein in the egg white
and it is considered to be the second most important allergen in
egg hypersensitivity. Ovalbumin is  a  water soluble glycoprotein
made up of 385 amino acids and has a  molecular weight of 45 kDa
(Nisbet et al., 1981).  Mine and  Zhang (2002b) reported that car-
boxymethylation, urea treatment or  heat denaturing at 95 ◦C  of
ovalbumin does not signiﬁcantly affect its IgE binding capacity.
This suggests that anti-ovalbumin IgE primarily recognises linear
epitopes than conformational epitopes. Similar to ovomucoid, this
indicates that cooking may  not signiﬁcantly affect the allergenicity
of ovalbumin, however digestive enzymes may  affect the aller-
genecity. The major function of ovalbumin in the chicken egg is
currently unknown, however it  is  a member of  the serpin family
of proteins although it is incapable of inhibiting protease activity.
This lack of protein inhibitory activity is  explained by the absence
of an  important serpin conformational change in the reactive cen-
tre loop of ovalbumin (Huntington and Stein, 2001).  Ovalbumin is
also  known to exhibit biological functions including antibacterial
and immunomodulating activities (Kovacs-Nolan et al., 2005). The
antibacterial properties are however not exerted by intact oval-
bumin, instead, proteolytic digestion of  the protein has shown to
produce peptide fragments capable of  acting against organisms
such as, but not limited to,  Bacillus subtilis and Candida albicans
(Pellegrini et al., 2004).  It is also believed that ovalbumin may  act
as a  source of amino acids for embryonic development (Abdou et al.,
2013).
6.3. Ovotransferrin (Gal d 3)
Transferrins are a group of iron-binding proteins found in ver-
tebrates that has structural and functional similarities among each
member. The molecular mass of these monomeric glycoproteins is
about 76.6 kDa, and a molecule of transferrin can bind to two  Fe3+
with high afﬁnity. Ovotransferrin is  one of the members of transfer-
rins expressed in the chicken oviduct. Expression of ovotransferrin
in  the oviduct is  under steroid control and it differs from serum
hen  transferrin only by an attached carbohydrate (Kurokawa et al.,
1995;  Williams et al., 1982). In vitro, ovotransferrin exhibits antimi-
crobial and immunomodulating activities (Kovacs-Nolan et al.,
2005).  Ovotransferrin is capable of penetrating the outer mem-
brane of  Escherichia coli, allowing selective penetration of ions
which causes decadence of electrical potential of the cell, which
in turn halts the ability of the bacteria to reproduce (bacterio-
statis) (Aguilera et al., 2003). Some research has been conducted
to  study the changes in allergenicity and conformational struc-
ture of  ovotransferrin when heated. A study conducted by Tong
et al. (2012) showed that the allergenicity of ovotransferrin corre-
lated with the structural changes caused by heating. Unfolding of
the  structure caused an increase in allergenicity and cleavage and
rearrangement of disulﬁde bonds lead to a  decrease in allergenicity
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Fig. 2. A depiction of chicken egg allergens and their properties. This ﬁgure shows basic properties of allergens found in the chicken egg white and egg yolk.
(Tong et al., 2012).  This suggests that ovotransferrin is one of the
allergens responsible for hypersensitivities caused by consumption
of  cooked eggs as well as raw eggs. Therefore, it is  wise to suggest
that  research should be focused on ovotransferrin as much as on
ovomucoid and ovalbumin.
6.4. Lysozyme (Gal d 4)
Lysozyme, 14.3 kDa in size, is  an enzyme that exhibits anti-
microbial activity in the chicken egg, thus providing protection
from potential microbial hazards. It is known to exert lytic activity
on  cell walls of microbes, therefore it  is widely used in pharmaceuti-
cal products (Perez-Calderon et al., 2007). It is also used in various
food products such as cheese(Fremont et al., 1997; Weber et  al.,
2009), which therefore poses a risk to egg allergic patients. Struc-
turally, lysozyme contains conformational and sequential epitopes
and it has in vitro biological functions such as antibacterial, antiviral,
immunomodulating and  antitumor activities (Kovacs-Nolan et al.,
2005; Weber et al., 2009).  Although lysozyme is  less  allergenic
than ovomucoid and ovalbumin (Caubet and Wang, 2011),  the high
occurrence in many food and pharmaceutical products makes it an
important target in egg allergy research.
7.  Allergy to egg yolk
Chicken’s egg yolk is also responsible for causing IgE medi-
ated allergy, although with much lower prevalence than egg
white hypersensitivity. Unlike allergy to egg white, which is  com-
monly seen in young children with atopic dermatitis, allergy to
egg  yolk mostly affects during the adulthood. However, under-
lying immunological reactions to egg yolk allergens are mainly
IgE-mediated, and usually produce symptoms such as urticaria,
vomiting, abdominal pain and diarrhoea, as in allergy to egg white
(de Maat-Bleeker et al., 1985; Mandallaz et al., 1988; Szepfalusi
et al., 1994).
8. Allergens in the egg yolk
8.1. Chicken serum albumin (Gal d 5  or ˛-livetin)
Chicken serum albumin is the ﬁrst allergen identiﬁed from the
hen’s egg yolk. It is  a water soluble globular glycoprotein with a
molecular weight of 69 kDa. The main function of this protein is  to
transport metals in the blood stream (Predki et al., 1992). Serum
albumin had been conﬁrmed as an inhalant allergen as well as
a food allergen through bronchial provocation and oral challenge
tests, respectively. The  main route of sensitisation for serum albu-
min  is  through the respiratory tract as seen in bird-egg syndrome.
However, the vice versa of bird to egg allergy is also true, where
initial sensitisation to egg yolk proteins pave the way to respira-
tory allergic symptoms in egg-bird syndrome. Serum albumin is
a  partially heat resistant allergen, thus some patients are able to
tolerate extensively heated egg yolk, but not raw egg yolk (Quirce
et  al., 2001).
8.2. YGP42 (Gal d 6)
Yolk glycoprotein 42 (YGP42) is  the second allergen identiﬁed
from the hen’s egg yolk. It is a  glycoprotein with a  molecular weight
of  35 kDa. According to the homology search conducted by BLAST,
YGP42 is a  fragment of the vitellogenin-1 (VTG-1) precursor. YGP42
contains three glycosylation signals at  positions: 1662, 1698 and
1703. The periodate oxidation treatment of YGP42 did not abol-
ish  the IgE binding capacity indicating that sugar residues are not
related to allergenicity. Furthermore, heat treatment and  reduction
did not affect allergenicity of YGP42 at all, while simulated gas-
tric acid digestion completely eliminated its  IgE reactivity. YGP42
was also investigated for any implication in bird-egg syndrome.
However, inhibition immunobloting experiments did not demon-
strate any degree of inhibition of allergens from chicken meat and
feather extracts. Therefore, YGP42 is not considered to be involved
in bird-egg syndrome (Amo et al., 2010).
8.3. Other IgE binding proteins in  the egg yolk
Apart from the recently discovered egg yolk allergens Gal d 5
and Gal d 6,  few other proteins from the hen’s egg yolk proteome
have exhibited a possible allergenic potential (Anet et al., 1985;
Walsh et al., 1988).  Three abundant egg yolk proteins from the egg
yolk  known as apovitellenin I, VI and  phosvitin have demonstrated
substantial IgE binding capacity in egg allergic patients’ sera. Fur-
thermore, all the proteins were found to be effective at binding
of  egg yolk speciﬁc IgE. However, the clinical relevance of these
proteins to egg yolk allergy have not been established to date,
and  therefore their status as allergens is uncertain (Walsh et al.,
1988).
P. Dhanapala et  al. /  Molecular Immunology 66 (2015) 375–383 379
9. The bird-egg syndrome
Bird-egg syndrome is an IgE-mediated hypersensitivity disor-
der where a human develops an allergy to egg yolk, speciﬁcally
to  serum albumin, following sensitisation to inhalant avian anti-
gens derived from sources such as bird’s blood serum, feathers,
droppings and dander (Mandallaz et al., 1988) (Fig. 3). This is dif-
ferent to allergen cross reactivity in which a patient allergic to
a  certain allergen is reactive to homologous or non-homologous
allergens from the same or other species (Bublin et  al., 2013;
Rhijn et al., 2013).  Majority of patients with bird-egg syndrome
claim to have regular exposure to pet birds or poultry where
sensitisation to airborne avian allergens take place, which then
proceed to egg yolk allergy. Patients suffering from bird-egg syn-
drome suffer from both respiratory and gastrointestinal allergic
symptoms such as asthma, rhinoconjunctivities, edema, diarrhoea
and vomiting. However, unlike allergy to egg white, which is
predominantly seen in children with atopic dermatitis, bird-egg
syndrome mainly affects adults with an obvious gender predispo-
sition where majority of patients tend to be females. In addition,
allergens produced by birds at  workplace may  also increase IgG
levels in excess and can  lead to allergic alveolitis. Currently,
these IgG levels can be quantiﬁed and qualitatively evaluated
using the UniCAP system, a  type of ImmunoCAP (Lopata et al.,
2004).
The common antigen present in hen’s egg yolk and other avian
antigens responsible for bird-egg syndrome is recognised as -
livetin, which corresponds to chicken serum albumin (Szepfalusi
et al., 1994; Williams, 1962).  Serum albumin belongs to a  group of
protein fraction known as livetins in the egg yolk. Livetines are
water soluble glycoproteins that are derived from blood serum
proteins of the hen. Furthermore, radioallergosorbent (RAST) test
inhibition experiments had demonstrated inhibition of IgE bind-
ing to livetins of hen’s egg yolk by avaian antigens from different
bird species. This result indicates that serum proteins from different
bird species have highly conserved epitopes which allow speciﬁc
IgE  antibodies to cross react (Mandallaz et al., 1988).  The clini-
cal relevance of serum albumin in bird-egg syndrome had been
established by immunological methods in order to validated it as a
food allergen designating the allergen name Gal d 5  (Quirce et al.,
2001).
An individual develops allergy to hen’s egg yolk following expo-
sure  to birds, where sensitisation to inhalant avian allergens takes
place resulting in respiratory allergy symptoms. The cross reacting
allergen which is  responsible for producing both respiratory and
gastrointestinal allergy symptoms in bird-egg syndrome is  identi-
ﬁed  as chicken serum albumin present in bird antigens and in the
egg  yolk as well.
10. Diagnosis of egg allergy
Different diagnostic techniques are used for successful diagno-
sis  of egg allergy. Similar to other allergic conditions, the foremost
step in egg allergy diagnosis is  assessment of the medical history
of  the patient for potential evidence for clinical reactivity to eggs
and physical examination. This helps to determine whether the
patient has experienced adverse reactions to eggs and the poten-
tial involvement of the immune system (Metcafe and Sampson,
1990; Sicherer, 1999). The medical history examination essentially
takes into consideration the allergic conditions the patient’s par-
ents are/were exposed to and evaluates these information with the
current symptoms, the type and the amount of food ingested and
the timing of the reaction. The physical examination involves test-
ing  for gastrointestinal symptoms and detection of atopic features
in  the body. The next step involves the use of in vitro or in vivo
tests such as SPT and ImmunoCAP speciﬁc IgE blood tests (formerly
known as radioallergosorbent tests or RAST) (Bock et al., 1977;
Chinoy et al., 2005).  These tests assist in determining if  the patient
possesses egg allergen speciﬁc antibodies in their immune system.
Although these tests provide an estimation of allergen speciﬁc IgE
in the patient, which positively correlates to the clinical reaction
(wheal formation), they fail to fully ascertain diagnosis of clini-
cal symptoms of  egg allergy. Increasing levels of IgE may  predict
the  presence of an allergy, however, there is no universal agreed
level of IgE to conﬁrm the condition as the IgE levels can differ
between different individuals. This may  also be due to the discrep-
ancies between the testing method, testing criteria and prevalence
of  the allergy between studies. However, a recent study conducted
by  Sicherer et al. (2014) has further conﬁrmed the signiﬁcant pre-
dictive capacity of IgE as a marker in egg allergy. They also report
of a  web-based calculator that uses an algorithm, which is based
on novel ﬁndings on egg speciﬁc IgE, that may  allow clinicians to
predict the likelihood of the resolution or persistence of the dis-
ease.  Supplementary studies on IgE as a  reliable egg allergy marker
may  provide useful information for the development of effective
diagnostic approaches.
In addition to SPTs and ImmunoCAP tests, elimination diets and
oral  food challenges can be used for the diagnosis of egg allergy.
In  an elimination diet diagnosis, once the patient is suspected of
being allergic to eggs, a  diet excluding eggs is followed to study the
ability of the patient to maintain the diet without any hypersen-
sitive reactions over a period of time (Sicherer, 2013). In an oral
food challenge, the patient is asked to eat/ingest a small amount
of egg to reproduce the hypersensitivity symptoms. It is  also done
in  a dose dependant manner where the egg ingestion is increased
until the symptoms are observable. Oral food challenge can be
done  openly, single-blinded, double-blinded placebo controlled,
with  the latter being considered the gold standard in diagnosis of
major food allergies because it provides information such as the
amount of food needed to cause an allergic reaction and the extent
of the patient’s reaction (Rance et al., 2009).  However, the safety
of oral food challenge has not been well established or  scrutinised
and may  not be ideal if  the patient is known to be anaphylactic
to  eggs, therefore much care should be taken when implementing
this method. Overall, medical history and physical examination,
SPTs  or ImmunoCAP tests and oral food challenge combined
together provides successful diagnosis of egg allergy (Fig. 4),  which
can lead to the implementation of treatment strategies for the
condition.
11.  Treatment of egg allergy
As for other food allergies, currently there is  no temporary or
permanent cure for egg allergy. Upon successful diagnosis for egg
allergy, the most effective treatment is strict dietary avoidance of
eggs  and products containing traces of eggs. Eggs are an important
source of nutrients and thus strict avoidance may  cause malnutri-
tion  or  eating disorders. The egg yolk is known to carry numerous
health beneﬁts, but since it is  impossible to fully separate the egg
yolk from the egg white without allergen contamination, complete
avoidance of the egg is  the only option, which results in reduced
or  no uptake of this important nutrient source (David et al., 1984;
Friedman, 1996).  As a  part of avoidance of eggs, it is important to
educate patients how to identify potential egg allergens or traces
of eggs in various food products such as cakes, biscuits, cereal and
breads, as well as educate them about foods/supplements that can
potentially replace eggs in their diet. This may  include involvement
of a  dietician for patients with dietary limitations, such as vegetar-
ians and multiple food allergic patients, to ensure proper intake of
vital  nutrients.
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Fig. 3.  An illustration of the bird-egg syndrome.
Fig. 4. A typical diagnosis procedure of egg  allergy. Once a suspected a reaction to egg  is reported a patient undergoes the  appropriate steps shown in this ﬁgure.
Figure adapted and modiﬁed from Eggesbø et  al. (2001).
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In addition to dietary avoidance, egg allergic patients are
required to avoid vaccines and medications derived from eggs. For
example, inﬂuenza vaccine is developed in chicken extra embry-
onic ﬂuid and used extensively worldwide every year (Caubet and
Wang, 2011). Although the majority of egg allergic patients may
not  have adverse effects upon administration of inﬂuenza vaccine
(Chung et al., 2010), it is  important to take caution to avoid severe
or anaphylactic reactions in the individuals that may  well react to
the egg allergens (Zeiger, 2002). These patients should receive the
vaccine via a desensitisation protocol upon diagnosis with a posi-
tive skin test. Yellow fever vaccine is another vaccine derived from
chicken egg, with few reported cases of anaphylaxis upon admin-
istration (Kelso et al., 1999). Moreover, there are reported cases of
anaphylaxis due to the use of lipid emulsions and pharmaceutical
products derived from eggs (Artesani et al., 2008; Buchman and
Ament, 1991; Hofer et al., 2003). Occurrence of egg allergens in our
daily diet, vaccines and  other pharmaceutical products complicates
strict avoidance of eggs. Therefore, alternatives are required to treat
patients in case of accidental exposure to the egg allergens.
In  allergic conditions such as asthma, speciﬁc immunotherapy
(SIT) is used to induce tolerance to the allergens. This method
essentially involves administration of small amounts of allergens
to patients in, with slight increments, to induce tolerance to that
particular allergen. A  study conducted by Buchanan et al. (2007)
indicates that oral immunotherapy (OIT), a  form of SIT, may  provide
a  promising treatment strategy for patients without anaphylac-
tic history to eggs. The authors suggest that OIT may  even cause
a shift in food allergy treatment paradigm from allergen avoid-
ance to active immunotherapy. This is  further supported by a recent
study in which OIT showed successful desensitisation to eggs, how-
ever tolerance was maintained only in 1/3 of the study population
following discontinuation of the egg diet (Caminiti et al., 2015).
However, extreme care should be taken during immunotherapy
to  avoid potential anaphylactic reactions. In case of an accidental
exposure to egg allergens, and acute anaphylaxis, the most common
treatment is administration of the hormone and neurotransmit-
ter epinephrine (Kemp et al., 2008; Sampson, 2004; Waserman
and  Watson, 2011).  Upon administration of epinephrine at the
right dosage and appropriate route, peripheral vasodilatory effects
and bronchoconstriction caused by histamines and  other chemical
mediators released by  allergic reactions are reversed, conditions
such as urticaria, erythema and angioedema are reduced and
further release of chemical mediators are suppressed. Currently,
epinephrine is available for self-administration by auto-injectors
such as Epipen. In summary, allergen avoidance, SIT and admin-
istration of epinephrine provide temporary relief from egg allergic
reactions. However, these methods can be costly and may  have neg-
ative effects on the lifestyle of the patient. Therefore, it is  imperative
to  investigate and research on permanent and affordable ways to
treat egg allergy.
12. Future perspectives in  egg allergy research –  cracking
the  egg problem
Various research teams around the world are involved in ﬁnd-
ing answers or cures for different types of allergies. Development
of  hypoallergenic variants of the egg allergens is  given utmost pri-
ority by many egg allergy researchers, because hypoallergens may
be used in immunotherapy to desensitise egg allergic patients. In
fact, a group from University of Guelph in Canada has studied the
efﬁcacy of an engineered ovomuoid third domain at desensitizing
a murine model (Rupa and Mine, 2006). This hypoallergenic third
domain has been produced by directly targeting the IgE biding sites
of  that domain. A  similar approach has been tested in 2004 by an
Australian research team in which they successfully developed a
T-cell reactive hypoallergenic variant of the latex allergen, Hev b
6.10, by targeting the disulphide bridges of  that allergen (Drew
et al.,  2004),  therefore it can be suggested that similar methods
can be used for the development of hypoallergenic variants of egg
allergens. In addition to the aforementioned methods, it has been
recently reported that allergen conjugation with reducing sugars
through the Maillard reaction may  help attenuate allergic reac-
tivity to allergens (Rupa et al., 2014). Production of IgE reactive
recombinant variants of egg allergens is  also important in diag-
nostic methods such as SPT and treatment methods such as SIT
(Dhanapala et al., 2015; Valenta et  al., 2011).  Although the current
results seem promising, all  of the research conducted on hypoal-
lergen and IgE reactive recombinant allergen production requires
clinical trials before administration to patients.
The focus of egg allergy research should not  be limited to the
aforementioned strategies and invention of  drugs/vaccines. The
advanced molecular and genetic techniques used in other medi-
cal research and life sciences can be utilised for tackling egg allergy
from the root of the cause. A team in New Zealand has developed
a transgenic calf lacking the milk allergen -lactoglobulin using
RNAi technology (Jabed et al., 2012).  Similar methods can be used
in  egg allergy research providing promising methods of egg allergy
treatment or  management. The advancement of techniques such as
CRISPR (clustered regularly interspaced short palindromic repeats)
(Sander and Joung, 2014) based genome editing may  also allow pre-
cision  engineering of the chicken genome to edit/change the IgE
binding epitopes to produce transgenic hens capable of producing
hypoallergenic eggs. If any of the current research on egg allergy
proves  successful in the future, a large number of families will ben-
eﬁt by being less apprehensive about eggs or egg contaminated
products.
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a b s  t  r  a  c t
IgE-mediated  allergy  to  chicken  egg  affects  a  large  number  of  children and  adults  worldwide.  The current
management strategy for egg allergy  is  strict  avoidance, however this  is  impractical  due  to  the presence
of eggs in  a range of  foods  and  pharmaceutical products  including  vaccines.  Strict  avoidance  also poses
nutritional disadvantages  due  to high  nutritional value  of  eggs.  Allergen  speciﬁc immunotherapy  is being
pursued as a  curative  treatment,  in which  an allergic individual  is  gradually exposed to  the  allergen
to induce tolerance.  Use  of  recombinant  proteins  for  immunotherapy  has been  beneﬁcial  due  to  the
purity of  the  recombinant  proteins  compared  to natural  proteins.  In  this  study,  we  produced  IgE  reactive
recombinant egg white proteins  that can  be used for  future  immunotherapy.  Using  E. coli  as an expression
system, we  successfully produced  recombinant  versions  of  Gal  d 1,  2 and 3,  that were IgE  reactive  when
tested against a pool  of  egg  allergic  patients’  sera.  The  IgE reactivity indicates that these recombinant
proteins are  capable  of  eliciting  an immune  response, thus  being  potential candidates  for immunotherapy.
We have, for the ﬁrst time, attempted  to produce recombinant  versions of  all  4 major  egg white allergens
in E. coli, and successfully  produced  3, with only  Gal  d 4 showing  loss  of IgE  reactivity  in  the  recombinant
version. The  results  suggest  that egg  allergy  in  Australian  populations may  mainly  be due  to  IgE reactivity
to Gal  d 3 and  4, while Gal  d 1 shows  higher  IgE reactivity.  This is  the ﬁrst report  of a collective  and
comparative immunological  analysis  of  all  4 egg white  allergens.  The signiﬁcance  of  this  study  is  the
potential use  of  the  IgE reactive recombinant  egg  white proteins  in  immunotherapy  to  treat egg  allergic
patients.
© 2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Allergy to chicken (Gallus gallus) egg is a widespread condition
affecting 0.5–2.5% of  children worldwide (Rona et al., 2007). It
is known to be the predominant food allergy among children
with atopic dermatitis and, among all children, it is  the second
Abbreviations: OIT, oral immunotherapy; SIT, speciﬁc immunotherapy; SPT, skin
prick tests.
∗ Corresponding author at: NeuroAllergy Research Laboratory (NARL), School of
Life and Environmental Sciences, Faculty of Science, Engineering and Built Environ-
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most common food allergy (Sampson, 1983,  Langeland, 1985,
Caubet and Wang, 2011). A study conducted by the Murdoch
Children’s Research Institute (MCRI) in Australia revealed that 8.9%
of  infants are allergic to eggs (Osborne et al., 2011).  Symptoms and
conditions caused by hypersensitivity to chicken egg include, but
not  limited to, atopic dermatitis, bronchial asthma, IgE mediated
egg allergy (with urticarial, angioedema, vomiting, diarrhoea and
anaphylaxis), and allergic eosinophilic gastroenteritis (with pain,
irritability, colic, and possibly oesophageal stricture and food
impaction) (Eigenmann, 2000; Jaffe et  al., 1994,  Fremont et al.,
1997,  Quirce et al., 2001).
Egg  allergy is  mainly caused by 4  major proteins within the egg
white (Leduc et al., 1999), namely Gal d 1 (ovomucoid), Gal  d 2
(ovalbumin), Gal d 3 (ovotransferrin) and Gal  d 4 (lysozyme), with
Gal  d 1 being the most allergenic of the four and Gal d 2 being
http://dx.doi.org/10.1016/j.molimm.2015.01.006
0161-5890/© 2015 Elsevier Ltd. All rights reserved.
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the most abundant. These proteins are produced in the magnum
portion of the chicken oviduct, speciﬁcally by tubular gland cells
(Kohler et al., 1968, Palmiter et al., 1970).  Previous studies involv-
ing administration of  oestrogen into chicks have shown that, post
injection of oestrogen, the chicks produced the allergenic proteins,
indicating that expression of the allergens present in the egg white
are  highly dependent on oestrogen (Palmiter and Wrenn, 1971,
Kohler et al., 1969, Oka and Schimke, 1969).  Consumption of raw
or  cooked egg may  cause allergic reactions, although the majority
of patients with egg allergy are tolerant to cooked egg (Lemon-
Mulé et al., 2008). Egg allergy can also be caused by  allergens in
the  egg yolk (de Maat-Bleeker et al., 1985),  however these are not
addressed in this study.
Production of recombinant versions of natural allergenic pro-
teins is an option for treating allergies since these recombinant
proteins can be used in treatment methods such as allergen spe-
ciﬁc immunotherapy (SIT) and diagnostic methods such as skin
prick tests (SPT). It is  a way of producing allergens with high
purity without contamination from other allergens since individ-
ual  proteins are expressed separately in host systems. Valenta and
colleagues (Valenta et al.,  2011) broadly discuss the importance of
using recombinant allergens for immunotherapy and production
of  safer vaccines to better manage allergies. In this study, we have
produced IgE reactive recombinant egg allergens and compared
them with their natural counterparts. For the ﬁrst time, we have
performed collective and comparative immunological analysis of
the natural and recombinant proteins of all 4 egg white allergens
against an Australian population, which forms the overall aim of
this  study.
2. Methods
2.1. PCR of allergen coding sequences from oviduct total mRNA
Animal experimentation/sampling was conducted under proto-
col AEC1496, approved by the Australian Animal Health Laboratory
(CSIRO-AAHL) Animal Ethics Committee and in accordance with
the Australian code of practice for the care and use of animals for
scientiﬁc purposes.
The magnum portion of a  fresh oviduct was obtained from an
egg laying hen. Upon extraction from the hen, the oviduct was
chopped into ∼5 mm pieces and stabilised in RNAlater RNA sta-
bilising reagent. Total mRNA was then extracted from 180 mg
of  oviduct using a  Oligotex Direct mRNA extraction kit (Qiagen,
Cat.No.:72022), following the manufacturer’s guidelines. Gal d 1,
2  & 4 coding sequences were isolated directly from the total
mRNA using Qiagen OneStep RT-PCR kit (Qiagen, Cat.No.: 210210).
The forward (F) and the reverse (R) primers for each allergen
were (bold letters represent inserted restriction sites): Gal d 1  F
with XhoI 5′CGCCTCGAGAT GGCCATGGCAGGC-3′,  Gal d 1 R with
HindIII  5′-CGCAAGCTTTCAGCATTTTCCAAA ATG-3′,  Gal  d 2  F with
BamHI 5′-CGCGGATCCATGGGCTCCATCGGTGCA G-3′,  Gal d 2 R with
EcoRI  5′-CGCGAATTCTTAA GGGGAAACACATCT-3′,  Gal d 4 F with
BamHI  5′-CGCGGATCCATGAGGTCTTTGCTAATC-3′,  Gal d 4 R with
EcoRI 5′-CGCGAATTCTCACAGCCGGCAGCCTCT-3′.  For PCR ampliﬁ-
cation of Gal d 3,  the total RNA was used to produce a  cDNA
library using Omniscript Reverse Transcription kit (Qiagen, Cat.No.:
205110). Qiagen LongRange PCR kit (Qiagen, Cat.No.: 206401),
which uses the PCR optimising reagent Q-solution, was used to
amplify the coding sequence from the cDNA library. The primers
used  for ampliﬁcation of Gal d 3  were: Gal d 3 F with XhoI 5′-
CGCCTCGAGATGAAGCTCATCCTCTGC-3′ and Gal d 3 R with HindIII
5′-CGC AAGCTTTTACTTGCCCTCAAGGAA-3′.  The PCR products were
run on a 1% agarose gel and puriﬁed using a  MinElute gel extraction
kit  (Qiagen, Cat.No.: 28604).
2.2. Cloning of allergens into pTrcHisA vector and expression in
Express Iq E. coli
The four gel puriﬁed PCR products (1 g of each) were digested
with  the appropriate restriction enzymes; Gal  d 1 and Gal d 3
with XhoI  and HindIII &  Gal d 2  and Gal d 4  with BamHI and
EcoRI.  Separately, two  1 g batches of pTrcHisA vector (Invitro-
gen,  Cat.No.: V360-20) were digested with XhoI  and HindIII &
BamHI and EcoRI. The digests were then gel puriﬁed using E-Gel
Clonewell 0.8% SYBR Safe agarose gels and concentrations were
measured. The four digested PCR fragments and the pTrcHisA
vectors were then used in separate ligation reactions. The liga-
tions were carried out with a  vector:insert ratio of 1:1 (∼20 ng
of each) and T4 DNA ligase and ligase buffer with ATP (Promega,
Cat.No.: 1801). Ligation reactions were incubated overnight at
4 ◦C. The four ligation reactions, conducted for each PCR product,
were then transformed into Express Iq chemically competent E. coli
cells (New England BioLabs, Cat.No.: C3037H) following manufac-
turer’s guidelines. The transformants were plated on LB agar (one
plate for each allergen) with 50 g/mL ampicillin and incubated
overnight at 37 ◦C. Next day, single colonies from each LB agar
plate were picked and grown overnight in LB +  ampicillin at 37 ◦C.
Afterwards, 2 mL of each culture was  centrifuged at  13,000 rpm to
pellet the cells, and supernatant discarded. These cell pellets were
used to isolate the pTrcHisA vectors containing the inserts using
QIAprep Miniprep kit (Qiagen, Cat.No.: 27104) following manu-
facturer’s guidelines. The isolated plasmids were sequenced to
conﬁrm insert of the PCR product (allergen) using pTrcHisA for-
ward  and reverse primers: F 5′-GAGGTATATATTAATGTATCG-3′ and
R 5′-  GATTTAATCTGTATCAGG-3′.  The sequences were compared
with  published allergen sequences on IUIS/NCBI.
For expression of the proteins, overnight cultures of E. coli
colonies containing each allergen construct were grown separately
in LB media with ampicillin. The overnight cultures were then re-
inoculated in 10 mL of fresh LB media and grown to mid-log phase
(OD600 0.4–0.6). A 1 mL sample of  each culture was collected and
pelleted and frozen for later analysis. Expression was induced with
40 L of 100 mM IPTG to give a  ﬁnal concentration of 0.4 mM and
grown for six hours at  37 ◦C with shaking. Samples were collected,
pelleted and frozen every 1  hour for determination of optimum
expression time.
2.3.  SDS-PAGE and Western blotting of the expressed proteins
Each frozen cell pellet collected at different time points was
resuspended and lysed with 400 L of Cell Lytic B  cell lysis reagent
for  ∼10 min. Only the samples collected at 0,  2, 4, 5, 6 h  were used
for  the analysis. The lysed cells were then centrifuged at 13,000 x  g
for  5 min  and the insoluble (pellet) and soluble (supernatant) frac-
tions were separated. The insoluble fractions were resuspended in
100 L of 2x Tris-Glycine SDS sample loading buffer (Life Tech-
nologies, Cat. No.: LC2676). 9 L  of these resuspended samples
were combined with 1 L of NuPAGE reducing agent (10x) (Life
Technologies, Cat. No.: NP0004). The soluble samples (4  L)  were
combined with 5 L loading buffer and 1 L reducing agent. All
samples were then heated at 85 ◦C for 2  min  and loaded onto
4–20% gradient Novex Tris-Glycine gels (Life Technologies, Cat.
No.: EC60252BX5). The gel was  run for ∼1.5 hrs  at  125 constant
voltage. Upon completion, the proteins on the gels were trans-
ferred onto nitrocellulose membranes on a  XCell IITM Blot Module
(Life Technologies, Cat. No.: EI0002) according to manufacturer’s
guidelines. The proteins on the nitrocellulose membranes were
detected using WesternBreeze® chromogenic detection kit (Life
Technologies, Cat. No.: WB7103) according to the manufacturer’s
instructions using Anti-Xpress mouse monoclonal antibody (Life
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Technologies, Cat. No.: R910-25) as the primary antibody at a con-
centration of 0.5 g/mL.
2.4. Mass spectrometry analysis of the recombinant proteins
Selected gel bands of the optimum time points of each allergen
(2  h) were incised and subjected to mass spectrometry analysis.
The gel bands were in-gel-digested with trypsin and incubated
overnight at 37 ◦C to digest the proteins into peptides. In-gel-digest
samples were analysed on a  LTQ Orbitrap Elite (Thermo Scien-
tiﬁc)  coupled to an Ultimate 3000 RSLC nanosystem (Dionex). The
nanoLC system was equipped with an Acclaim Pepmap nano-trap
column and an Acclaim Pepmap analytical column. 2  l of  the
peptide mix  (i.e. each digested band) was loaded onto the trap
column of 3% CH3CN containing 0.1% formic acid for 5  min  before
the enrichment column is  switched in-line with the analytical col-
umn. The LTQ Orbitrap Elite mass spectrometer was operated in
the data-dependent mode, whereby spectra were acquired ﬁrst
in  positive mode followed by collision induced activation (CID).
Ten of the most intense peptide ions with charge states ≥2  were
isolated and fragmented using normalized collision energy of  35
and  activation Q of 0.25 (CID). Data analysis was  carried out
using Proteome Discoverer (Thermo Scientiﬁc version 1.4) with
Mascot against the BIRDS database. Search parameters were pre-
cursor mass tolerance of 10 ppm, fragment mass tolerance of 0.6 Da
(CID). Carbamidomethyl of cysteine was set as ﬁxed modiﬁca-
tion and oxidised methionine as a  variable modiﬁcation. Trypsin
with maximum of 1 missed cleavage was used as the cleavage
enzyme.
2.5.  Immunoassay of natural egg white using serum from allergic
patients
Experimentation involving patients’ sera was conducted in
compliance with the National Statement on Ethical Conduct in
Human Research (2007) with approval from Deakin University
Faculty of Science, Engineering and Built Environment Human
Ethics Advisory Group (HEAG), with a project approval number of
STEC-34-2013-DHANAPALA.
Egg white from a  freshly laid egg was separated from the egg
yolk and 1 volume of the egg white was diluted with 3 volumes
of dH20. 10 g of the diluted egg white (per well) was  run on gels
and blotted onto nitrocellulose as previously discussed. The blots
were then cut into individual lane strips, a  total of 36 strips were
obtained. Allergic patients’ sera were obtained from the Royal Chil-
dren’s Hospital (Melbourne, Australia): 25 egg allergic and 5  other
allergies. 100 L of each serum sample was diluted with 900 L of
blocking buffer (hammerstein casein solution in buffered saline-
supplied in WesternBreeze® Chromogenic kit). The nitrocellulose
strips with immobilised egg white proteins were then incubated
with each of the diluted serum sample overnight at  4 ◦C  (i.e. 1 strip
per  patient). Next, the strips were incubated with anti-human IgE
(alkaline phosphatase conjugated) secondary antibody produced
in  mouse. The detection was carried out using the WesternBreeze®
Chromogenic kit as previously mentioned. 3 nitrocellulose strips
were incubated with only the secondary antibody as a  negative
control.
2.6.  Mass spectrometry analysis of the natural proteins
The 4 bands that appeared to be the 4 allergens were incised and
a  mass spectrometry analysis was conducted to conﬁrm the identity
of  the proteins, according to the method described in Section 2.4.
2.7. Immunoassay of  recombinant proteins against allergic
patients sera
The recombinant proteins were freshly expressed and 5  mL cul-
tures were pelleted after 2 h  post induction with IPTG. The cell
pellets were lysed as previously discussed and the fraction that
shows expression were run on SDS-PAGE and blotted onto a nitro-
cellulose membrane. For Gal d 1 and Gal d 2, the soluble fraction
was used and for Gal d 3 and Gal d 4, the insoluble fraction was
used. This was done in duplicate, one to be used with allergic sera
and  the other with non-allergic control sera. Another nitrocellulose
blot was  prepared by immobilising the soluble and insoluble frac-
tions of E. coli extract (i.e. E. coli containing the vector without an
insert were IPTG induced for 2  h  and soluble and insoluble fractions
were collected).
A pool of egg allergic patients’ sera was  prepared by combining
50 L  of patients 4, 5, 6 & 7 with 1800 L of blocking buffer. The
2 mL allergic patients’ serum pool was ﬁrst pre-incubated with the
nitrocellulose membrane containing the appropriate E. coli extract
for  2  h  at room temperature. Then one of the nitrocellulose mem-
branes with the recombinant proteins was  incubated with the same
E. coli depleted serum pool overnight at 4 ◦C. The remaining recom-
binant protein membranes was incubated in a pool of non-allergic
patients sera prepared by combining 50 L  of 10 non-allergic serum
pool with 1500 L  blocking buffer. All  the blots were then incubated
with anti-human IgE (alkaline phosphatase conjugated) secondary
antibody produced in goat (1:1000), and detected using the chro-
mogenic substrate, as described above.
3. Results
3.1. PCR ampliﬁcation of the egg white allergen cDNA
The mRNA isolated from chicken oviduct were used to PCR
amplify egg white allergens Gal d 1, 2  and 4 using one-step PCR
method. For Gal d 3, a  long-range PCR, that utilises the traditional
two-step method, was  used. The PCR gel results showed a band for
Gal  d 1 at 800 bp (expected 630 bp), Gal d 2 between 800–2000 bp
(expected 1158 bp), Gal d 3 at 2000 bp (expected 2115) and Gal d
4  at above 400 bp (expected 441) (Fig. 1).  The long-range PCR con-
ducted for Gal d 3 produced a  brighter band when used without
Q-solution (Fig. 1).
3.2. Cloning and expression of recombinant egg white allergens
The  ampliﬁed PCR products were then digested by restric-
tion enzymes and ligated into pTrcHisA vector that adds a 6xHis
tag to the expressed proteins. The vector-insert constructs were
transformed into Express Iq chemically competent E. coli cells and
expression induced with IPTG. Expression was conducted for 6 h
and samples were collected every 1-h to determine the optimum
expression time for each allergen. The collected samples were pel-
leted, lysed and the soluble and insoluble fractions were run on
SDS  gels for analysis. These gels were then western blotted, incu-
bated with detection antibody and visualised with a chromogenic
substrate. For Gal d 1 and 2, the western blot analysis showed
that  the proteins are found in both soluble and insoluble fractions
with an optimum expression time of 2  h. Gal  d 2  shows increase
in expression every hour, at the same time showing an increase
of  breakdown of the protein. Gal d 3  and 4  showed expression
only in the insoluble fraction, with an optimum expression time
of  2 h. Gal d 3  showed breaking down of the protein throughout the
expression period, while Gal d 4 showed a  decrease in the amount
of  protein after 2 h  and increasing again in 5–6 h (Fig. 2).
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Fig. 1. PCR ampliﬁcation of the  egg white allergens. The allergens were isolated from mRNA using one-step (A) and long-range (B) PCR methods. For the long-range method,
the  PCR was  conducted with and without the  optimisation reagent Q-solution (this method was used to amplify Gal d 3).  For all 4 allergens, bands appeared at approximately
the expected size.
Fig. 2. Expression of recombinant allergens to determine the  optimum time point of expression and the fraction where the expressed proteins are found. The transformed
Express Iq E. coli cells (for each allergen) were induced with IPTG and grown for 6  h. Samples were collected and pelleted every 1-hour, including before IPTG induction
(0 hours). The pellets representing the time points 0, 2, 4, 5 and 6  were lysed and the  soluble and insoluble fractions were run on SDS gels. The gels were then blotted onto
nitrocellulose and incubated with anti-Xpress antibody for detection purposes. The blots were then detected using a chromogenic substrate. (A) Gal d  1, (B) Gal  d  2, (C) Gal
d 3, (D) Gal d 4.
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3.3. Mass spectrometry analysis of recombinant egg white
allergens
The  mass spectrometry analysis of the recombinant protein
bands (Fig. 3) shows that Gal d 2, 4  and 4 are positively identi-
ﬁed (Table 1). The analysis showed no indication of presence of  Gal
d  1 in the protein bands 1–4, that were incised from the gel run
with Gal d 1 expressed E. coli extract. Bands 5–8 incised from the
Gal  d 2 gel were identiﬁed as ovalbumin, 9–12 incised from Gal d
3  gel were identiﬁed as ovotransferrin, and bands 13–16 incised
from  Gal d 4 gel were identiﬁed as lysozyme.
3.4. Immunological analysis of  natural and recombinant egg
white allergens
Prior to testing of the recombinant proteins, natural egg white
was tested against a population of egg allergic and other allergic
sera  to test for IgE reactivity (allergenicity). The western blots con-
ducted shows that 10 patients were allergic to Gal d 1, 4  to Gal d
2,  14 to Gal d 3 and 18 to Gal d 4 (Fig. 4).  A number of individuals
showed reactivity to more than 1  allergen as depicted in Table 2.
Patients who showed reactivity to all 4 allergens had higher egg
speciﬁc serum IgE levels when compared to the others (Table 2).
The  mass spectrometry analysis conducted on the 4  bands, iden-
tiﬁed as the allergens, conﬁrmed the identities, except for Gal d 1
(Table 3).
The recombinant proteins were then blotted onto nitrocellulose
membranes and tested against anti- egg allergic sera and non-
allergic sera. The allergic sera was ﬁrst pre-incubated with E. coli
extract, this blot did not appear to have any bands post incubation
with secondary antibody and chromogenic development. The blot
incubated with allergic sera had multiple bands appearing for all
allergens, except Gal d 4. The blot incubated with non-allergic sera
did not have any bands.
4. Discussion
Egg white allergy is  a  widespread disorder mainly affecting
children. The wide use of chicken eggs in various food and phar-
maceutical products complicates avoidance of egg white, which is
the only current management available for egg allergic patients.
However, strict avoidance of egg allergens may  be very difﬁ-
cult to achieve due to its extensive use in processed foods and
pharmaceutical products. Avoidance of eggs may  also have nutri-
tional disadvantages to the individual (Moﬁdi, 2003,  Caubet and
Wang, 2011). Allergen speciﬁc-immunotherapy (SIT) is  currently
being pursued as a promising curative treatment for food allergy,
including egg allergy. SIT involves the administration of allergen
starting at very small amounts and increasing to a  higher mainte-
nance  dosing, to the patients to promote tolerance by the immune
system (Akdis and Akdis, 2011).  Egg allergic patients react to each
allergen at  different intensities; therefore, it  will be important to
administer the allergens separately in SIT to better manage adverse
reactions. However, isolating egg white allergens without contam-
ination from the remaining allergens is extremely difﬁcult, time
consuming and expensive. Production of recombinant variants of
allergens is  an effective alternative to natural allergens, since the
allergen is produced independently of the others. In this study, we
aimed to produce recombinant egg white allergens and compared
their IgE reactivity within a  deﬁned Australian patient group. The
recombinant versions of Gal d 1, 2 and 3 that we produced showed
IgE reactivity when tested against allergic patients’ sera.
When  PCR amplifying cDNA sequences for cloning purposes, it
is  vital to use methods that generate minimal errors. Gal d 1, 2  and 4
were successfully ampliﬁed using the standard PCR methods, how-
ever for Gal d 3  a  long-range PCR was used to amplify its  longer
length. The PCR products shown in Fig. 1 did not appear on the
gel exactly at  the right molecular weight. This can  be attributed to
the conditions of gel run including the percentage of agarose in the
gel. The amount of DNA loaded onto the gel may  also have affected
the predicted size. The subsequent cloning in pTrcHisA vector and
sequencing (results not shown) conﬁrmed that the PCR ampliﬁ-
cation of cDNA was successful. Gal d 2  and Gal d 3 showed 99%
similarity to the published sequences on IUIS/NCBI, this may be
attributed to PCR or  sequencing error due to their larger number of
nucleotides compared to Gal d 1  and Gal  d 4  which showed 100%
similarity to the published sequences. The Express Iq E. coli strain
was  chosen for expression of the allergens because this BL21 deriva-
tive is  tolerant to toxic proteins. Gal d 1  is  a  trypsin inhibitor and
Gal  d 4 is  an antibacterial agent, therefore this strain of E. coli was
ideal for protein expression.
Expression of all four proteins in insoluble fraction indicates for-
mation of  inclusion bodies when the proteins are expressed. This
is common in E. coli since the introduced proteins are deemed for-
eign  inside the host. However, Gal  d 1 and 2  were also found in
the soluble fraction, which explains that the functional properties
of  the two  proteins may  not have had a signiﬁcant effect on the
host cells. One may  argue that over-expression of the proteins may
have caused the formation of inclusion bodies, but the expression
was carried out under the same conditions for all  four proteins,
therefore formation of inclusion bodies can likely be ascribed to the
response of the host to the function of the proteins. E. coli is  known
to contain mechanisms of degrading abnormal proteins (Goldberg,
1972),  which may  explain why  Gal d 1, 2  and 3  shows breaking
Table 1
Mass spectrometry analysis result of the  recombinant proteins.
Database Gel section Identiﬁed Protein name Protein score Sequence coverage (%)
Birds 1  –  – –
Birds 2  –  – –
Birds 3  –  – –
Birds 4  –  – –
Birds 5  Ovalbumin (Gal d  2) 3248 70
Birds 6  Ovalbumin (Gal d  2) 5495 76
Birds 7  Ovalbumin (Gal d  2) 6341 90
Birds 8  Ovalbumin (Gal d  2) 4909 82
Birds 9  Ovotransferrin (Gal d  3) 708 53
Birds 10 Ovotransferrin (Gal d  3) 668 48
Birds 11 Ovotransferrin (Gal d  3) 621 50
Birds 12 Ovotransferrin (Gal d  3) 879 48
Birds 13 Lysozyme (Gal d  4) 298 48
Birds 14 Lysozyme (Gal d  4) 223 38
Birds 15 Lysozyme (Gal d  4) 292 54
Birds 16 Lysozyme (Gal d  4) 183 29
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Fig. 3. Recombinant egg white allergen gel slices for mass spectrometry. Four slices of gel were incised from the area of the  gel each allergen is expressed. Each was  numbered
according to the ﬁgure and subjected to trypsin in-gel digestion and subsequent mass spectrometry analysis.
down of the protein by showing multiple bands in Fig. 2. It is  quite
intriguing that Gal d 4 (lysozyme) is not affected by protein degra-
dation machinery, possibly because the antibacterial properties of
Gal d 4 counteracts the cell mechanism to degrade it, which is an
important characteristic for an antibacterial agent. The localisation
of  the proteins in different fractions did not affect this study since
we  used the crude extracts for immunological analysis. The mass
spectrometry analysis, although successfully identiﬁed Gal d 2,  3
and 4, failed to identify Gal d 1. Trypsin in-gel digestion was used
for  the digestion/preparation of the gel slices. The trypsin inhibitory
activity of Gal d 1 may  have affected the results indicating that
the recombinant protein is  partially or fully functional. An ideal
suggestion to conﬁrm the identity of recombinant Gal d 1  would
be to either use Gal d 1 speciﬁc antibodies or N-terminal amino
Fig. 4. Immunological analysis of chicken egg white against egg allergic patients’ sera. (A) Western blots of natural egg  white conducted against patient’s sera. Control strips
were incubated with only the secondary antibody to study for non-speciﬁc binding of the secondary antibody. (B) Number of individuals allergic to each allergen as extracted
from the Western blots.
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Table 2
The number of allergens each patient is allergic to (as  extracted from Western blots shown in Fig. 4) and their corresponding egg  speciﬁc serum IgE levels.
Patient Egg speciﬁc serum IgE level (IU/ml)a Gal d 1  Gal d 2 Gal d  3  Gal d 4  Other allergies
1 1.25
√
–
√  √
Peanut
2  1.78
√
–
√  √
Peanut
3  3.62
√
–
√  √
–
4  28.8
√ √ √ √
–
5  13.6
√ √ √ √
–
6  9.26
√
–
√  √
–
7  93.5
√ √ √ √
Peanut
8  18.5  –  – –
√
–
9  13.2
√ √ √
Peanut
10  16.5
√
–
√ √
–
11  2.58 –  – – – –
12  2.21 –  – – – –
13  2.08 –
√ √
– Peanut
14  6.89
√ √ √
Peanut
15  4.13 –  – –
√
Peanut
16  1.72 –  – – – –
17  1.32 –  –
√
– –
18  1.21 – – – – Peanut
19  8.63 –  – – – –
20  1.02 –  – – – Peanut
21  1.05 –  – – – Peanut
22b 0  –  – – – Rye grass
23b 0  –  – –
√
Rye grass
24b 0  –  – –
√
Rye grass
25  0.47 – –
√ √
Peanut &  Rye grass
26b 0  –  –
√ √
Rye  grass
27  0.32 –  – –
√
Peanut
28  0.18 –  – –
√
Peanut
29b 0  –  – – – Peanut
30  1.19 – – – – Peanut
a Serum IgE levels were supplied with the  blood samples by the Royal Children’s Hospital, Melbourne.
b Patients not allergic to  egg, but to  other allergens.
acid sequencing. However, the appearance of the protein in Fig. 2
near the molecular weight of 30 kDa corresponds to the expected
molecular weight of 28 kDa of Gal d 1.
Prior to testing the produced recombinant allergens against
allergic patients’ sera for IgE reactivity, it was necessary to test the
obtained patient sera against natural egg white to choose the most
allergic serum samples. The Western blot shown in Fig. 4 indicates
that the serum population we obtained did not react to all of  the
allergens at similar intensities, with some samples showing reac-
tivity to only one allergen. This result suggests that egg allergy in
Australian populations may  be mainly due to allergic reactivity of
Gal d 3 and 4, although individuals allergic to Gal d 1 show higher
reactivity. Patients that showed reactivity to all 4 allergens had
higher egg speciﬁc serum IgE levels, suggesting a  possible corre-
lation between the high serum IgE levels and multi-reactivity to
different allergens. However, this correlation cannot be conﬁrmed
without a larger number of samples to show statistical signiﬁcance.
It  should be noted that some individuals with serum IgE levels of
more than 0 IU/mL did not react to any of the allergens, which can
be attributed to allergy to egg yolk in these patients, an aspect not
addressed in this study. A considerable number of individuals in
the egg allergy population we used were also allergic to peanut,
and some were allergic to rye grass, however a  correlation cannot
be  established due to the lack of literature reporting on any possible
cross reactivity between egg allergens, peanut allergens and/or rye
grass allergens. The blot also shows that Gal d 1  has appeared at a
higher molecular weight when compared to the recombinant pro-
tein, possibly due to the heavy glycosylation of natural Gal d 1 in egg
white (Mine and Zhang, 2002). Similarly to the recombinant pro-
tein, mass spectrometry analysis failed to identify Gal d 1  in natural
egg white, which further supports our aforementioned suggestion
that  the recombinant Gal d 1  may  be biologically functional.
The 4 serum samples that showed most IgE reactivity to natu-
ral  egg white were then used to make a  serum pool that showed
reactivity to all 4 allergens, which was used to test  the recombinant
allergens against IgE reactivity. The results shown in Fig. 5 indicate
that 3 of the 4  allergens were IgE reactive; with only Gal d 4 not
showing reactivity. The blot shows that Gal d 1 and 3 had more
reactivity when compared to Gal d 2, consistent with the result
seen in Fig. 4 in which natural Gal d 1 and 3  were more allergenic
to the 4  chosen serum samples. We pre-incubated the serum pool
with E. coli extract to deplete the pool of any E. coli speciﬁc IgE,
which could have given a  false positive in the experimental blots.
However, the results indicate that there were no E. coli speciﬁc IgE
present in the serum pool. The successful use of crude extract shows
that  it is  not vital to purify the natural egg proteins for preliminary
IgE  reactivity studies like the current study. In addition, the results
also  show that heating of the protein samples at  85 ◦C for 2 min
before SDS-PAGE does not appear to affect the IgE reactivity of the
proteins.
The production of IgE reactive recombinant counterparts of
natural egg allergens opens doors for downstream applications,
Table 3
Mass spectrometry analysis of natural egg white allergens.
Database Gel section Identiﬁed protein name Protein score Sequence coverage (%)
Birds Gal d  1  –  – –
Birds Gal d  2  Ovalbumin (Gal d  2) 2840 76
Birds Gal d  3  Ovotransferrin (Gal d  3) 4219 75
Birds Gal d  4  Lysozyme (Gal d  4) 1087 72
P. Dhanapala et  al. /  Molecular Immunology 65 (2015) 104–112 111
Fig. 5. Immunological analysis of recombinant proteins against allergic patients sera and non- allergic sera. The allergic serum pool was pre-incubated with E. coli extract
(A). Then two blots were prepared, one was incubated with the pre-incubated allergic sera pool (B) and the  other was incubated with non-allergic sera pool (C). All blots
were then incubated with anti-human IgE secondary antibody and developed with a chromogenic substrate.
including SIT. IgE reactive Gal d 1  has been previously produced by
Rupa  and Mine (Rupa and Mine, 2003),  however the current study
focuses on an Australian population, which has not been tested pre-
viously. Other research groups have expressed Gal d 2, 3 and 4  in
various expression systems, however their IgE reactivity has not
been tested simultaneously against egg allergic patients’ sera, or,
poorly studied. The clinical signiﬁcance of  this study is the poten-
tial  use of puriﬁed recombinant proteins for SIT and for diagnostic
methods such as skin prick tests (SPT). Currently, SPT utilizes whole
egg extracts or components isolated from natural eggs for diagnosis
(Cortot et al., 2012,  Schoos et al., 2014).  The  recombinant proteins
we produced, due to the lack of contamination with other allergens,
may  be used in SPT to pinpoint which allergen a patient might be
allergic to. Another important application of the produced recom-
binant proteins is  oral immunotherapy (OIT), a type of SIT, in which
heat denatured proteins can be administered orally to induce toler-
ance. Gal d 1 and Gal d 3  are known to contain conformational and
linear IgE binding epitopes, making them IgE reactive even after
heat denaturing, with Gal d 3  showing an increase in IgE reactivity
after heat denaturing (Cooke and Sampson, 1997, Tong et al., 2012).
These properties make these two proteins ideal candidates for OIT.
All  of the proteins were simultaneously expressed with N-
terminal 6xHexa-His tags, therefore Ni-NTA afﬁnity puriﬁcation
followed by HPLC can be used to purify the proteins for downstream
animal based studies or clinical testing. A circular dichroism (CD)
spectroscopy analysis of the puriﬁed recombinant allergens can be
used to obtain detailed structural information, especially for Gal d
1  which was not identiﬁed by mass spectrometry in this study. In
addition, a puriﬁed version of the produced Gal d 4 can be used in a
refolding experiment which may  assist in retaining its IgE reactiv-
ity. The most important characteristic of the produced recombinant
allergens is that they are not contaminated with other egg white
proteins, which can potentially be used in SIT for patients allergic
to a particular/speciﬁc egg white allergen. For patients allergic to
more than one allergen, the recombinant proteins can be used in
a  step-wise manner in SIT to induce tolerance without causing an
augmented immune response. In summary, this is  the ﬁrst study
to  simultaneously express all 4  egg white allergens in the same
expression system in order to assess their relative IgE reactivity in
a  well-deﬁned Australian patient group. The availability of puriﬁed
preparations of such recombinant allergens promises to contribute
signiﬁcantly to egg white allergy diagnostics and therapeutics in
the  near future.
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